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 1 
1 Introduction 
1.1 LEUKEMIA  
Leukemia arises from the malignant transformation of hematopoietic cells, 
most probably through the transformation of a hematopoietic stem or early 
progenitor cell.  Depending on the clinical course of the disease, leukemias 
can be broadly divided in to (i) Acute leukemias, which, if left untreated, would 
lead to death within days or weeks, and which are characterised by a block in 
cellular differentiation, leading to an imbalance between differentiation and 
proliferation and hence predominance of immature cells in the bone marrow 
and peripheral blood and (ii) Chronic leukemias, which are characterised by 
an expanded pool of proliferating cells which retain their capacity to 
differentiate into mature cells. Chronic leukemias have a protracted clinical 
course and would lead to the death of the patient within several months to 
years. The leukemias are further divided into myeloid and lymphoid types 
depending on the phenotype of the malignant cells. Though there are many 
different types of leukemia, the four most common types of leukemia can be 
introduced briefly as follows: 
1.1.1 Acute myeloid Leukaemia (AML) 
Acute myeloid leukemia is characterized by a massive proliferation of myeloid 
(the granulocytes; bacteria-destroying cells, or monocytes; macrophage-
forming cells) precursor cells and entry of immature cells into the blood 
stream. The total incidence of AML is 2.5/100,000 per year and it is more 
common in adults; particularly in older adults above the age of 55-60 years 
(Sverre Heim, 1995b). The two most commonly used classification schemes 
for AML are The French-American-British (FAB) sytem and the World Health 
Organization (WHO) system.  
1.1.1.1  The FAB classification of AML  
The FAB classification system was first proposed in 1976 and was 
subsequently expanded, modified and clarified. The FAB classification 
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devides the acute myeloid leukemias into the subtypes M0 through M7, based 
on the type of cell from which the leukemia developed and the degree of 
maturation displayed by the leukemic cells (Bennett et al., 1976).  The FAB 
classification is based mainly on morphology, i.e. how the leukemia cells look 
under the microscope after routine staining (Table 1.1).  
 
French-American-British (FAB) classification of AML 
M0 minimally differentiated 
M1 myeloblastic leukemia without maturation 
M2 myeloblastic leukemia with maturation 
M3 hypergranular promyelocytic leukemia 
M4 myelomonocytic leukemia 
M4Eo variant, increase in marrow eosinophils 
M5 monocytic leukemia 
M6 erythroleukemia (DiGuglielmo's disease) 
M7 megakaryoblastic leukemia 
Table 1.1: AML subtypes defined by the French-American-British (FAB) 
classification 
1.1.1.2  The WHO classification of AML 
The WHO classification system of AML is based on clinical data (previous 
clinical history, age) and cellular characteristics like, morphology, expression 
of certain proteins (cytochemistry, immunophenotype), and genetic lesion, 
which are assayed by cytogenetics and/or molecular biology techniques 
(Table 1.2) (Jaffe ES, 2001). This classification system allows the separation 
of more homogeneous classes to distinguish prognostic parameters and to 
identify groups of patients sensitive to specific drugs or to specific treatment 
regimens.  Thus the WHO classification is superior to the older FAB 
classification for diagnostic, prognostic and therapeutic purposes. 
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1.1.2 Acute lymphoblastic leukemia (ALL) 
Acute lymphoblastic leukemia (ALL) is characterised by the accumulation of 
malignant, immature lymphoid cells in the bone marrow and frequently also in 
the peripheral blood. ALL is much more common in children than in adults. 
The total incidence of ALL in children is 3/100,000 per year (Sverre Heim, 
1995a).  
 
Table 1.2:  AML categories defined by the WHO classification 
The FAB classification (Table 1.3) is the most widely used classification 
scheme for ALL, in which both the characteristic morphology of individual cells 
and the degree of heterogeneity within the leukemic cell population are taken 
into account (Bennett et al., 1976). In contrast to the FAB classification of 
AML, ALL FAB subgroups L1, L2 and L3 do correlate to some extent with 
clinical ALL subcategories and with immunologic characteristics of leukemic 
cells (Table 1.4).  In addition, in 70-90% of ALL cases cytogenetic 
abnormalities can be found. Some of these cytogenetic abnormalities are 
World Health Organization (WHO) Classification of AML 
AML with recurrent cytogenetic translocations 
AML with t(8;21)(q22;q22); fusion gene: RUNX1RUNX1T1 
Acute promyelocytic leukemia: AML with t(15;17)(q22;q12) and variants; fusion gene 
PML/RARA 
AML with abnormal bone marrow eosinophils and with inv(16)(p13;q22) or 
t(16;16)(p13;q22) / fusion gene: CBFB/MYH11 
AML with 11q23 / MLL abnormalities 
AML with multilineage dysplasia 
With prior MDS 
Without prior MDS 
AML with myelodysplastic syndrome, therapy related 
AML not otherwise categorized 
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associated with both B- and T-lineage ALL (e.g., 6q-, 9p-), while others are 
specific to one lineage or to a specific immunophenotype in a lineage.  For 
example, translocations involving immunoglobulin genes are generally B 
lineage specific and those involving the TCR (T-cell receptor) genes are 
specific to T-lineage ALL. Considering these facts, a classification system 
integrating morphology, immunophenotype and cytogenetics was proposed. 
This classification was named MIC (morphology, immunophenotype, 
cytogenetics) classification (MIC Cooperative Study Group, 1986; MIC 
Cooperative Study Group, 1988). 
 
FAB category-> L1 ALL L2 ALL L3 ALL 
Cell size Mainly small 
Large, 
heterogeneous 
Large, 
homogeneous 
Nuclear chromatin 
Fairly 
homogeneous 
Heterogeneous 
Finely stippled, 
homogeneous 
Nuclear shape Mainly regular 
Irregular; clefting 
and indentation 
common 
Regular; oval or 
round 
Nucleolus 
Not visible or 
small 
Usually visible, 
often large 
Usually prominent 
Amount of cytoplasm Scanty 
Variable, often 
abundant 
Moderately 
abundant 
cytoplasmic basophilia 
Slight to 
moderate 
Variable Strong 
Cytoplasmic 
vacuolation 
Variable Variable Often prominent 
Table 1.3: Acute lymphoblastic leukaemia (ALL) subtypes defined by the FAB 
Classification (Bennett et al., 1976).  
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Table 1.4: Clinical correlation of the FAB and immunologic subtypes of ALL 
 
FAB category L1 ALL L2 ALL L3 ALL 
% of total ALL 70-80% 20-25% 1-2% 
Age group Children Mainly Adults - 
Cell lineage B lineage T lineage B lineage T lineage 
mainly mature 
B-cell 
Immunophenotype 
CD10+/ 
CALLA+ 
T-cell 
Surface 
receptor 
negative 
T-cell 
surface 
receptor 
positive 
CALLA+ 
T-cell Surface 
receptor 
negative 
T-cell surface 
receptor 
positive 
Expression of 
cell surface Ig-
light chain 
Relevant 
Immunologic 
subgroup of ALL 
early preB-
ALL, 
cALL, 
pre-B-ALL 
early pre T-
ALL 
T-ALL 
early preB-
ALL, cALL, 
pre-B-ALL 
early 
pre T-ALL 
T-ALL B-ALL 
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However, current protocols for diagnosing and treating ALL are based on the 
underlying genetic abnormality. This approach is also supported by newer 
data from microarray-based gene expression profiling. The data from the 
microarray expression analysis has shown that the aberrant expression of 
certain transcription factor oncogenes defines distinct biological, clinical and 
molecular subtype of ALL (Ferrando et al., 2002). 
1.1.3 Chronic Myeloid Leukemia (CML)  
Chronic myeloid leukemia (CML) is a disease of the hematopoietic stem cell 
characterized by the overproduction of granulocytes. The annual incidence of 
CML is 1/106 in childhood and 30/106 after the age of 60 years  
[http://atlasgeneticsoncology.org/Anomalies/CML.html]. In contrast to the 
situation in AML, in CML the maturation proceeds in an orderly manner in the 
different lineages without any differentiation arrest or block. After the initial, 
relatively benign “chronic phase”, which on an average lasts for about 3 years, 
the disease typically enters a more malignant “accelerated phase” and 
eventually the terminal “blast crisis”. Almost all chronic phase CML patients 
have a t(9;22)(q34;q21) as their sole cytogenetic abnormality, which results in 
the formation of the BCR/ABL fusion gene. However, when the disease 
progresses to the accelerated phase and blast crisis, 75-80% of the cases 
acquire additional chromosomal abnormalities, which may serve as valuable 
prognostic indicators (Sverre Heim, 1995c).  The morphologic characterisics 
of the leukemic cells in the terminal CML stages vary; myeloblastic or 
lymphoblastic features may predominate. 
1.1.4 Chronic Lymphocytic Leukemia (CLL) 
Chronic Lymphocytic Leukemia is characterized by the malignant proliferation 
and accumulation of small B-cells in the bone marrow and the peripheral 
blood.  CLL of T-cell origin is exceptionally rare. The annual incidence of CLL 
is 30/106 at a median age of 60-80 years [http://atlasgeneticsoncology.org/ 
Anomalies/CLL.html]. The disease represents 70% of all lymphoid leukemias 
and one-fourth of all leukemias. The clinical course of the disease is very 
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benign, with some forms of CLL having a survival, which is similar to age 
matched controls even without therapy.  
Trisomy 12, deletion 13q14.3, deletion of 11q22-q23 and loss of p53 gene are 
the commonly observed cytogenetic abnormalities in CLL. Deletion 11q22-
q23, involving ATM gene and deletion 17p13, involving p53 are the two most 
important cytogenetic prognostic markers (Hamblin, 2007).  
1.2 GENETIC ALTERATIONS IN CANCER 
As mentioned above, we are more and more moving into an era, in which 
cancer diagnostics and cancer therapies are based on the specific genetic 
aberrations found in the cancer to be treated. Some of the genetic aberrations 
serve as efficient prognostic markers in a particular disease, while others are 
even used as targets for therapeutic agents. Looking at the history of genetic 
aberrations and cancer, the idea that chromosomal alterations might be the 
cause of cancer was already put forward by Theodor Boveri in 1914 (Boveri, 
1914). 
This prescient hypothesis could only be verified after half a century of 
technical improvements, which led to the reliable visualization of human 
chromosomes (Tijo and Levan, 1956). The hypothesis was clearly supported 
by the consistent observation of a very small chromosome, named 
„Philadelphia chromosome“, in the cells of Chronic Myeloid Leukemia (CML) 
patients by Nowell and Hungeford (Nowell and Hungerford, 1960). A decade 
later, after the introduction of chromosome banding techniques (Caspersson 
et al., 1970), Janet Rowley discovered that the Philadelphia chromosome 
found in CML was the result of a balanced t(9;22) translocation (Rowley, 
1973). In the early 70ies many specific and recurring chromosomal 
translocation were described in various tumor types especially in leukemias.  
The last two decades have seen the molecular characterization of a large 
number of balanced chromosomal translocation with the discovery of fusion 
gene and aberrant gene regulation. These efforts have provided us with the 
conclusive verification of Boveri’s hypothesis. Now it is well accepted that 
cancer is a genetic disease with two major types of initiating genetic events: 
(1) The inactivation of tumor suppressor genes by deletions, point mutations 
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or maybe even by epigenetic mechanisms and (2) the activation or 
deregulation of oncogenes by point mutations, amplifications or balanced 
cytogenetic abnormalities like inversion, insertion or translocation.  
In addition to onocogene activation and tumor suppressor gene inactivation, a 
few other general priniciples underlying malignant transformation have been 
postulated such as a block in differentiation, increased proliferation, 
resistance towards apoptosis resulting in prolonged cell survival, and 
enhanced self-renewal capacity of tumor propagating cells (or tumor stem 
cells) (Weissman, 2000; Warner et al., 2004). It is also important to note that 
malignant transformation in general and also in leukemia is a multistep 
process for which several somatic mutations are required rather than only a 
single event. It has been postulated that for leukemic transformation at least 
two genetic events are required with one of this genetic lesions driving 
increased cellular proliferation (class I mutation) and the second mutation 
leading to a differentiation block (class II mutation) (Kelly and Gilliland, 2002).  
To better understand the concept of class I and class II mutations, we have to 
consider that the hematopoietic organ, like any organ with a high cellular turn-
over, has a very defined and orderly differentiation and proliferation hierarchy. 
The production of new blood cells (erythrocytes, granulocytes and 
lymphocytes) starts from the hematopoietic stem cells, which divide 
asymmetrically. One daughter cell retains the stem cell phenotype and 
continues to reside in the stem cell niche. While the other daughter cell starts 
a hierarchical differentiation program turning into a progenitor cell for one of 
the many blood lineages. Lineage specific transcription factors play an 
important role in these differentiation processes from primitive progenitors to 
mature blood cells. Interestingly, mutations of these key transcription factors 
have been identified in several leukemias (e.g. mutations in the granulocyte 
lineage specific transcription factor (TF) CEBPA). Several leukemia-
associated fusion genes either directly affect lineage specific TFs or disrupt 
the function of lineage specific TFs thus leading to a block of differentiation. 
These are called class II mutations. However, several studies using mouse 
models could clearly demonstrated that such a "class II" fusion protein (eg. 
the fusion proteins PML/RARA or RUNX1/RUNX1T1, wich are class II 
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mutations) is in most cases not sufficient to cause a full blown leukemia 
(Grisolano et al., 1997; Pollock et al., 1999; de Guzman et al., 2002). 
However, the coexpression of a protein with a class I mutation (eg. an 
activated tyrosine kinase like the FLT3-ITD), which drives cellular proliferation, 
will lead to leukemic transformation. It was shown that mutations in the 
receptor tyrosine kinase FLT3 collaborate with PML/RARα (Kelly et al., 2002) 
and with AML1/ETO (Schessl et al., 2005) to cause leukemia. Similarly, many 
activated tyrosine kinases are sufficient to induce a myeloproliferative disease 
on their own in murine models (Pear et al., 1998; Zhang and Ren, 1998; Li et 
al., 1999; Million et al., 2002), but for the development of a leukemia they 
require the help from other oncogenes which cause a differentiation block 
(Schessl et al., 2005). 
As with all theories and concepts it should be kept in mind that these are just 
concepts which are more beneficial for the human mind and which can only 
be an approximation of the true nature of things. Thus, it is quite often not 
possible to clearly group a mutation or fusion gene found in a patient sample 
clearly into one of the two classes proposed by Gilliland and colleagues. Even 
if the grouping of a mutation seems obvious, it might not behave as predicted. 
There are bona fide class I mutations (eg. activated tyrosine kinases like the 
BCR/ABL protein) which are capable of inducing an aggressive leukemia in 
certain mouse models without a long latency period. Similarly, there are also 
bona fide class II mutation like the CALM/AF10 fusion or the MLL/AF9 fusion 
which lead to the rapid onset of leukemia in bone marrow transplantation 
models without the apparent help from a class I mutation (Deshpande et al., 
2006; Somervaille and Cleary, 2006).  
To fully understand the complicated process of malignant transformation in 
cancer and in leukemia in particular it is therefore necessary to discover and 
study in detail as many primary genetic lesions in these diseases as possible. 
One of the most fruitful methods to discover new genetic lesions in leukemia 
has been the study of chromosomal translocations. 
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1.2.1 Chromosomal Translocations In Leukemia 
In human leukemia, the study of balanced chromosomal translocations has 
contributed greatly to our understanding of the pathogenesis of this disease in 
particular and, in addition, provided us with many paradigms for 
carcinogenesis in general. Balanced chromosomal translocations have 
pinpointed those genes, which are the important players in leukemia. 
 
Figure 1.1: Balanced chromosomal translocation: The two non-homologous 
chromosomes are indicated by different colour patterns. The “BP“ indicates the 
breakpoint region on the two non-homologous chromosomes.  
Balanced chromosomal translocations lead to the exchange of genetic 
material between two non-homologous chromosomes (Figure: 1.1), resulting 
in the alteration of the function of the genes in the vicinity of the translocation 
breakpoints. Basically, translocations alter gene function by two distinct 
mechanisms: (1) Overexpression of a gene at the translocation breakpoint by 
the juxtapposition of the promoter of another gene (Figure 1.2 A) and (2) 
Creation of a fusion gene, which encodes for a fusion protein with new, 
oncogenic properties (Figure 1.2 B).  
The classic example of the first type of molecular mechanism is the 
t(8;14)(q24;q32), where the MYC gene from chromososme 8 is juxtapposed to 
the IGH enhancer on chromososme 14 and becomes constitutively expressed 
owing to the influence of regulatory elements of the IGH promoter (Taub et al., 
1982; ar-Rushdi et al., 1983). This mechanism is more commonly found in 
gene fusions in lymphoid malignancies but has recently also been discovered 
in the majority (80%) of prostate cancer (Tomlins et al., 2005).  
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Figure 1.2: Consequences of balanced chromosomal translocation: (A) 
Overexpression of gene B by the juxtaposing the promoter of gene A to the 
whole coding sequence of gene B (B) Expression of a fusion protein by a 
chimeric gene formed by the in frame fusion of the parts of coding sequence of 
gene A and gene B.  
The second type of molecular mechanism is exemplified by the 
t(9;22)(q34;q11) observed in CML, AML and ALL, which brings together the 5’ 
part of BCR (Breakpoint Cluster Region) gene on chromosome 22 and the 3’ 
part of ABL1 (Abelson) tyrosine kinase gene from chromosome 9, leading to 
the formation of the BCR/ABL1 fusion gene (Shtivelman et al., 1985) and 
subsequently to the production of a chimeric BCR/ABL1 protein with 
constitutive tyrosine kinase activity (Witte et al., 1980; Konopka et al., 1984). 
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During the last two decades an increasing number of chromososmal 
translocations have been characterized at the molecular level, leading to the 
identification of many genes involved in the induction of malignant 
transformation. Up to now a total of 264 gene fusions, involving 238 different 
genes, have been described in haematologic disorders including malignant 
lymphomas (Mitelman et al., 2007). As a consequence, a network of fusion 
genes has emerged in which several genes are involved in more than one 
translocation forming fusion genes with several partner genes (Bohlander, 
2000; Mitelman et al., 2007). One of the subsets of this fusion gene network 
are the tyrosine kinase fusion genes (Cross and Reiter, 2002; Bohlander, 
2005) (Figure 1.3). 
 
Figure 1.3: Network of tyrosine kinase fusion genes associated with 
hematologic malignancies. The colored boxes indicate tyrosine kinases. 
1.3 TYROSINE KINASES 
Tyrosine kinases (TK) are enzymes that are essential for many cellular 
signaling pathways and regulate key cellular functions like growth, 
proliferation, differentiation, cell shape, cell adhesion and programmed cell 
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death. TKs phosphorylate other proteins by transferring a phosphate group 
from ATP to a tyrosine residue in the substrate protein. This phosphorylation 
changes the function of the protein usually resulting in the activation of the 
downstream signaling pathways. TKs can be divided into two major classes: 
Receptor Tyrosine Kinases (RTK) and cellular or non-receptor tyrosine 
kinases (NRTK). An RTK contains an extracellular ligand binding domain, a 
trans-membrane domain, which anchors the receptor in the plasma 
membrane, and an intracellular domain, which includes the tyrosine kinase 
domain and multiple regulatory domains, which include tyrosines for auto 
phosphorylation.  
1.3.1 Normal activation of tyrosine kinases 
In its inactive state the RTK is present as a monomer, but when a ligand 
(growth factors or hormones) binds to the extracellular domain of two RTKs, 
the RTKs are dimerized. The dimerized RTKs then phosphorylate each 
other's tyrosine residues by cross-phosphorylation. This cross-
phosphorylation results in stably active RTKs providing phosphotyrosine-
docking sites for other proteins which transduce downstream signals into the 
cell. In contrast to the RTKs, non-receptor tyrosine kinases are located in the 
cytoplasm, nucleus, or are anchored to the inner surface of the plasma 
membrane. They do not have a ligand binding domain or a transmembrane 
domain, but they use similar mechanism of activation like the RTKs; i.e. cross-
phosphorylation via dimerization or oligomerization, but they are also 
regulated by phosphorylation through other (upstream) TKs. 
1.3.2 Constitutive activation of tyrosine kinases in oncogenic 
tyrosine kinase fusion proteins 
ABL, JAK2, FGFR3, PDGFR-alpha, PDGFR-beta, and NTRK are some of the 
tyrosine kinases involved in the formation of tyrosine kinase fusion proteins in 
leukemia and solid tumors. In these fusion proteins, the partner protein is 
joined to the entire catalytic domain of the tyrosine kinase. All these partner 
proteins contribute one important protein domain to the fusion protein: a 
dimerization or oligomerization domain. This structural feature of the fusion 
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partner leads to the dimerization or oligomerization of the fusion protein, 
which mimics the process of ligand-mediated dimerization and results in the 
constitutive activation of the tyrosine kinase portion of the fusion protein.  
1.3.3 Tyrosine kinase inhibitors as cancer drug  
The first TK fusion protein discovered and studied extensively was the 
BCR/ABL fusion resulting from the reciprocal translocation t(9;22)(q34;q11). 
The abnormal TK activity of the BCR/ABL fusion protein was studied in great 
detail. One of the aims of these studies was the development of specific 
competitive tyrosine kinase inhibitors.  Among the various tyrosine kinase 
inhibitors, Imatinib (formerly known as CGP 57148B and STI571) was 
selected as being the best suited drug for the treatment of BCR/ABL positive 
CML. Imatinib, which was developed by Brian Druker and colleagues 
(Buchdunger et al., 1996; Druker et al., 1996) was the first targeted cancer 
therapy. Imatinib is a competitive inhibitor of ABL, c-Kit and the PDGFR-beta 
tyrosine kinase. Imatinib, which has a 2-phenylaminopyrimidine structure, 
occupies the ATP-binding pocket in the TK domains of ABL1, c-Kit and 
PDGFR-beta inhibiting the kinase function of these proteins. Imatinib is used 
for the treatment of aberrantly activated ABL1, c-Kit and PDGFR-beta. This 
targeted therapy has proved to be extremely beneficial for patients with CML, 
improving greatly the quality of life for these patients (Druker et al., 2001a; 
Druker et al., 2001b; Sawyers et al., 2002). Although long-term remissions in 
CML patients can be achieved with Imatinib, it does not appear to cure CML. 
When the treatment with Imatinib is discontinued the patients relapse, and 
even while Imatinib is given resistance mutations can arise in the BCR/ABL 
fusion gene.  
Other compounds, which specifically inhibit other tyrosine kinases such as 
FGFR1 (eg. SU5402 and PD173074) but are inactive against BCR/ABL have 
recently been developed (Mohammadi et al., 1997; Demiroglu et al., 2001). 
1.4 ABL1 FUSION PROTEINS 
Up to now 6 different fusion partners of the ABL1 tyrosine kinase gene have 
been reported in hematological malignancies (Figure 1.3). Other than 
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BCR/ABL1, the ETV6/ABL1 fusion (Papadopoulos et al., 1995) is also well 
characterized and responds well to Imatinib treatment. In addition, three other 
ABL1 fusion partners: the nuclear pore complex protein 214 kDa protein 
NUP214 (9q34) (Graux et al., 2004), EML1 (14q32) (De Keersmaecker et al., 
2005), RCSD1 (1q24) (De Braekeleer et al., 2007) and ZMIZ1 (Soler et al., 
2008) have been reported in different subtypes of leukemia.  
 
Fusion Translocation Disease 
di or oligomerization 
domain contributed by 
the ABL1 partner 
BCR/ABL1 t(9;22)(q34;q11) CML, ALL, AML Coiled-coil  
ETV6/ABL1 t(9;12)(q34;p12) ALL, AML, CML Helix-loop-helix  
NUP214/ABL1 t(9;9)(q34;q34) 
Amplified episomes 
T-ALL Coiled- coil 
EML1/ABL1  t(9;14)(q34;q32) T-ALL Coiled-coil 
RCSD1/ABL1 t(1;9)(q24;q34) B-ALL Unknown at present 
ZMIZ1/ABL1 t(9;10)(q34;q22.3) B-ALL Unknown at present  
Table 1.4: List of known ABL1 fusions with the di- or oligomerization 
domains within the fusion partner. The chromosomal rearrangements 
generating the respective ABL1 fusion are indicated. Relative disease is also 
indicated. 
All these ABL1 fusion partners activate the ABL1 tyrosine kinase by providing 
a di- or oligomerization domain (Table 1.4). For example, in the BCR/ABL 
fusion protein the coiled-coil domain of BCR serves as a 
dimerization/oligomerization domain facilitating the constitutive activation of 
the ABL tyrosine kinase. 
In addition to the five known fusion partners of ABL1, we have discovered a 
novel fusion partner of ABL1, the SHIP1 gene. The SHIP1 gene (SH2 
containing Inositol Phosphatase 1), named officially inositol polyphosphate-5-
phosphatase (INPP5D) is located on the long arm of chromosome 2 (2q37). 
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This novel SHIP1/ABL1 fusion gene was discovered in the leukemic cells of 
an 18-year old female patient with B-ALL. 
It is the aim of this doctoral thesis to: 
(1) Characterize this novel fusion at the genomic and transcript level. 
(2) Study the transformation potential of the SHIP1-ABL1 fusion protein. 
(3) Test whether SHIP1/ABL1 is responsive to Imatinib.  
(4) Analyze the protein domains of SHIP1, which are responsible for the 
TK activation SHIP1/ABL1 and its transforming potential. 
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2 Materials and Methods 
2.1 MATERIALS 
2.1.1 Reagents 
Reagent  Company 
1,4- Diaminobenzol Sigma-Aldrich, USA 
1-kb-DNA Ladder Invitrogen, Karlsruhe, Germany 
3-amino-1,2,4-triazole (3-AT) Sigma, Taufkirchen, Germany 
Acetic acid Merck, Darmstad, Germany 
Acrylamid Rotiphorese® Gel 30 (37, 5:1) Carl Roth, Karlsruhe, Germany 
Agar Carl Roth, Karlsruhe, Germany 
Agarose ICN Biomedicals Inc. 
Amino acids Sigma, Taufkirchen, Germany 
Ammonium acetate (NH4Ac) Sigma, Taufkirchen, Germany 
Ammonium chloride (NH4Cl) solution CellSystems, Vancouver, Canada 
Ammonium persulfate (APS) Sigma, Taufkirchen, Germany 
Ampicillin Na-Salt Pan Biotech, Aidenbach, Germany 
Antibiotic-Antimycotic Gibco, Invitrogen corp. 
Aqua ad iniectabilia Braun B Melsungen AG, Germany 
ß-Mercaptoethanol Sigma, Taufkirchen, Germany 
Biocoll separating solution Biochrom AG, Berlin, Germany 
Big dye terminatorTM Mix  (V 1.1) PE Applied biosystems, Foster city, CA 
Bovine serum albumine (BSA) Sigma, Taufkirchen, Germany 
Bradford Reagent (BioRad Protein Assay reagent) BioRad Laboratory GmbH, Munich, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
Calcium cloride (CaCl2) Sigma, Taufkirchen, Germany 
Chloramphenicol Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Cot-1 DNA Vysis Inc., USA 
D(+)-glucose-monohydrate Merck, Darmstadt, Germany 
d2H2O Millipore, Eschborn, Germany 
DAPI Sigma, Taufkirchen, Germany 
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Reagent  Company 
Deoxyribonuclease I, Amplification Grade Invitrogen, Karlsruhe, Germany 
Dextran sulfate Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Carl Roth, Karlsruhe, Germany 
DNA molecular weight marker II Boehringer Manheim GmbH, Germany 
DNA molecular weight marker III Boehringer Manheim GmbH, Germany 
DNA molecular weight marker VI Boehringer Manheim GmbH, Germany 
dNTP Set, PCR Grade Invitrogen, Karlsruhe, Germany 
DPBS Pan Biotech, Aidenbach, Germany 
ECL™ Plus Western Blotting Detection Reagent Amersham, Freiburg, Germany 
EDTA (ethylenediaminetetraacetic acid) Carl Roth, Karlsruhe, Germany 
EGTA (Ethylen Glycol-bis(2-aminoethylether)- 
N,N,N′,N′-tetraacetic acid)  
Sigma, Taufkirchen, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
Fetal bovine serum (FBS) Gibco Invitrogen Cell Culture, Karlsruhe, Germany 
FISH probes; BCR-ABL DCDF Abbott-Vysis, Germany 
Fluorescein-12-dATP Perkin Elmer Life Sc. Inc., USA 
Fluorescein-12-dCTP Perkin Elmer Life Sc. Inc., USA 
Formaldehyde 37% Carl Roth, Karlsruhe, Germany 
Formamide Carl Roth, Karlsruhe, Germany 
Gelatin Merck, Darmstadt, Germany 
Glass beads Sigma, USA 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Merck, Darmstadt, Germany 
Heparin Sigma, Taufkirchen, Germany 
HEPES (N-(2-Hydroxyethyl) piperazine-N´- (2-
ethanesulfonic acid)) 
Sigma, Taufkirchen 
Hydrochloridric acid 37% Merck, Darmstadt, Germany 
Hydrochloridric acid  (0.1N) Merck, Darmstadt, Germany 
Hydrogen peroxide (H2O2) solution 35 %  Merck, Darmstadt, Germany 
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Reagent  Company 
IPTG Roche, Mannheim, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
Kaisers Glyceringelatine Merck, Darmstadt, Germany 
Kanamycin Pan Biotech, Aidenbach, Germany 
Klenow Fragment MBI Fermentas, St. Leon-Rot, Germany 
L-Glutamine  Pan Biotech, Aidenbach, Germany 
Lithium acetate Sigma, Taufkirchen, Germany 
LSI/WCP hybridization buffer Abbott Molecular Inc., USA 
Magnessium Chloride (MgCl2) Sigma, Taufkirchen, Germany 
Maleic acid Sigma, Taufkirchen, Germany 
Methanol Merck, Darmstadt, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
NP40 (nonyl phenoxylpolyethoxylethanol) Roche, Mannheim, Germany 
Penicillin/streptomycin Pan Biotech, Aidenbach, Germany 
Pepsin Sigma-Aldrich, USA 
Phenol/chloroform/isoamyl (25:24:1) Invitrogen, Karlsruhe, Germany 
Phenylmethylsulfonylfluorid (PMSF) Sigma, Taufkirchen, Germany 
Platinum® Pfx DNA Polymerase Invitrogen, Karlsruhe, Germany 
Platinum® Taq DNA Polymerase Invitrogen, Karlsruhe, Germany 
Polyethylenglycol (PEG) 4000 Merck, Darmstadt, Germany 
Polyethylineimine (PEI) Sigma, Taufkirchen, Germany 
Potassium chloride (KCl) Calbiochem, San Diego, USA 
Propidium iodide Sigma, Taufkirchen, Germany 
Protamine sulphate Sigma-Aldrich, St. Louis, MO 
Protein A-Agarose Roche, Mannheim, Germany 
Protein G-Agarose Roche, Mannheim, Germany 
Proteinase inhibitor cocktail Sigma, Taufkirchen, Germany 
Random examer primers p(dN)6  Roche Diagnostics, Mannheim, Germany 
Recombinant murine IL3 (rm IL-3)  Immunotools GmbH, Germany 
Restriction enzymes MBI Fermentas, Germany 
Restriction enzymes NewEngland Biolabs, Schwalbach, Germany 
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Reagent  Company 
Rnasin Plus Rnase inhibitor Promega, WI, USA 
SDS (sodium dodecyl sulfate) Carl Roth, Karlsruhe, Germany 
SeeBlue® Plus2 pre-stained standard Invitrogen, Karlsruhe, Germany 
Sequenase version 2.0 DNA polymerase USB corporations, USA 
S.O.C. medium Invitrogen, Carlsbad, USA 
Sodium acetate, Anhydrous (NaAC) Calbiochem, San Diego, USA 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium citrate (Na3C6H5O7) Carl Roth, Karlsruhe-, Germany 
Sodium deoxycholate Sigma, Taufkirchen, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium orthovanadat (Na3VO4) Sigma, Taufkirchen, Germany 
Sodium phosphate dibasic anhydrous (Na2HPO4) Sigma, Taufkirchen, Germany 
Sodium phosphate monobasic monohydrate 
(NaH2PO4) 
Calbiochem, San Diego, USA 
Spectrum green- dUTPs Vysis Inc., USA 
Spectrum orange- dUTPs Vysis Inc., USA 
STI571 (Imatinib) Novartis, Basel, Switzerland 
Sucrose Sigma, Taufkirchen, Germany 
T4 DNA Ligase NewEngland Biolabs, Schwalbach, Germany 
Tetramethylethylendiamin (TEMED)  Serva, Heidelberg 
Tetrazole salt, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazoliumbromid (MTT), 
Sigma, Taufkirchen, Germany 
Texas-Red-5-dATP Perkin Elmer Life Sc. Inc., USA 
Texas-Red-5-dCTP Perkin Elmer Life Sc. Inc., USA 
Trichloroacetic acid (TCA) Sigma, Taufkirchen, Germany 
Tris (2-Amino-2-hydroxymethyl-propane-1,3-diol) Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Trypan blue Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA  Gibco™, Germany 
Tween® 20 Sigma, Taufkirchen, Germany 
X-alpha-gal (5-Bromo-4-Chloro-3-indolyl a-D-
galactopyranoside) 
Clontech, Heidelberg, Germany 
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Reagent  Company 
Yeast extract Sigma, Taufkirchen, Germany 
Yeast nitrogen base without aa Difco, Detroit MI, USA 
2.1.2 Materials and Kits 
Name Company 
Blotting paper GB003 and GB002 Schleicher & Schuell, Dassel, Germany 
Cell Strainer 40 µm Nylon Falcon® BD Biosciences, Palo Alto, CA 
CENTRI Sep8 well strips Princeton Separations, USA 
Coverslips Menzel-Gläser®, Braunschweig, Germany  
Cryotube™ vials Nalge Nunc Internacional, Denmark 
Electroporation cuvettes 2 mm EquiBio, Kent, UK 
Endofree® Plasmid Maxi kit (10) Qiagen, Hilden, Germany 
Eppendorf tubes Eppendorf, Hamburg, Germany 
FACS Polystrene round-bottom tubes Becton Dickinson, Meylan, France 
Ficoll (type 400)  Sigma, Taufkirchen, Germany 
Filter unit 0.22 µm Millipore, Belford, USA 
Filter unit 0.45 µm Millipore, Belford, USA 
Freezing container (Cry0 1° C) Nalgene TM, USA 
Glass beads  Sigma, Taufkirchen, Germany 
Glassware  Schott, Jena, Germany 
Herring Testes Carrier DNA denatured DB  Biosciences Clontech, Heidelberg, Germany 
Hybond-P PVDF membrane Amersham, Freiburg, Germany 
Hypercassete™ 18x24 cm Amersham, Freiburg, Germany 
Hyperfilm ECL high performance Amersham, Freiburg, Germany 
MagNaPure LC mRNA Isolation Kit Roche Diagnostics Mannheim Germany 
Marabu Fixogum Rubber Cement Marabuwerk GmbH, Tamm, Germany 
Microcentrifuge tube (1.5 ml) Eppendorf, Hamburg, Germany 
Microscope slides Menzel-Gläser®, Braunschweig, Germany 
pGEM-Teasy vector system Promega, WI, USA 
Pipette tips Carl Roth, Karlsruhe, Germany 
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Name Company 
Plasmid Midi kit (25) Qiagen, Hilden, Germany 
Plastic cuvettes for biophotometer Carl Roth, Karlsruhe, Germany 
Plastic ware for cell culture Greiner Labortechnik, Frickenhausen, Germany 
Plastic ware for cell culture Sarstedt, Nümbrecht, Germany 
Plastic ware for cell culture Corning, USA 
Polypropylene conical tubes Becton Dickinson, Meylan, France 
QIAshredder™ columns Qiagen, Hilden, Germany 
QIAquick gel extraction kit   Qiagen, Hilden, Germany 
S.O.C. medium Invitrogen, Carlsbad, USA 
SuperScript™ II RNase H- Reverse Transcriptase Invitrogen, Karlsruhe, Germany 
Surgical blades Feather Safety Razor Co. Med. Div., Japan 
Syringes  Braun, Melsungen, Germany 
2.1.3 Buffers and solutions 
2.1.3.1 Buffers and solutions used in microbiology 
Name Components 
10x TE buffer 0.1 M Tris-HCl 
 10 mM EDTA 
  pH 7.5, Autoclave. 
  Storage: RT 
   
10x LiAc solution  1 M  Lithium acetate 
  
Adjust to pH 7.5 with acetic acid and 
autoclave 
  Storage: RT 
   
1x TE/LiAc solution 1 vol. 10x TE buffer 
Prepared fresh 1 vol. 10x LiAc solution 
 8 vol. ddH2O 
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Name Components 
PEG/LiAc solution  8 vol. 50 % PEG 4000 
Prepared fresh 1 vol. 10x TE buffer 
 1 vol. 10x LiAc solution 
   
Resuspension buffer for plasmid preparations 50 mM Tris.Cl, pH 8.0 
(Buffer P1, Qiagen) 10 mM EDTA 
 100 µg/ml RNase A 
  Storage: 2-8° C 
   
   
Alkaline lysis buffer for plasmid preparations 200 mM NaOH 
(Buffer P2, Qiagen) 1% (w/v)  SDS 
  Storage: 15-25° C 
   
Neutralization buffer for plasmid preparations 3.0 M Potassium acetate 
(Buffer P3, Qiagen)  pH 5.5 
  Storage: 15-25° C 
2.1.3.2 Buffers and solutions used in molecular biology 
Name Components 
1X TBE (Tris-Borate-EDTA) buffer 0.1 M Tris 
 90 mM Boric acid 
 1mM EDTA 
 
10X TBE buffer was purchased from Invitrogen 
Life technology and diluted to 1X. 
  Storage: RT 
   
3x loading dye 15 g Ficoll 400 
(For agarose gel electrophoresis) 0.1 mg Bromophenol blue 
 ad 100 ml  ddH2O 
  Storage: 4° C 
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Name Components 
10x T4 DNA ligation buffer 
(Supplied with the T4 DNA ligase) 
400 mM Tris-HCl (pH 7.8 at 25°C)  
for pH maintenance 
 100 mM MgCl2 for Mg++ 
 100 mM DTT, reducing agent 
 5 mM ATP as co-factor 
  Storage: -20° C 
Restriction enzyme buffers:  
The restriction enzyme buffer contains salt (MgCl2, KCl or NaCl) for ionic stregth and proper 
enzyme function, Tris for the maintainance of the required pH for the reaction and bovine 
serum albumine for the stability of the restriction enzyme. Different enzmes have different 
preferences for ionic strength. We used the recommended buffers for the optimum activity of 
each restriction enzyme, supplied by the manufacturers. 1x  Tango buffer is one of the 
universal buffers which can be used for a large number of restriction enzymes and for double 
digests. 
Name Components 
1x Tango buffer; Fermentas 33 mM Tris-acetate pH 7.9 at 37° C 
(Restriction enzyme buffer) 10 mM  Mg-acetate 
 66 mM K-acetate 
 0.1 mg/ml BSA 
  Storage: -20° C 
   
10x PCR amplification buffer without MgCl2 200 mM  Tris-HCl (pH 8.4) 
(Invitrogen) 500 mM KCl 
  Storage: -20° C 
   
Resuspension buffer for plasmid preparations 50 mM Tris.Cl, pH 8.0 
(Buffer P1, Qiagen) 10 mM EDTA 
 100 µg/ml RNase A 
  Storage: 2-8° C 
   
Alkaline lysis buffer for plasmid preparations 200 mM NaOH 
(Buffer P2, Qiagen) 1% (w/v)  SDS 
  Storage: 15-25° C 
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Name Components 
Neutralization buffer for plasmid preparations 3.0 M Potassium acetate 
(Buffer P3, Qiagen)  pH 5.5 
  Storage: 15-25° C 
2.1.3.3 Buffers and solutions used in cell culture 
Name Components 
Sodium phosphate buffer  684 ml 1 M Na2HPO4 
(required solutions for 1 l) 316 ml 1 M NaH2PO4 
  pH 7.2 
  Storage: RT 
   
2x HBS  50 mM HEPES 
 12 mM  KCl 
 12 mM  Dextrose 
 280 mM NaCl 
 1.5 mM  Na2HPO4 
  pH 7.0-7.1 
  Storage: -20° C 
   
FACS buffer  1x PBS 
 2% FBS 
 1 mg/l propidium iodide 
  Storage: 4° C 
   
Freezing medium 10% (v/v) DMSO in FBS 
  Storage: 4° C 
2.1.3.4 Buffers and solutions used in protein biochemistry 
Name Components 
Tris-HCl 1.5 M, pH 8.8  Tris powder in d2H2O, adjusted pH with HCL 
 1 M, pH 6.8 Tris powder in d2H2O, adjusted pH with HCL 
 1 M, pH 8.0 Tris powder in d2H2O, adjusted pH with HCL 
 1 M, pH 7.5 Tris powder in d2H2O, adjusted pH with HCL 
  Storage: RT 
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Name Components 
EDTA 0.5 M, pH 8.0 EDTA in d2H2O, adjusted pH 
  Storage: RT 
   
10 % SDS  10 % (w/v)  Sodium dodecylsulfate in d2H2O 
  Storage: RT 
   
10% APS 10 % (w/v)  Amonium Persulphate in d2H2O 
  aliquoted and stored at -20° C 
   
NTE (Na-Tris-EDTA) buffer 150 mM NaCl 
 10 mM Tris, pH 7.5 
 1% NP40 
 5 mM EDTA 
  Storage: 4° C 
   
Lysis buffer No. 1  50 mM HEPES pH 7.5 
 150 mM NaCl 
 1 mM EGTA 
 10% Glycerol 
 1% Triton-X 100 
 100 mM NaF 
 10 mM Na4P2O7-10H2O 
  Storage: 4° C 
   
2.5x Laemmli stacking buffer  0.3 M Tris/HCl pH 6.8 
 0.25 % SDS 
  Storage: up to 1 month at 4°C 
   
2x Laemmli loading buffer  10% β-mercaptoethanol 
 6% SDS 
 20% Glycerol 
 0.2 mg/ml Bromophenol blue 
 0.025x Laemmli stacking buffer (optional) 
  Storage: RT, up to 2 months 
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Name Components 
10x Tris-Glycine  250 mM Tris 
electrophoresis buffer 1.92 M Glycine 
 1% SDS 
  Storage: RT 
   
1x Gel Transfer buffer   25 mM Tris    
(For western blotting) 192 mM Glycine   
 20% Methanol 
  Storage: 4° C 
   
1x TBS  10 mM Tris/HCl pH 8.0 
 150 mM NaCl 
  Storage: RT 
   
1x TBST washing buffer  1x TBS 
 0.1 % Tween® 20 
  Storage: RT 
   
Stripping solution for WB  62.5 mM Tris/HCl pH 6.8 
 0.1 M β-mercaptoethanol 
 2% SDS 
  Storage: RT 
   
20% TCA (for yeast lysis) 20% w/v TCA in d2H2O 
  Storage: 4° C  
   
TCA Buffer 20 mM Tris-HCL (pH 8) 
Use deionized H2O 50 mM Ammonium acetate 
 2 mM EDTA 
 60 µl/ ml PIC (Protease inhibitor cocktail, Sigma) 
  PIC was added immediately prior to use 
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2.1.3.5 Buffers and solutions used for cytogenetics and FISH 
Name Components 
Saline sodium citrate buffer 3 M NaCl 
(SSC) 20x 0.3 M Sodium citrate 
  pH 7.0 
  Autoclave, Storage: RT 
   
10x MAP 400 mM Tris HCl pH 7.5 
 100 mM MgCl2 
 500 mM NaCl 
 50 mM DTT 
  Storage: -20° C 
   
10x BP buffer 66 mM Tris HCl pH 9.0 
 550 mM KCl2 
 0,11 % (w/v) Gelatin 
  Storage: -20° C 
   
10x DNase adjusting buffer 0.5 M Tris HCl pH 7.5 
 50 mM MgCl2 
  Storage: 4° C 
   
DNase stock solution 50% Glycerol 
 20 mM Tris HCl pH7.5 
 1 mM MgCl2 
  Storage: -20° C 
   
DNase buffer solution 2.0 ml 1M Tris HCl pH7.5 
 0.1 ml 1M MgCl2 
 97.9 ml d2H2O 
  Storage: RT 
   
Pepsin solution (stock) 0.2 gm Pepsin (Sigma, #P7012) 
 10 ml  d2H2O 
  500 µl aliquots, stored at -20° C 
   
Pepsin solution (working) 100 ml 0.01 N HCl, preheated at 37° C 
Prepared fresh 500 µl Pepsin solution (stock) 
Materials and Methods 
29 
Name Components 
Post fixation solution 1x PBS 
 1% (v/v) Formaldehyde 
 50 mM MgCl2 
  Storage: Up to 3-5 days at 4° C 
   
FISH hybridization buffer 11 ml Formamide 
 2 gm Dextransulphate 
 1 ml 20x SSC 
  
dissolved at 70°C O/N, adjusted pH7.0, Adjust 
volume to 14 ml with d2H2O; Storage: -20° C 
   
FISH Wash solution I 0.4x SSC 
 0.3% (v/v) Triton-X 100 
  pH 7.0-7.5, Storage: RT 
   
FISH Wash solution II 2x  SSC 
 0.1% (v/v) Triton-X 100 
  pH 7.0-7.5, Storage: RT 
   
FISH Wash solution III 4x  SSC 
 0.05% (v/v) Triton-X 100 
  Storage: RT 
   
Blocking solution (FISH) 3% (w/v) BSA in FISH wash solution III 
Prepared fresh   
   
Antifade-solution A 1x PBS 
 1% (w/v) 1,4 diaminobenzol 
  Used immediately for antifade (Working solution) 
   
Antifade (Working solution) 5 ml Antifade-solution A 
 45 ml  Glycerol 
  Mixed well, 1ml aliquots 
  Storage: -20° C 
   
DAPI counter stain 125 ng/ml DAPI in the Antifade (Working solution) 
  Storage: -20° C 
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2.1.4 Equipment 
Name Company 
AxioCam HR digital camera Carl Zeiss, Jena, Germany 
Axioplan 2 Imaging microscope Carl Zeiss, Jena, Germany  
Axiovert 200M microscope Carl Zeiss, Jena, Germany 
BioPhotometer 6131 Eppendorf, Hamburg, Germany 
Centrifuge 5417 C Eppendorf, Hamburg, Germany 
Centrifuge 5417 R Eppendorf, Hamburg, Germany 
Centrifuge RC5B Plus  SORVALL®, Langenselbold, Germany 
Centrifuge Rotanta 460R Hettich zentrifugen, Germany 
Centrifuge Super T21 SORVALL®, Langenselbold, Germany 
Electroporator (Easyject Prima)  EquiBio Peqlab, Erlangen, germany 
SunriseTM ELISA reader TECAN group Ltd., Switzerland 
FACSVantage SE System BD Biosciences, Palo Alto, CA 
Film developing machine M35X-OMAT 
Processor  
Kodak AG, Stuttgart, Germany 
Fluorscence microscope Carl Zeiss, Jena, Germany 
Fridge (4°C, -20°C)  Siemens AG 
Fridge (-80°C) UF80-450S  Colora Messtechnik GmBH, Lorch 
Gel electrophoresis systems  Bio-rad, Munich 
Genetic analyzer automated DNA sequencer 
ABI PRISM 3100 
PE Applied Biosystems, Foster City, CA 
GS Gene Linker™ UV Chamber Bio-Rad Laboratories, Hercules, CA 
Hybridization incubator GFL 7601 GFL incubators, Czech Republic 
HYBriteTM Vysis GmbH, Germany 
Incubator (For mammalian cell culture: CO2 
control) 
Heraeus Instruments, Langenselbold, Germany 
Incubator (with shaker): Certomat-R, 
Certomat-H 
Sartorius Stedim biotech GmbH, Göttingen, 
Germany 
Incubator BE 200- Memmert, Schwabach, Germany 
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Name Company 
Innova™ 4400 Incubator Shaker New Brunswick Scientific, Nürtingen, Germany 
Liquid nitrogen tank  Cryoson, Schöllkrippen, Germany 
MagNaPure LC  Roche Diagnostics Mannheim Germany 
Mini Trans-Blot Electrophoretic Transfer Cell Bio-Rad Laboratories, Hercules, CA 
NanoDrop ND 1000 spectrophotometer Thermo scientific, Delaware, USA 
Orbital shaker (KS 250.3 basic) IKA-labortechnik, Germany 
pH-meter 766  VWR International, Ismaning, Germany 
Thermocycler: Cyclone 25 PeQlab, Erlangen, Germany 
Thermocycler: PTC-200 DNA engine cycler MJ Research Inc., Nevada, USA 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Trans-Blot® SD Semi -Dry Transfer Cell Bio-Rad Laboratories, Hercules, CA 
Vortexer  Cenco, Breda, The Netherlands 
Water bath  HAAKE, Karlsruhe 
XCell SureLock™ Mini-Cell Invitrogen Ltd., UK 
X-Ray Automatic Processor Curix 60 Agfa, Köln Germany 
Printer P91D MITSUBISHI, Japan 
Gel Jet imager INTAS  
2.1.5 Software 
Name Company Usage 
ISIS FISH imaging 
system 
Metasystems, Germany For capturing and processing FISH 
images 
MS-Office Microsoft Corporation, 
USA 
For text editing, data analysis and 
graphs generation  
Adobe Photoshop® 7.0 Adobe Systems, 
Unterschleißheim 
Image processing 
EndNote 8.0 Thompson ISI, 
Carlsbad, CA, USA 
Management of bibliography 
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Name Company Usage 
Mac Vector™ 9.0 Oxford Molecular Group Used for primer design, restriction 
enzyme mapping, construct design 
and sequence annotation an 
display 
Sequencher 4.7 Oxford Molecular Group Used for generating sequence 
contigs  
Macromedia Freehand 
11.2 
Freehand Systems, 
USA 
High end illustrations 
CellQuest Version 3.1(f)  BD Biosciences, Palo 
Alto, CA 
Analysis of flow cytometry data  
2.1.6 Culture medium 
2.1.6.1 Tissue culture media 
The following cell culture media were used and handled under sterile 
conditions and stored at 4°C.  
Type of cell culture Medium Company 
Dulbecco ́s Modified Eagle medium 
(DMEM) 
Gibco® Invitrogen cell culture 
Roswell Park Memorial Institute culture 
medium (RPMI 1640) 
Gibco® Invitrogen cell culture 
2.1.6.2 Bacterial culture medium 
LB medium contents: 
 1 %   Tryptone  
 0.5 %  yeast extract  
 1 %   NaCl  
 1.5 %  agar (for plates only) 
   pH 7.0 
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A ready to use mixture of the above components for LB-broth or LB-agar was 
used from Carl Roth GmbH, Germany. An appropriate amount of the powder 
was desolved in d2H2O and autoclaved.  
In order to select transformants, ampicillin, kanamycin or chloramphenicol 
was added to the medium at final concentration of 50 µg/ml, 25 µg/ml or 12.5 
µg/ml, respectively.  The LB-agar medium with antibiotic was poured into Petri 
dishes and stored at 4° C. 
2.1.6.3 Yeast culture medium 
All yeast media and solutions were prepared and handled under sterile 
conditions.  
YPD medium  
 20 g/l  peptone  
 10 g/l  yeast extract  
 20 g/l  agar (for YPD agar plates only)  
 950 ml  d2H2O  
The pH was adjusted to 6.5 (with NaOH), if required followed by autoclaving. 
The medium was allowed to reach approx. 55°C, followed by the addition of 
50 ml of 40 % glucose stock solution (2% final concentration). At the same 
temperature YPD-agar medium was poured into Petri dishes and stored at 
4°C.  
A combination of a minimal SD base and a dropout (DO) solution was used to 
produce a defined minimal yeast medium lacking one or more specific 
nutrients. The nutrients were added separately for each selective SD/DO 
medium according to the desired selection. A 10x stock dropout solution and 
SD medium lacking amino acids adenine, histidine, leucine, and tryptophan 
were prepared as follows. 
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10x DO, -Trp, -Leu, -His, -Ade  SD -Trp, -Leu, -His, -Ade  (per liter) 
200 mg  Arginine 6.7 g  yeast nitrogen base without aa 
300 mg  Isoleucine  20 g  agar (for SD plates only) 
300 mg  Lysine  850 ml  d2H2O 
200 mg  Methionine 100 ml  10X dropout solution  
500 mg  Phenylalanine  (-Trp, -Leu, -His, -Ade) 
2000 mg  Threonine   
300 mg  Tyrosine   
200 mg  Uracil   
1500 mg  Valine   
1000 ml   ddH2O, autoclave   
For SD -Trp, -Leu, -His, 200 mg Adenine was added to 1 l of the SD -Trp, -
Leu, -His, -Ade.   
For SD -Trp, -Leu, 200 mg Adenine and 200 mg Histidine were added to 1 L 
of the SD -Trp, -Leu, -His, -Ade.   
Adjusted the pH to 5.8 when required and autoclaved. Allowed the  medium to 
reach approx. 55°C and added 50 ml of 40 % glucose stock solution. For SD -
Trp, -Leu, -His, -Ade plates supplemented with 3-AT appropriate amount of 1 
M 3-AT stock solution was added to the SD-agar medium, mixed well and 
poured into Petri dishes. The petridishes with SD-agar medium were 
subsequently stored at 4°C.  
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2.1.7 Bacterial strain (Escherichia coli) 
Bacterial 
strain 
Usage Genotype Source 
XL1 Blue Host for plasmid 
amplification 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB 
lacIqZ?M15 Tn10 (Tetr)] 
Stratagene, USA 
JM109 Host for plasmid 
amplification 
endA1,  recA1, gyrA96, thi,  hsdR17 
(rK–, mK+), relA1, supE44, ?(lac-
proAB),  [F´,  traD36, proAB 
lacIqZ?M15] 
Promega GmbH, 
Germany  
SCS110 Host for plasmid 
amplification 
rpsL (Strr) thr leu endA  
thi-1 lacY galK galT ara tonA tsx dam 
dcm supE44 ?(lac-proAB)  
[F´ traD36 proAB 
lacIqZ?M15] 
Stratagene, USA  
2.1.8 Yeast strain 
Strain Reporters 
Transformation 
markers  
Source 
AH 109 
HIS3, ADE2, 
lacZ, MEL1 
trp1, leu2 
BD Biosciences Clontech, Heidelberg, 
Germany 
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2.1.9 Mammalian cell lines 
All cell lines were originally obtained from the Cell Culture Collection from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), 
unless otherwise noted.  
Name Cell type/ Origin  
NIH3T3 Swiss mouse embryo fibroblast  
Ba/F3 
mouse pro B-cells, IL-3 dependent line established from peripheral 
blood   
Phoenix Ecotropic 
Packaging cell line producing gag-pol and envelop proteins for 
ecotropic viruses; derivative of 293T cell line 
293T Human embryonic kidney cell line 
2.1.10 Human sample  
The peripheral blood and bonemarrow samples were obtained from an 18-
year-old female patient diagnosed with acute leukemia in the Laboratory for 
leukemia diagnostics, Klinikum Grosshadern. 
2.1.11 Plasmids 
pBluescript II KS (+/-)  Cloning vector, Stratagene, La Jolla, USA; used as transformation 
control. 
pGEM®-T Easy  Cloning vector with 3’-T overhangs at the cloning site for direct 
cloning of PCR products, Promega, Madison, USA.  
pEYFP-C1  Expressing yellow (YFP) fluorescent proteins, BD Biosciences 
Clontech, Heidelberg, Germany; used as transfection control. 
pMSCV-IRES-GFP  A modified MSCV vector containing a bicistronic expression cassette 
with an internal ribosomal entry site followed by GFP. 
pGBKT7  Shuttle vector, expressing GAL4-DBD (amino acids 1-147) fusion 
proteins in the yeast system, DB Biosciences Clontech, Heidelberg, 
Germany. 
pGADT7  Shuttle vector, expressing GAL4-AD (amino acids 768-881) fusion 
proteins in the yeast system. DB Biosciences Clontech, Heidelberg, 
Germany. 
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2.1.12 Constructs 
Construct Detail Source 
pcDNA3-BCR-ABL Expression construct for BCR-ABL Ying Chen 
pACT2-IKAROS Expressing a GAL4-AD-IKAROS 
fusion protein 
Belay Tizazu 
pGBKT7-AF10 (658-1027) Expressing GAL4-DBD-AF10 (658-
1027) fusion protein 
Belay Tizazu 
pMIY-BCR/ABL1 Retroviral expression construct for 
BCR-ABL 
Dr. Karsten Spiekermann 
2.1.13 Oligonucleotides 
 BCR-ABL1 primers used during the diagnostic screening 
1. diagnostic p190 F 70 5'-ACCATCGTGGGCGTCCGCAAGA-3' 
2. diagnostic p190 R 20 5'-TGATTATAGCCTAAGACCCGGA-3' 
3. diagnostic p210 F 60 5'-GAGCGTGCAGAGTGGAGGGAGAACATCCGG-3' 
4. diagnostic p210 F 40 5'-CCATTTTTGGTTTGGGCTTCACACCATTCC-3' 
 BCR-ABL1 primers used for the sequencing of the aberrant transcript 
5. p190 nested 7i 5'- AGATCTGGCCCAACGATGGCGAGGGC -3' 
6. p191 nested 2i 5'- ATCTCCACTGGCCACAAAATCATACA -3' 
7. p210 nested 6i 5'- GAAGAAGTGTTTCAGAAGCTTCTCC -3' 
8. p210 nested 4i 5'- TGTGATTATAGCCTAAGACCCGGAGCTTTTC -3' 
 Primers for the confirmation of presence of 5'SHIP1/3'ABL1 
transcript 
9. INPP5D-ABL1F997-1015     5'- TTGCTGCACGAGGGTCCTG -3' 
10. INPP5D-ABL1B1474-1454     5'- TCTCCAGACTGTTGACTGGCG -3' 
 Oligonucleotides for the detection of 5'ABL1/3'SHIP1 transcript 
11. ABL1-INPP5D402-421F      5'- CCAAGAAGGGGCTGTCCTCG -3' 
12. ABL1-INPP5D741-721B      5'- GGGATGTAGTCCGCAGAGTCG -3' 
 Oligonucleotides for the cloning of the full length coding sequence of 
SHIP1/ABL1 
13. SHIP-ABL-F20-38       5'- TAAGCTGGTGGCAGCAGCC -3' 
14. SHIP-ABL-B1520-1502   5'- TACTCAGCGGCATTGCGGG -3' 
15. SHIP-ABL1-F38-57       5'- CGAGGCCACCAAGAGGCAAC -3' 
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16. SHIP-ABL1-B1508-1489     5'- TTGCGGGACACAGGCCCATG -3' 
17. SHIP-ABL1-HindIII-MunI-F39-59 5’-GCACAAGCTTCAATTGAGGCCAC 
-CAAGAGGCAACGG-3’ 
 Oligonucleotides for the cloning of full length SHIP1/ABL1 with 5’ 
epitope tags 
18. Hind3-Mun1-Flag-SHIP1No3 5'-GCACAAGCTTCAATTGCCACCATGGACTAC-3' 
19. Hind3-Mun1-Flag-SHIP1No2 5’-TGCCACCATGGACTACAAGGACGACGATGACA-3' 
20 Hind3-Mun1-Flag-SHIP1No1 5'-AGGACGACGATGACAAGATGGTCCCCTGCTGG-3' 
21. Hind3-Mun1-HA-SHIP1No3 5'-GACAAGCTTCAATTGCCACCATGGTCTACCCA-3' 
22. Hind3-Mun1-HA-SHIP1No2 5'-CCATGGTCTACCCATATGACGTCCCAGACTAC-3' 
23. Hind3-Mun1-HA-SHIP1No1 5'-ACGTCCCAGACTACGCTATGGTCCCCTGCTGG-3' 
 Sequencing primers for pGEM-T-easy inserts 
24. pGEM-T-easy SP6 5'-ATTTAGGTGACACTATAGAATAC-3' 
25. pGEM-T-easy T7 5’-TAATACGACTCACTATAGGGCGA-3’ 
 Oligonucleotides used for the sequencing of full length SHIP1/ABL1 
fusion cloned in to the pMSCV-IRES-GFP back bone 
26. pMIG-F-1368-1389     5'-TCCCTTTATCCAGCCCTCACTC-3' 
27. pMIG-B-1572-1548     5'-GCTTCCTTCACGACATTCAACAGAC-3' 
28. [2] pMIG-SHIP-ABL(2)1859-1880     5'-CTGAGGAGGACACAGTAGAAAG-3' 
29. [33] pMIG-SHIP-ABL(33)3175-3194     5'-AAGTGGGAGATGGAACGCAC-3' 
30. [34] pMIG-SHIP-ABL(34)3626-3644     5'-TGAGCAGGTTGATGACAGG-3' 
31. [43] pMIG-SHIP-ABL(43)3980-3999     5'-TCTCAGACGAAGTGGAAAAG-3' 
32. [45] pMIG-SHIP-ABL(45)4287-4308     5'-CAAGAAGAAGAAGAAGACAGCC-3' 
33. [46] pMIG-SHIP-ABL(46)4713-4732     5'-GTTTGACTCGTCCACATTTG-3' 
34. [54] pMIG-SHIP-ABL(54)5148-5165     5'-ATTGTCCAGGCTCAAACC-3' 
36. [60] pMIG-SHIP-ABL(60)5689-5708    5'-GATTCCATCCAGCAAATGAG-3' 
37. [69] pMIG-SHIP-ABL(69)1924-1905     5'-TCAGCGGGATGTTTCTTGGG-3' 
38. [101] pMIG-SHIP-ABL(101)3268-3250     5'-TGTATTTCTTCCACACGCC-3' 
39. [126] pMIG-SHIP-ABL(126)5844-5826     5'-TTCCTTCACCGAACTGAGG-3' 
 Oligonucleotides used for the preparation of bacterial-Yeast shuttle 
vector constructs for Yeast-two-hybrid experiments 
40. SHIP-SH2-BamH1F(161-176) 5'- CTAGGATCCCCTGCTGGAACCATGG -3' 
41. SHIP-SH2-Pst1R(480-465) 5'- GTACTGCAGCTAGCCTGTGTCCTCTTCC-3' 
42. SHIP-D1-EcoR1F(442-457) 5'- GTAGAATTCCTGCAATACCCTGTGC-3' 
43. SHIP-D1-BamH1R(900-886) 5'- GTAGGATCCTAACGTGGACGGAGGCC-3' 
Materials and Methods 
39 
44. SHIP-D2-EcoR1F(829-844) 5'- GTAGAATTCCGGACCCTCCCATCCC-3' 
45. SHIP-D2-BamH1R(1188-1170) 5'- CGAGGATCCTACAGGATTTTCTTGTGGCTG-3' 
46. SHIP-D2-Not1R(1182-1164) 5'- CGAGCGGCCGCTATTTCTTGTGGCTGTAGAAC-3' 
47. SHIP-SH2-Xho1R(480-465) 5'- GTACTCGAGCTAGCCTGTGTCCTCTTCC-3' 
48. SHIP-D2-Xho1R(1182-1164) 5'- CGACTCGAGCTATTTCTTGTGGCTGTAGAAC-3' 
 Primers for the cloning of the SHIP1/ABL1 deletion constructs 
49. Hind3-Mun1-Flag-
SHIPD1No1(460-474) 
5’-AGGACGACGATGACAAGCTGGAGGAAGAGGAC -3’ 
50. Bcl1-SHIPD1 (898-884)B* 5’- GTACTGATCAGTGGACGGAGGCCCG-3’ 
51. Bcl1-ABL1BP(1184-1197)F 5’- CGACTGATCAAAGCCCTTCAGCGGCCA-3’ 
52. SHIP-ABL-Apa1-Spe1-
R1508-1494 
5’- ACAGTGGGCCCTTGCGGGACACAGGC-3’ 
53. HpaI-SHIP-D2 F903-919  5’- GCACGTTAACTCAGGTTCCTGGTGAGG-3’ 
54. Bpu10I-SHIP-D2 F904-921 5’- GCACCCTGAGCAGGTTCCTGGTGAGGCC-3’ 
55. Hind3-Mun1-HA-
SHIPD1No1(460-474) 
5'- ACGTCCCAGACTACGCTCTGGAGGAAGAGGAC-3' 
56. Hind3-Mun1-SHIPD1(463-
478)F 
5'-CAAGCTTCAATTGCCACCATGGAGGAAGAG 
   -GACACAG-3' 
57. HindIII-Mun1-D2-F(829-844) 5'-CAAGCTTCAATTGCCACCATGCGGACCCTC 
  -CCATCCC -3’ 
58. Hind3-Mun1-Flag-
SHIPD2No1 
5’- AGGACGACGATGACAAGCGGACCCTCCCATCCC -3’ 
59. Hind3-Mun1-HA-SHIPD2No1 5'- ACGTCCCAGACTACGCTCGGACCCTCCCATCCC -3' 
 Primers for sequence independent amplification (SIA) 
(Bohlander et al., 1992) 
60. Primer A 5’-TGGTAGCTCTTGATCANNNNN-3’  
61. Primer B original SKB 5'- AGAGTTGGTAGCTCTTGATC-3'  
2.1.14 Antibodies 
Antibody Company Working dilution 
Alexa Fluor 488, donkey-anti-goat IgG (H+L) Molecular probes, Invitrogen 1:100 
Alexa Fluor 488, goat-anti-rabbit IgG (H+L) Molecular probes, Invitrogen 1:100 
Anti-c-Abl (Ab-3) Mouse mAb (24-21) Calbiochem, Merck KGaA, 
Germany 
1:3000 
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Antibody Company Working dilution 
anti-FITC/OG, Rabbit IgG, Alexa fluor 488 
conjugate 
Molecular probes, Invitrogen 1:50 
Anti-Flag M2 Monoclonal (mouse) Sigma-Aldrich, USA 1:3000-5000 
Anti-GAL4 (DBD) (RK5C1), Mouse 
monoclonal IgG2a 
Santa Cruz biotech, USA 1:3000 
Anti-GAL4-TA (C-10), Mouse monoclonal 
IgG2b 
Santa Cruz biotech, USA 1:3000  
Anti-HA-high affinity (Rat monoclonal 
antibody, clone 3F10) 
Roche applied science, 
Germany 
1:3000 
Goat-anti-mouse IgG-HRP conjugated Santa Cruz biotech, USA 1:3000 
Goat-anti-rat IgG-HRP conjugated Santa Cruz biotech, USA 1:3000 
Normal mouse IgG  Santa Cruz biotech, USA 
Normal rat IgG  Santa Cruz biotech, USA 
Used for IP, 2µg for 
400 µg total cell 
lysate 
2.1.15 Bacterial artificial chromosomes 
Clone name Location Source 
RP11-400N9 3' to SHIP1  BACPAC resources center, CHORI, Oakland 
RP11-512N9 5' to SHIP1  " 
RP13-497I2 5' end of SHIP1 " 
RP13-916J2 3' end of SHIP1 " 
RP11-17L7 5' to ABL1, spanning the 
FUBP3 gene 
Prof. Mariano Rocchi, Bari, Italy 
RP11-57C19 5' end of ABL1 BACPAC resources center, CHORI, Oakland 
RP5-1132H12 5' part of ABL1 Prof. Mariano Rocchi, Bari, Italy 
RP5-835J22 3' par of ABL1 " 
RP11-544A12 3' to ABL, corresponds to the 
NUP214 gene 
BACPAC resources center, CHORI, Oakland 
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2.2 METHODS 
2.2.1 Microbiology Techniques 
2.2.1.1 Bacterial cultures 
For routine bacterial cultures the frozen cells from the glycerol stocks were 
streaked out on to LB-agar plates containing appropriate selective antibiotics 
and incubated O/N (over-night) at 37°C to obtain single colonies. A single 
colony was then inoculated in the desired volume of LB medium containing 
appropriate antibiotic and incubated O/N at 37°C in a shaking incubator at 
190 rpm. To prepare competent bacterial cells, LB agar and medium without 
antibiotics were used. 
2.2.1.2 Preparation of bacterial stocks 
850 µl of an overnight bacterial culture was mixed with 150 µl of glycerol and 
stored at -20°C or at -80°C for long-term storage. 
2.2.1.3 Preparation of electro competent bacteria 
A single bacterial colony was inoculated in 10 ml of LB medium and incubated 
O/N with vigorous shaking at 37°C. The O/N culture was diluted into 400 ml of 
fresh LB medium and incubated at 37°C for approximately 2-3 hours until the 
cell density reached an OD600 of 0.5-0.7. In order to stop the bacterial growth, 
the cultures were put on ice immediately. The cells were harvested by 
centrifugation at 4°C. The cells were washed twice with 40 ml ice cold, double 
distilled water (ddH2O), twice with 20 ml ice-cold 10 % glycerol in ddH2O and 
finally resuspended in 800 µl of ice-cold 10 % glycerol in ddH2O. The 
competent cells were aliquoted (40 µl vol.) and stored at -80°C. All 
centrifugation steps were carried out at 4500 rpm (6000 x g) for 5 min at 4°C. 
2.2.1.4 Delivery of plasmid DNA into bacterial cells 
2.2.1.4.1 Electroporation 
Electrocompetent cells (XL1 blue, 40 µl aliquots) (2.2.1.3) were thawed on ice 
for about 5 minutes. 1 µl plasmid DNA (0.1-2.0 ng) or 2-5 µl ligation reaction 
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(2.2.2.4.6) was mixed with the competent cells by gentle pipetting, incubated 
on ice for 1 min and transferred to a pre-chilled electroporation cuvette (2 mm 
electrode gap). The cuvette was placed in an electroporator (Easyject Prima, 
Equibio) and the cells were electroporated at 2.5 kV (12.5 kV/cm, 15 µF, 335 
Ω, 5 ms pulse duration). After electroporation, 1 ml pre warmed LB medium 
(37°C) was immediately added to the cells, the suspension was transferred to 
a fresh 1.5 ml tube and incubated for 1 hr with vigorous shaking (190-210 
rpm) at 37°C.  A 100 µl aliquot from this 1 ml culture was plated onto LB agar 
containing appropriate selective antibiotic (10% plate) and the remaining 900 
µl were briefly centrifuged (3000 g, 2 minutes) to pellet down the cells, 800 µl 
of the supernatant was removed, the cell pellet was resuspended in the 
remaining 100 µl medium and spread onto a second LB agar plate (90% 
plate). The plates were incubated O/N at 37°C. Thus each transformation 
reaction was plated on two plates: one with 10% and the other with 90% 
volume of the reaction. This allowed us to pick single transformant colonies 
even in cases of very efficient transformation experiments with a large number 
of transformants. The transformants were further analyzed either by the so 
called Colony PCR using the DNA obtained after direct thermal denaturation 
of the bacterial cells (2.2.2.4.1) or by restriction enzyme digestion after 
plasmid minipreparations (2.2.2.4.5).  
In case of the pGEM-Teasy constructs, the transformants were initially 
identified by the blue-white selection provided by the pGEM-Teasy vector 
system. The high copy-number pGEM-T easy vectors contains T7 and SP6 
RNA polymerase promotors flanking a multiple cloning region within the α-
peptide coding region of  the enzyme β-galactosidase. Insertional inactivation 
of α-peptide allows recombinant clones to be directly identified by a blue/white 
selection on indicator plates containing IPTG, X-Gal and ampicillin. 
Recombinant clones result in white colonies, because of the insertional 
inactivation of the α-peptide. White colonies were further analyzed either by 
the colony PCR or by plasmid minipreparation and restriction enzyme 
digestion.  
All the PCR fragments generated for construct cloning were first cloned into 
pGEM-Teasy vectors in order to avoid repetitive amplifications in case of 
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experimental failures and to verify the sequences before proceeding with the 
subsequent cloning steps.  
2.2.1.4.2 Transformation of chemically competent bacteria 
For some cloning experiments, highly efficient chemically competent bacterial 
cells were purchased. The transformation was performed largely according to 
the manufacturer’s suggestions. Briefly, the competent cells (strain JM109) 
were thawed on ice for 5-10 minutes. 1 µl plasmid DNA (0.1-2.0 ng) or 2-5 µl 
ligation reaction (2.2.2.4.6) was pipetted in a prechilled 1.5 ml Eppendorf tube 
and 50 µl of the competent cells were added to the tube, mixed by gentle 
flicking, incubated on ice for 20 minutes, heat-shocked at 42°C for 45 
seconds, put on ice for two minutes, and resuspended in S.O.C. medium to a 
volume of 1 ml. The cultures were incubated at 37°C, 190 rpm for 60-90 
minutes. Then 10% and 90% volume of the transformation reactions was 
plated on LB agar containing appropriate antibiotics as described in the 
previous section (2.2.1.4.1).  
2.2.1.5 Delivery of plasmid DNA into yeast cells 
2.2.1.5.1 Preparation of competent yeast cells 
Yeast cells were transformed using the Lithium acetate method. One or more 
yeast colonies (≤ 4 weeks old and more than 2 mm in diameter) were 
resuspended in 1 ml YPD medium, mixed by vortexing and transferred to 20 
ml YPD medium (2.1.6.3), incubated O/N (16-18 hrs) at 30°C and 250 rpm 
(stationary phase OD600 >1.5). The culture was then transferred to 300 ml 
YPD and incubated for approx. 3 hrs until an OD600 of 0.4-0.6 was reached. 
The cells were harvested by centrifugation at 1000 x g for 5 min at RT and 
resuspended in 30 ml of ddH2O. After a second centrifugation step, the 
supernatant was discarded, and the cells were resuspended in 1.5 ml freshly 
prepared 1x TE/LiAc (2.1.3.1). These freshly prepared competent cells were 
used directly for the transformation (2.2.1.5.2). 
2.2.1.5.2 Transformation of yeast cells 
100 µl of the freshly prepared yeast competent cells (2.2.1.5.1) were mixed 
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with 10 µl carrier DNA (10 mg/ml of herring sperm DNA), 100 ng of the 
plasmid to be introduced and 600 µl PEG/LiAc. For the yeast two hybrid 
interaction assay both the bait and the prey plasmids were added together in 
the reaction at a molar ratio of 2:1 (200 ng prey plasmid encoding the GAL4-
DNA-Binding Domain (GAL4DBD) fusion, and 100 ng bait plasmid encoding 
the GAL4-Activation Domain (GAL4AD) fusion). The reaction was incubated 
for 30 min shaking at 30°C (200 rpm). 70 µl DMSO was added and gently 
mixed by inversion. The cells were heat shocked for 15 min in a 42°C water 
bath, chilled on ice for 2 min, pelleted by centrifugation at 14000 rpm (>20000  
g) at RT for 5 sec and resuspended in 1 ml YPD. In order to allow cells to 
recover from the stress, they were incubated for 1 hr at 30°C, shaking at 230 
rpm. After that, cells were washed twice in 1 ml TE buffer (>21000 x g, 5 sec 
at RT) and finally plated on SD plates lacking tryptophan and/or leucine 
(selection for the presence of plasmid expressing the GAL4DBD and GAL4AD 
fusions, respectively) and incubated at 30°C for 2 to 4 days.  Colonies positive 
for both bait and prey plasmids, which were able to grow on the double 
selection plates, were then assayed for protein interaction by re-plating on 
appropriate SD drop out plates. Plates were incubated at 30°C and colony 
growth was monitored for several days. 
2.2.1.6 Preparation of yeast stock 
Glycerin stocks were prepared for long-term storage of the yeast clones. A 
single colony was inoculated into 3 ml YPD medium (2.1.6.3) and incubated 
O/N shaking at 30°C. 1 ml of the O/N yeast-culture plus 300 µl glycerol were 
pipetted into a fresh 1.5 ml cryo tube, mixed by vortexing and stored at -80°C. 
2.2.2 Molecular biology techniques 
2.2.2.1 Plasmid DNA isolation 
Plasmid and BAC DNA was isolated from bacteria using the alkaline lysis 
method (Sambrook, 1989). To obtain plasmid DNA for transfection into 
mammalian cells, the DNA was purified by an affinity column purification step 
using Qiagen kits (2.1.2). 
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2.2.2.1.1 Small scale preparation of plasmid or BAC DNA from E. 
coli 
This method was used to isolate small amounts of DNA (mini prep) from a 
large number of clones simultaneously, i.e., during cloning. First, a single E. 
coli colony was inoculated into 3 ml of LB medium containing selective 
antibiotics and incubated O/N with vigorous shaking at 37°C. From the O/N 
culture, 1.5 ml was centrifuged for 2 min at 8000 rpm (6000 x g) and the 
supernatant was discarded. The pellet was resuspended in 150 µl of P1 buffer 
(2.1.3.2) and the cells were lysed by adding 150 µl P2 lysis buffer (2.1.3.2) 
followed by gentle mixing and 5 min incubation at RT (room temperature). The 
lysate was then neutralized by adding 150 µl of buffer P3 (2.1.3.2), gently 
mixed and incubated on ice for 10 minutes. The reaction was centrifuged for 
10 min at 21000 x g, and the supernatant containing the plasmid DNA was 
transferred to a fresh 1.5 ml tube. The DNA was precipitated by adding 300 µl 
(0.7 vol of the collected supernatant) of  RT isopropanol, mixing and 
incubating on ice for 20-30 minutes followed by centrifugation at 4°C, 19000 g 
for  20 minutes. The DNA pellet was washed with 90 µl 70 % ethanol (10 min; 
19000 x g, 4°C), air dried and dissolved in 50 µl TE. The DNA was stored at -
20°C. 
For the BAC (Bacterial artificial chromosomes) DNA mini preps, the DNA was 
isolated from 4 ml of O/N bacterial cultures following the above mentioned 
protocol using 200 µl of the buffer P1, P2 and P3 and the volume of the other 
reagents was scaled up accordingly.  The BAC DNA minipreps were used for 
the preparation of FISH probes by SIA (Sequence independent amplification) 
and PCR labeling (2.2.5.2.1).  
2.2.2.1.2 Large scale preparation of plasmid from E. coli. 
Endotoxin free plasmid DNA (maxi preparations) were prepared for cell 
culture applications, i.e., delivery of plasmid DNA into mammalian cells 
(2.2.3.3, 2.2.3.4). This was done using the endotoxins free plasmid DNA 
isolation kit from Qiagen according to the manufacturer’s instructions.   
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2.2.2.2 RNA extraction 
Poly-A mRNA was isolated from human blood or bone marrow mononuclear 
cells using the MagNA Pure LC mRNA isolation kit and the MagNa Pure 
instrument from Roche Applied science.  
2.2.2.2.1 Isolation and lysis of mononuclear cells 
Mononuclear cells were isolated by gradient density centrifugation, using the 
Biocoll separating solution (Biochrom AG, Berlin, Germany.) The Biocoll 
separating solution contains Ficoll 400® (Polysucrose 400), a polymer with a 
molecular weight of approx. 400 kD. Ficoll has a higher density than 
lymphocytes or monocytes and a lower density than erythrocytes and 
granulocytes. By centrifugation with Ficoll, the mononuclear cells, which 
include monocytes, lymphocytes and natural killer cells, are enriched in the 
interphase layer between the whole blood/ bone-marrow and the Ficoll 
solution and can be recovered by pipetting.  
To obtain the mononuclear cells, 15 ml of Biocoll separating solution (density 
= 1.077 gm/ml at +20°C) was pipetted into a 50 ml centrifugal tube. In parallel, 
equal amounts of heparinized whole blood or bone-marrow  and phosphate 
buffer saline (PBS) were mixed in another 50 ml centrifugal tube and slowly 
added to the tube containing the Biocoll separating solution with a sterile 10 
ml pipette, taking care not to disturb the Ficoll layer. The tube was centrifuged 
for 20 minutes at 1200 x g at RT to allow the formation of density gradients. 
Using a 10 ml pipette the layer of enriched (70 - 100%) mononuclear cells 
(between plasma and Biocoll) was aspirated and carefully transferred to a 
new 50 ml centrifuge tube. The cells were washed with 1x PBS (10 min at 300 
x g) and a cell count was obtained by a Microcell counter (Sysmex, Germany). 
Aliquots of 5x106 cells were prepared and the cells were immediately lysed in 
300 µl of RLT buffer. The RLT lysates were stored in 1.5 ml centrifuge tubes 
at -80°C until mRNA isolation.  
2.2.2.2.2 Isolation of mRNA 
For mRNA isolation, the RLT lysates were thawed on ice and homogenized 
by passing them through a QIAshredder spin column (Qiagen, Germany) at 
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21000 x g for 2 min. The flow through was used to extract the mRNA by the 
MagNA Pure LC mRNA isolation kit in a MagNa Pure machine (Roche 
Applied science) according to the manufacturer’s instructions.  
The following steps are performed automatically by the MagNa Pure machine, 
the homogenized RLT lysates are mixed with Biotin-labeled oligo(dT) in 
hybridization buffer, to allow the hybridization of the oligo(dT) to the 3’ 
poly(A+) tails of the mRNA. The oligo(dT)-mRNA complexes are removed 
from the solution by Streptavidin-coated-magnetic particles (SMPs), which 
bind to the complex through the Biotin-labeled oligo(dT). Residual genomic 
DNA is removed from the mixture by a DNase I treatment and the 
contaminants are removed by repeated washing steps. The purified mRNA is 
eluted from the mRNA-Oligo(dT)-SMP complexes in elution buffer at 70ºC 
and the Biotin-labeled Oligo(dT)-SMP complexes are removed by a magnet.  
We eluted the mRNA in 30 µl of elution buffer and the yield was determined 
by measuring the RNA concentration with a spectrophotometer for small 
volumes (Nanodrop, Thermo Scientific, Schwerte Germany). The isolated 
mRNA was stored at -80°C until cDNA synthesis. 
2.2.2.3 DNA Analysis and purification 
2.2.2.3.1 Agarose gel electrophoresis 
Non-denaturing gel electrophoresis was employed for DNA separation, which 
was used for both analysis and isolation of the DNA fragments. The agarose 
concentration of the gels was determined according to the desired range of 
separation of linear DNA according to the table shown below: 
Agarose (%) Range of separation of linear DNA Used for 
0.8 500 bp to 15 kb 
1.0 250 bp to 12 kb 
>3.5 kb 
1.2 150 bp to 6 kb 
1.5 80 bp to 4 kb 
1.5 kb to 3.5 kb 
1.8 50 bp to 3 kb 50 bp to 1.5 Kb 
The gel was prepared by boiling the desired amount of agarose in 1x TBE 
buffer (2.1.3.2). After the gel had cooled to approx. 50°C, 3.5 µl Ethidium 
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bromide (Ethidium bromide stock: 10 mg/ml) (2.1.1) was added per 100 ml of 
gel volume. The gel was poured onto a horizontal gel bed. After the gels had 
completely cooled they were transferred into appropriate gel boxes. The DNA 
samples were loaded in the gel slots with loading dye added to 1x final 
concentration (2.1.3.2). Then the DNA fragments were separated by applying 
an electrical field of approximately 700 V/m. Under these conditions the 
negatively charged DNA molecules would migrate to the anode at speeds 
inversely proportional to the length of the individual DNA fragments. The gels 
would typically be run for 1 to 2 hours.  
2.2.2.3.2 Isolation of DNA fragments from agarose gels 
DNA fragments that would be used in subsequent cloning experiments were 
cut out from the gels without exposing them to the UV light of the 
transilluminator. For this, a fraction (indicator sample) of the same DNA 
sample was run in adjacent wells on both sides of the main DNA sample in 
parallel on a gel without Ethidium bromide. After the run, the gel was cut apart 
in such a way that the main sample lane was separated from the flanking 
lanes containing the indicator sample. The gel pieces with the indicator 
samples were stained with Ethidium bromide for approx. 20 minutes. Then the 
desired DNA band was excised from the indicator lanes on the UV 
transilluminator. After this, the gel was reassembled and the cuts in the 
indicator lanes on either side of the gel fragment containing the main sample 
were used to guide the excision of the desired band in the main sample under 
normal light.  
Cutting the DNA fragments (vectors and inserts) in the absence of UV 
increased the cloning efficiency in the subsequent experiments by a factor of 
approximately 1000. The excised gel slice was then transferred to a 1.5 ml 
Eppendorf tube and the DNA fragments were extracted from the gel using the 
Gel Extraction kit from Qiagen (2.1.2) according to the instruction manual. The 
DNA fragments were eluted in 30 µl Elution Buffer provided with the kit. 
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2.2.2.3.3 Determination of DNA and RNA concentration 
DNA concentration was measured with a Nanodrop spectrophotometer by 
using 1.7 µl of the undiluted DNA sample. The purity of the sample was 
determined by the OD260/OD280 ratio. For pure DNA sample this ratio should 
be between 1.8 to 2.0. 
Alternatively, the an Ethidium bromide stained agarose gel was used to 
estimate the DNA concentration. For this, the intensity of the sample DNA 
band was compared to the bands of a DNA maker of known concentration 
loaded on the same gel. The concentration of the band of the marker with the 
same intensity was estimated to be the concentration of the sample DNA. 
2.2.2.4 Enzymatic manipulation of DNA and RNA 
2.2.2.4.1 Polymerase chain reaction (PCR) 
The PCR technique is employed to amplify DNA fragments of interest in an 
exponential fashion. The amplification is achieved using synthetic 
oligonucleotides, so called primers, flanking the sequence to be amplified. 
These primers, under appropriate conditions, anneal to the denatured target 
sequence and, in the presence of a heat stable DNA polymerase enzyme and 
dNTPs, direct the synthesis of a complementary strand of the target 
sequence. As a template 1 µl cDNA (about 10 to 200 ng), 1 µl genomic DNA 
(0.1 to 1 µg) or 0.5 ng plasmid DNA was used. The PCR reactions were 
prepared as follows: 
PCR reagents Amount in µl 
  (Per 25 µl reaction) 
Final concentration 
10X PCR Buffer 2.0 1 x 
50 mM MgCl2 0.6 1.5 mM 
10 mM dNTP mix 0.4 0.2 mM 
10 µM primers F 1.0 0.5 µM 
10 µM primers R 1.0 0.5 µM 
DNA (0.5 ng/µl to 1 µg/µl) 1-5 N. A. 
DNA Polymerase (5 U/µl) 0.1 1U 
ddH2O up to 20.0  
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Alternatively, reactions were scaled up to 50 µl vol. 
The reaction was cycled through a temperature profile in a thermocycler with 
the following basic program: 
The annealing temperatures varied between 42º and 65°C depending on the 
primer pair used and the extension times varied according to the expected 
size of the PCR product allowing about 1 minute extension time per 1000 bp 
of product size.  
For the so called Colony PCR, which was used to identify bacterial clones 
carrying the DNA sequence of interest during the cloning procedure, DNA 
templates were obtained by boiling the bacterial cells at denaturing 
temperature. In detail, a single bacterial colony from an LB-agar plate 
(2.1.6.2) was picked with a tooth-pick, put into 40 µl of TE in an Eppendorf 
tube. The genomic DNA and plasmid DNA was  then liberated by boiling at 
95°C for 10 minutes. The cell debris were pelleted by centrifuging at 16000 g 
for 1 minute and 5 µl from the supernatant was used as a template in the 
colony PCR reaction (typically 20 µl total PCR volume). 
2.2.2.4.2 Tailing of the PCR products amplified by proof reading 
polymerases 
The pGEM-Teasy vector has single 3’-T overhangs at the cloning site, greatly 
increasing the efficiency of ligating PCR products with 3’-A overhangs with the 
plasmid. Thermostable DNA polymerases, such as Taq, Tfl and Tth, generate  
‘A’ overhangs at the 3’ ends of the amplified fragments, providing compatible 
ends for the pGEM-Teasy vectors.  In contrast, thermostable polymerases 
Steps Temperature 
(°C) 
Time (min:sec) No. of cycles 
Initial denaturation 94 4:00 1 
Subsequent 
denaturations 
94 0:45 
Annealing 60 0:45 
Elongation 72 3:00 
20 to 35 
Final elongation 72 7:00 1 
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with proof reading activity (Pfx and Pfu DNA polymerase) generate blunt 
ended fragments during PCR amplification. For efficient ligation of the PCR 
fragments amplified by these proof reading enzymes, 3’-A overhangs have to 
be added to the blunt ended PCR products. This process is called tailing.  
Briefly, for the tailing of the blunt ended PCR products, the products were first 
gel purified and eluted in 30 µl of elution buffer (EB) (2.2.2.3.2). A 40 µl 
reaction containing, 30 µl of the eluted PCR product, 1x PCR buffer, 1.5 mM 
MgCl2, 0.2 mM dNTPs and 1 unit of Taq DNA polymerase was set up. The 
reaction was incubated at 72° C for 15 minutes, chilled on ice and an aliquot 
was used for the ligation reactions. 
2.2.2.4.3 Reverse transcriptase reaction (cDNA synthesis) 
Reverse transcriptase reaction followed by PCR (RT-PCR) is a sensitive 
technique used to determine the presence or absence of specific RNA 
transcript or to quantify the level of gene expression. It is also a useful tool for 
the amplification of genes of interest. In the reverse transcriptase PCR (RT-
PCR), a cDNA strand, complementary to the RNA template is synthesized 
first using random hexamer primers by using the reverse transcriptase. The 
cDNA is then used as template in subsequent PCR reactions.  
Reagents Amt (µl)  
per 50 µl reaction 
Final 
concentration 
100 mM dNTP Mix  4.4 8.8 mM 
5x First-Strand Buffer 
(Supplied with the SuperscriptTM II RNase 
H- Reverse Transcriptase, Invitrogen) 
10.0 1x 
Random Primer p(dN)6 (1µM) 
(Roche diagnostics, Germany) 
2.5 50 nM 
RNasin® RNase inhibitor  
(40 U/µl) (Promega, USA) 
1.25 1 U/µl 
SuperScript II RT (200 U/µl) 
(Invitrogen, Germany) 
1.9 7.6 U/µl 
Template RNA 1-2 µg - 
RNase-free water up to 50 µl - 
For cDNA synthesis, 1-2 µg of the eluted mRNA (2.2.2.2.2.) was denatured at 
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70° C for 7-8 min. The denatured RNA was then added to the reverse 
transcriptase reaction as given in the above table. The reaction mix was 
incubated at 37° C for 60 min to allow for reverse transcription and cDNA 
synthesis. The reaction was stopped by thermal inactivation of the reverse 
transcriptase enzyme at 95° C for 5 min. The cDNA was stored at -20° C. 
2.2.2.4.4 Sequencing 
DNA Nucleotide sequencing was employed to confirm the identity of a clone 
and to check the fidelity of PCR products or of ligation junctions. For all 
sequencing the Sanger chain termination method was used. For most of the 
sequencing, we used a commercial service (“sequiserve", Ebersberg). Some 
of the sequencing was also performed by our molecular biology diagnostic 
group in the Leukemia Diagnostic Laboratory, Med III, Klinikum Großhadern, 
München. The commercial and the in-house sequencing was performed with 
a cycle-sequencing dye-dideoxy chain termination protocol. 
The cycle sequencing reaction consists of successive rounds of denaturation, 
annealing and extension in the presence of polymerase, dNTPs and dye-
labeled terminator dideoxy nucleotides. For the sequencing reaction 4 µl 
BigDye terminator was added to the DNA to be sequenced together with 1 µl 
primer (10 µM) in a 10 µl reaction. 10-100 ng PCR products (0.2-1.5 kb) or 1 
µg plasmid DNA was used as template in each sequencing reaction. The 
reaction was performed in a thermocycler with the following program: 
Steps Temperature (°C) Time (min) No. Of cycles 
Initial denaturation 96 2.0 1 
Subsequent denaturations 96 0.30 
Annealing 50 0.15 
Elongation 60 4.00 
25 
After cycle sequencing had been completed, 10 µl ddH2O was added to reach 
a 20 µl volume. This mixture was passed through a CENTRI Sep column 
(CENTRI Sep 8 well strip, Princeton, USA) at 750 x g for 2 minutes according 
to the manufacturer’s instructions. This step efficiently removes the excess 
dye terminators from the completed DNA sequencing reactions. 10 µl of the 
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purified sequencing reaction was then loaded in a single well of a 96-well 
sample plate of a Genetic Analyzer automated sequencer (ABI PRISM 3100, 
PE Applied Biosystems) for sequence analysis.  
2.2.2.4.5 Digestion of DNA with restriction enzymes 
Restriction endonucleases cut double stranded DNA at a short specific 
nucleotide recognition sequence. These endonucleases are widely used for 
the modification and manipulation of DNA. For site-specific digestion (cutting) 
of DNA, type II restriction endonucleases (enzymes) are required. These 
enzymes are capable of recognizing, binding and cleaving the phosphodiester 
bond at short specific nucleotide sequences within the target DNA. The 
restriction digestion of DNA was carried out with specific buffers that had 
different compositions of salts and buffering agents depending on the 
restriction enzyme used. When multiple enzymes were used, the Five Buffer 
Plus System such as Y+/Tango™ (MBI Fermentas) was used according to the 
manufacturer's recommendation. For single digestion the following 
components were mixed and the digestion was allowed for 2 hrs to O/N at an 
optimal temperature as recommended for each enzyme.  
Digestion reaction: 
Components Amount 
DNA 0.5-1.0 µg   
Appropriate restriction 
enzyme buffer 
1x final concentration 
Restriction enzyme 1-4 units (depending upon the enzyme activity) 
ddH2O  To make up the total vol of  10 µl 
Alternatively, the reactions were scaled up to 50 µl vol. 
2.2.2.4.6 Ligation 
To join DNA fragments after restriction digests in a covalent fashion, ligation 
reactions were used. For the ligations, both vector (V) and inserts (I) having 
compatible ends were prepared by restriction digestion (2.2.2.4.5) and gel 
purification (2.2.2.3.2).  The vector and the insert were used at a molar ratio of 
1:3 (V:I) in the ligation reaction as described in the following table. The 
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reaction was incubated for 1-2 hrs at RT or overnight at 4°C and then stored 
at -20°C. Alternatively, the ligation reactions were incubated in an open ice 
water-filled styrofoam container on the lab bench overnight. The ice would 
slowly melt, and the temperature of the ligation reaction would reach room 
temperature over a course of 12 to 16 hours. 
Ligation Reaction 
Components Amount 
Vector DNA (eg 3 kb in size) 50 ng 
Insert DNA (eg 1.5 kb in size) 75 ng 
T4 DNA ligase buffer  (with ATP) To 1x final concentration 
T4 DNA ligase (5 U/ l) 1 µl 
d2H2O Adjust to 10 µl reaction 
volume 
The ligations of PCR products with the pGEM-T-easy vector (2.1.2) were 
performed according to the manufacturer’s instructions. 
2.2.2.5 Yeast-two-hybrid system 
2.2.2.5.1 Principle 
The yeast-two-hybrid (Y2H) assay is an in vivo technique for the detection of 
protein-protein interactions. This technique is based on a transcriptional assay 
for the detection of protein-protein interactions in yeast. In yeast, GAL80 and 
GAL4 are the two regulatory proteins in galactose metabolism. When 
galactose is present, the GAL4 protein binds to GAL4 responsive elements 
(called Upstream Activating Sequences or UAS) upstream of several genes 
involved in galactose metabolism and activates transcription. When galactose 
is absent, the GAL80 protein binds to GAL4 and blocks GAL4-mediated 
transcriptional activation. The tight regulation of the GAL UASs by GAL4 
makes it an important tool for controlling the expression of reporter genes in 
the Y2H system. This technique can be used to confirm expected interactions 
between two known proteins or to discover an unknown interacting partner 
(prey) of a known protein (bait). If the two proteins interact, the transcription of 
a reporter gene is activated (Figure 2.1). 
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The Y2H system is based on the fact that transcription factors bind to specific 
DNA sequences in the promoter region of genes and then activate the 
transcription of these genes. For example, GAL4 regulates galactose 
metabolism by binding to the UAS in the promoter regions of genes involved 
in galactose metabolism. When the GAL4 protein binds to GAL4-UASs, the 
downstream genes are activated and transcribed. The GAL4 protein consists 
of two important domains: a DNA binding domain (GAL4-DBD) by which it 
binds to the UAS and a transcription activation domain (GAL4-AD), which 
activates the transcription of downstream genes.  
 
Figure 2.1: The Yeast-two-hybrid system. The DBD is amino acids 1-147 of 
the yeast GAL4 protein, which binds to the GAL4 UAS upstream of the reporter 
genes. The AD is amino acids 768-881 of the GAL4 protein and functions as a 
transcriptional activator. If the proteins fused to the DBD and the AD portion 
interact the transcription of the reporter gene is turned on. 
2.2.2.5.2 Adjusting for background HIS3 reporter gene expression 
In the yeast strain AH109, which was used for the Y2H assays, the complete 
HIS3 promoter (including both TATA boxes) is replaced by the entire GAL1 
promoter, leading to tight regulation of the HIS3 reporter. However, the 
expression of some GAL4-DBD-bait proteins produces background growth on 
SD plates lacking tryptophan and  histidine (SD/-Trp/-His) plates because of a 
low amount of HIS3 expression. The effect of this low level HIS3 expression 
on the SD/-Trp/-His plates can be suppressed with  3-aminotriazol (3-AT), a 
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competitive inhibitor of the enzymatic activity of the HIS3 protein. The 
concentration of 3-AT in the SD medium, required to suppress the effect of 
the low level HIS3 expression, was titrated by plating the transformed yeast 
cells on SD/-Trp/-His plates containing 0, 3, 5, 10, 15, and 20 mM 3-AT. The 
lowest concentration of 3-AT, which after one week, allowed small colonies to 
grow was then used in the Y2H assays.   
2.2.2.5.3 Yeast two hybrid assay 
For Y2H assays,  the coding sequence for the bait and the prey proteins were 
cloned into pGBKT7 and pGADT7 vectors separately to generate GAL4DBD 
and GAL4AD fusion genes, respectively. The two constructs were then used 
to co-transform the yeast strain AH109 (2.2.1.5.2) and the co-transformants 
were identified by plating the transformations onto SD plates lacking 
tryptophan and Leucine (SD/-Trp/-Leu), which are the selection markers on 
the pGBKT7 and pGADT7 plasmids, respectively. The double transformants, 
were replated on SD/-Trp/-Leu/-His plates (2.1.6.3) containing the appropriate 
concentration of 3-AT (2.2.2.5.2) to assess the potential interaction between 
the bait and the prey proteins by monitoring colony growth. Alternatively, SD/-
Trp/-Leu/-His/-Ade plates can also be used for more stringent experimental 
conditions, because the additional activation of the reporter gene ADE2 is 
required for colony growth. Those bait prey combinations that showed 
interaction under the most stringent experimental conditions, were later 
verified in co-immunoprecipitation experiments. 
2.2.3 Cell culture techniques 
2.2.3.1 Cultivation of mammalian cells 
All the mammalian cell lines used in the study  were cultivated in CO2 
incubators  at 37°C in presence of  95% relative air humidity and 5% CO2.  All 
the cell culture media used in the study (2.1.6.1) were supplemented with 
10% fetal calf serum (FCS) and penicillin-streptomycin (final concentration: 
penicillin: 100 U/ml and streptomycin: 100 µg/ml). 
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2.2.3.1.1 Cultivation of adherent cells  
All the adherent cell lines were grown in complete Dulbecco’s Minimum 
Essential medium (DMEM) under abovementioned conditions. For harvesting 
the adherent cells, the confluent cultures were washed once with pre-warmed 
(37°C) phosphate buffered saline (PBS) and treated with trypsin-EDTA (2.1.1) 
at 37°C for 5 minutes to achieve detachment of the cells from the surface of 
the culture flask and separation of the cells from each other. Adding complete 
DMEM stopped the activity of the trypsin and the cell suspension was either 
used for subculturing or for the preparation of frozen stocks. The cell lines 
were propagated and maintained by dividing the confluent cultures at a ratio 
of 1:3, 1:5 or 1:10 every 3-5 days depending on the growth characteristics of 
the cell lines.  
2.2.3.1.2 Cultivation of suspension cells  
The suspension cells used in the study (WEHI and Ba/F3) were cultivated in 
complete RPMI-1640 medium in the culture conditions mentioned above. For 
the IL-3 dependent murine pro-B cell line Ba/F3, the complete RPMI-1640 
was supplemented with 10% IL3 (WEHI) conditioned medium (2.2.3.1.3) as a 
source of murine IL3. Alternatively, recombinant murine IL3 (rmIL3) was used 
at a final concentration of 10 ng/ml. The Ba/F3 cell cultures were divided at a 
ratio of 1:5 or 1:10 every 2-4 days.  
2.2.3.1.3 Preparation of IL3 conditioned medium 
The murine myelomonocytic leukemic cell line WEHI-3B produces IL-3, which 
was used to supplement the growth medium for the Ba/F3 cells. The WEHI-
3B cells grow adherently and partially in suspension and are very sensitive to 
trypsin. To obtain the IL3 conditioned medium, WEHI-3B cells were grown in 
complete RPMI-1640 medium (2.1.6.1) and as they are trypsin sensitive, 
while sub-culturing and freezing, the cells were incubated with DPBS (without 
Ca2+ or Mg2+) for 10 minutes at 37°C and detached from the surface of the 
culture flask with the help of scrapers. The cells were then sub-cultured at a 
1:5 ratio every 3-5 days. The supernatant from the confluent cultures was 
filtered through a 0.22 µm pore size filter (Millipore, USA) and stored at -20°C 
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until used to supplement the culture medium for the IL-3 dependent Ba/F3 
cells. 
2.2.3.2 Freezing and thawing of cells 
Mammalian cells can be maintained for years by storing them in liquid 
nitrogen. They can be revived by proper thawing. For freezing, approximately 
1x107 cells were pelleted, resuspended in 1 ml of fetal calf serum containing 
10% vol DMSO (dimethyl sulphoxide) and transferred in a 1.5 ml cryotube 
(Nunc, Roslilde, Denmark). DMSO serves as a cryoprotective agent and is 
used to minimize the cellular injury induced by the freezing and thawing 
procedures. The cryotubes were then put in a cryo freezing container 
(NALGENTM, USA) in a -80° C freezer to gently freeze cells at a cooling rate 
of about 1° C/min. While short-term preservation of cell lines at -80°C is 
possible, storage in liquid nitrogen (-196°C) or its vapor (-120°C) is much 
preferred.   
For optimal recovery and viability of the cells, rapid thawing is essential. 
Therefore, the cells were thawed quickly in a 37°C water bath and, as DMSO 
in the freezing medium are toxic to the cells, the cells were subsequently 
washed by diluting them with 10-20 ml of DPBS or culture medium and 
centrifugation at 1000 rpm (~300 x g) for 5 min. The supernatant was 
discarded and the pellet resuspended in fresh culture medium. All the thawed 
cell lines were cultured for 3 days (split once) before being used for 
experiments.  
2.2.3.3 Transient transfection of adherent cells 
Different mammalian cell lines exhibit greatly varying transfection efficiency. 
The HEK293 cells (derived from human embryonal kidneys) can be 
transfected with high efficiency. Hence, these cells were transiently 
transfected for the overexpression of proteins. Transient transfection of 
adherent cells was performed by either using the cationic polymer, 
polyethylenimine (PEI), as a transfection reagent or using the CaPO4 
precipitation method. The day before the transfection, 1.5-2 x 106 cells were 
seeded in a 10 cm plate with 10 ml of appropriate complete growth medium. 
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The cells were then incubated for 16-24 hrs at 37°C in a CO2 incubator until 
they were about 70 % confluent. For the transfection using the cationic 
polymer, 10 µg of plasmid DNA (2.2.2.1.2) + 400 µl plain medium (DMEM 
without any supplements) and 15 µg PEI (2.1.1) were mixed thoroughly and 
incubated at RT for 10-60 min to allow DNA-cationic polymer complex 
formation. Meanwhile cells were washed once with DPBS and 3 ml antibiotic-
free medium with serum was added to the cells. The DNA-polymer complexes 
were added to the cells and the DNA was allowed to enter the cells by 
endocytosis at 37°C, 5% CO2 for about 16 hours (usually overnight). Then 7 
ml of complete growth medium was added to the cells, which were incubated 
for another 20-48 hrs. After that, cells were harvested for protein extraction 
(2.2.4.1). The CaPO4 transfection method was mainly used to obtain virally 
conditioned medium (2.2.3.4.1). 
2.2.3.4 Preparation of stably transduced Ba/F3 cells 
To establish stably transduced Ba/F3 cell-lines, the gene of interest is cloned 
into a retroviral expression vector and expressed in fibroblast cell line in 
presence of retroviral packaging proteins (packaging cell line), to obtain a high 
titer viral supernatant which is then used to transduce the Ba/F3 cells. 
2.2.3.4.1 Production of high titer virally-conditioned medium 
For the production of high titer retroviral supernatant, the ecotropic retroviral 
packaging cell line Phoenix Eco (2.1.9) was transiently transfected with the 
DNA of interest using the calcium phosphate precipitation method. 12-15 x 
106 Phoenix Eco cells were plated in a 15 cm dish, one day prior to the 
transfection and the medium was replaced with fresh medium 4 hours prior to 
the transfection. Per plate 30 µg of plasmid DNA of interest and water were 
mixed to make a total volume of 900 µl in a tube followed by drop wise 
addition of 100 µl of 2 M CaCl2 to the DNA-water mixture.  This mixture was 
then added drop wise to 1 ml of 2x HBS, pH 7.0 and mixed gently followed by 
incubating at room temperature for 3-4 minutes. After incubation, this mixture 
was added drop wise to the cultures covering the whole plate and distributed 
evenly by gently swirling the plate,  taking care not to disturb the monolayer. 
After 14-16 hours, the medium was changed. After an additional 24 hours the 
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first supernatant containing retroviral particles carrying the gene of interest 
(virally conditioned medium, VCM) was collected and fresh medium was 
added to the cells. This procedure of VCM collection and medium addition 
was repeated two more times at intervals of 10-12 hours. The VCMs were 
stored at -80° C until used for viral transduction of the Ba/F3 cells (2.2.3.4.2).  
2.2.3.4.2 Stable transduction of Ba/F3 cells 
For the preparation of stably transduced Ba/F3 cells, the appropriate VCM 
aliquot (2.2.3.4.1) was thawed and filtered with 0.45 µm pore size Millipore 
filter. 1.5 ml of the filtered VCM was mixed with 1.5 ml of Ba/F3 cell 
suspension containing 7.5 x 105 cells and 30 µg (final concentration 10 µg/ml) 
Protamine sulphate. This mixture (3 ml in total) was put in one well of a 6-well 
plate. The pipetting scheme was scaled up accordingly, when more than one 
well was used.  The cells were allowed to express green or yellow 
fluorescence protein from the transduced retroviruses and expanded to 
establish a stable cell line with repeated rounds of fluorescence activated cell 
sorting (FACS).   
2.2.3.4.3 Establishment of the stable Ba/F3 cell line by FACS 
sorting  
4-6 days after the viral transduction of Ba/F3 cells, the cells expressing 
YFP/GFP were sorted using the Vantage SE Flowcytometer equipped with a 
turbo-sort DEVICE (capable of sorting 20,000 cells/s), and the Cellquest 3.3 
software. For cell sorting, cells were pelleted at 1000 rpm (~300 x g) for 10 
minutes and resuspended in 1 ml of FACS buffer (2% FBS in PBS + 
Propidium iodide at a final concentration of 1 µg/ml). The sorted YFP/GFP 
positive cells were expanded and resorted if required to attain > 95% purity. 
The established stably transduced Ba/F3 cells carrying the gene of interest 
were stored frozen at -80°C or in liquid nitrogen for long-term storage 
(2.2.3.2), until used for further experiments. 
2.2.3.5 Determination of cell viability 
Determination of viable cell number is an important aspect of cell culture 
especially for seeding the cells and for proliferation experiments. We mainly 
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used the following two methods for the determination of the number of viable 
cells. 
2.2.3.5.1 Trypan blue exclusion assay 
Trypan blue stain distinguishes viable cells from non-viable cells. Viable cells 
actively exclude the stain, whereas the non-viable cells absorb the stain. For 
the determination of the number of viable cells, the cell suspension was 
diluted with trypan blue at a ratio of 1:1 to 1:9 (cell suspension:trypan blue) 
and the numbers of viable (unstained) cells in a 4 x 1 mm2 area (4 x 100 nl of 
the diluted cell suspension) were counted with the help of a Neubauer 
haemocytometer under a phase contrast microscope. The total number of 
viable cells per ml of the cell suspension (non-diluted) was calculated using 
the following formula. 
 
2.2.3.5.2 MTT assay 
As an alternative to the trypan blue exclusion assay, the MTT was also used 
to determine cell viability and cell number. The MTT viability test is a 
colorimetric assay based on the metabolism of a yellow Tetrazole salt, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromid (MTT), to an insoluble 
purple formazan salt by an enzyme produced in the mitochondria of living 
cells. The purple insoluble formazan crystals are disolved in a solubelization 
solution (0.04 M HCl in isopropanol or 10% acidified SDS). The cell viability is 
then quantified by the absorption of the colored cell suspension measured 
with the help of ELISA reader at 570 nm with reference to the absorption at 
650 nm. 
We used the MTT assays for studying the sensitivity of the SHIP/1ABL1 
fusion protein to the ABL1 tyrosine kinase inhibitor, Imatinib. For these 
assays, the cells were seeded at a density of 4x104/ml without IL3 and with or 
without Imatinib at different concentrations in quadruplicates in a micro-titer 
96-well plate (100 µl/well). After 48 or 72 hours 10 µL of MTT (stock: 5 mg/ml) 
was added per well and the cells were incubated for 4 hours. The reaction 
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was stopped by adding 200 µL of 0.04M HCl in isopropanol to each well and 
the purple crystals were dissolved by vigorous pipetting. The viability was 
measured by determining the OD with the help of a SunriseTM ELISA plate 
reader (TECAN, Switzerland). 
2.2.3.6 Cell proliferation assay 
Proliferation assays allow the determination of the number of proliferating 
cells in the presence or absence of certain factors affecting the proliferation, 
i.e., cytokines or inhibitors. We performed proliferation assays with Ba/F3 cell 
lines, to study the proliferative potential of the genes being studied and to 
demonstrate their sensitivity to the ABL1 tyrosine kinase inhibitor, STI571 
(Imatinib, Novartis). For these assays, Ba/F3 cells were seeded at a density of 
4 x 104 cells/ml in the presence or absence of IL-3, or inhibitors as required. 
The number of viable cells was determined either by the Trypan blue 
exclusion method or using the MTT assay at 24, 48 and 72 hours. To study 
the sensitivity of the genes of interest to Imatinib, the cell viability was 
assayed after 72 hours by MTT method. The concentration of STI517 at which 
50% of cells were viable compared to cells grown in the absence of inhibitor, 
defined as IC50Imatinib was also determined after 72 hours. All proliferation 
assays were performed in triplicates or in quadruplicates and repeated three 
times to confirm the reproducibility. 
2.2.4 Protein Biochemistry  
2.2.4.1 Protein extraction from mammalian cells 
Protein extraction from transiently transfected and non-transfected native 
HEK293T cells and the stably transduced and non-transduced Ba/F3 cells 
was performed as follows. The cells were harvested and washed twice in ice-
cold PBS (600 g for 5 min). The cell pellets were resuspended in an 
appropriate volume of lysis buffer No. I (2.1.3.4). A protease inhibitor cocktail 
(Sigma) and 0.1 M orthovanadate were added fresh to the lysis buffer at 
1:100 ratio (for a final concentration of 1 mM orthovanadate). To allow 
optimum lysis, the lysis reactions were incubated at 4° C for 30 min with 
gentle agitation (10 rpm). After the incubation, the whole cell extracts were 
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cleared by centrifugation at 16 000 g for 10 min at 4º C. The supernatant 
containing most of the soluble cellular proteins was transferred into a new 
tube and stored at -80° C until further studies. 
2.2.4.2 Protein extraction from yeast cells 
Yeast cells growing in log phase, at a density corresponding to an OD600 of 
0.4-0.5 were used for protein extraction. After attaining the desired cell 
density, 10 ml of the culture was immediately put in a prechilled tube 
containing approximately the same amount of ice. The tubes were then 
centrifuged at 1000 g and 4° C for 5 minutes followed by resuspension of the 
pellet in 10 ml of ddH2O and the centrifugation step was repeated one more 
time. The yeast cell pellet was resuspended in 100 µl of TCA buffer (2.1.3.4) 
per OD600 units of cells and was transferred into a 1.5 ml Eppendorf tube 
containing a mix of 100 µl glass beads (2.1.1) and 100 µl 20% TCA (2.1.3.4) 
for each 7.5 OD600 units of cells. To disrupt the cells, the tubes were vortexed 
for 1 minute 4 times at RT. To keep the temperature low the tubes were put 
on ice for 30 sec between each vortexing. Then the tubes were put on ice for 
5 minutes to let the glass beads settle down, and the supernatant was 
collected in a prechilled fresh Eppendorf tube. The glass beads were then 
washed by adding 500 µl of 1:1 mixture of 20% TCA and TCA buffer and 
vortexing twice for 1 min at RT and putting them on ice for 30 sec in between 
each vortexing. The glass beads were allowed to settle down. The 
supernatant was then pooled with the previously collected supernatants. The 
proteins in the collected supernatant pools were pelleted down at 16000 g at 
4° C for 10 min.  The protein pellet was resuspended in 10 µl of Laemmli 
loading buffer per 1 OD600 unit of cells and denatured at 100° C for 10 min. 
The samples were centrifuged at 16000 g  for 10 min at RT and the 
supernatant containing the proteins were collected in a new tube and stored 
at -80° C until further use. 
2.2.4.3 Protein quantification 
The protein concentration in cell lysates was determined by the Bradford 
method (Bradford, 1976), which is a colorimetric protein assay. The principle 
of this assay is based on an absorbance shift in the Coomassie dye, when the 
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red form of the dye changes and stabilizes into a blue form, Coomassie blue, 
by binding to protein. Thus the concentration of the total protein in the lysate 
can be measured by reading the absorbance at 595 nm with a spectro-
photometer.  
For the measurement of the protein amount, a standard regression curve was 
established first by preparing a series of protein dilution using BSA (stock: 1 
µg/µl in ddH2O) at a known concentration  as follows: 
BSA (µl) 0 1 5 10 15 20 25 
d2H2O (µl) 800 799 795 790 785 780 775 
Bradford reagent (µl) 200 200 200 200 200 200 200 
In parallel, for each protein lysate, 1 µl of the lysate was diluted in 799 µl of 
ddH2O followed by the addition of 200 µl of Bradford reagent and mixing. The 
measurements were performed with an Eppendorf BioPhotometer 6131. 
2.2.4.4 Immunoprecipitation 
Immunoprecipitation is a technique in which a known protein is precipitated 
from a solution containing many different proteins (typically a cellular lysate) 
using an antibody that is specific for that particular protein. We used this 
technique to study the homotypic di- or oligomerization of our fusion protein. 
For immunoprecipitation, 400 µl of total cell lysate were incubated with 
approximately 5 µg of the specific anti-body at 4° C for 3 hours with 
continuous gentle agitation at 15 rpm. This was done in order to form specific 
protein-anti-body complexes. In parallel, a control reaction was set up in 
which, 400 µl of the total cell lysate was mixed with 2 µg of non-specific anti-
IgG antibody and allowed to form protein-antibody complexes. Mean while 40 
µl of Protein A- or G-Agarose beads were prepared (washed). For the 
washing of the beads, 40 µl of chilled PBS was added to the 40 µl of bead 
slurry and centrifuged at 1600 rpm  (300 g) and 4° C for 5 min. The 
supernatant was carefully removed and this procedure was repeated once 
more followed by an additional wash with the lysis buffer mix  used for cell 
lysis. The washed beads were then added to the protein-antibody complexes 
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(obtained after 3 hours of incubation) and the reactions were incubated for 1.5 
hours at 4° C with gentle agitation at 11 rpm. This allows protein-antibody-
agarose beads complexes to form. After the incubation these complexes were 
washed three times with 1 ml of the lysis buffer No. 1 to remove unbound or 
weakly bound proteins  at 1600 g, 4° C for 5 min. After the last wash, the 
complexes were resuspended in 20 µl of 2x Laemmli loading dye and 
incubated at 95° C for 5 min. This releases the proteins from the anti-body-
agarose beads complexes. After denaturation at 95°C, the tubes were briefly 
centrifuged to settle down the beads and the supernatant containing the 
precipitated proteins was loaded on an SDS-PAGE gel.   
2.2.4.5 Polyacrylamide gel electrophoresis (PAGE) 
An SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their molecular weight under denaturing 
conditions. SDS-PA gels of appropriate concentration of polyacrylamide were 
prepared depending on the size of the proteins to be separated. We mainly 
used 8%, 10% and 12% gels. The SDS-PA gel is prepared in two layers of gel 
of two different concentrations. These layers are known as separating gel and 
stacking gel. As its name says, the separating gel separates the proteins and 
the stacking gel concentrates the proteins as a thin band before they enter the 
separating gel. This results in sharper protein bands in the separating gel. The 
separating gel is poured first and then the stacking gel is poured on top of the 
separating gel. The polyacrylamide concentration of the stacking gel is always 
the same (5% ). For the preparation of both gels the following reagents were 
mixed as follows: 
Separating Gel 
For 1 Gel (5 ml) 8 % Gel 10 % Gel 12 % Gel 
ddH2O 2.3 ml 1.9 ml 1.6 ml 
30 % Acrylamide mix 1.3 ml 1.7 ml 2.0 ml 
1.5 M Tris/HCl (pH 8.8) 1.3 ml  1.3 ml 1.3 ml 
10 % SDS 50 µl  50 µl 50 µl 
10 % APS 50 µl  50 µl 50 µl 
TEMED 3 µl  2 µl 2 µl 
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 Stacking Gel 
For 1 Gel (2 ml)  5 % Gel 
ddH2O 1.4 ml 
30 % Acrylamide mix 330 µl 
1 M Tris/HCl (pH 6.8) 250 µl  
10 % SDS 20 µl  
10 % APS 20 µl  
TEMED 2 µl  
TEMED and APS were always added last to the gel mixtures and just before 
the gel was poured. The separating gel mix was poured first into the gel 
cassette (2.1.2) and allowed to polymerize at RT. After the polymerization of 
the separating gel, the stacking gel mix was prepared and poured on top of 
the polymerized separating gel. Then the comb was positioned in the upper 
portion of the stacking gel to form the loading wells. The total cell lysates or 
immunocomplexes were denatured by boiling at 95°C for 5 minutes in SDS-
Laemmli buffer. The SDS-Laemmli buffer confers a negative charge to each 
protein in proportion to its mass, resulting in the movement of the protein 
towards the anode (+) at a speed that is roughly proportional to the molecular 
weight of the protein in a specific weight range. The proteins were resolved by 
applying 60-120 V (1 kV/m) for 4-8 hours at 4°C in 1x Tris-Glycine 
electrophoresis buffer (2.1.3.4). 10-50 µg of each protein sample was loaded 
in each well. A commercial protein size marker (See blue plus 2, Invitrogen) 
was also loaded so that the molecular weight of the proteins could be 
estimated.  
2.2.4.6 Western blot analysis 
After the separation of the proteins by SDS-PAGE, the proteins in the gel 
were transferred to an activated Polyvinylidene Fluoride (PVDF) membrane 
using a wet transfer system (Mini Trans-Blot Electrophoretic Transfer Cell, 
Bio-Rad). The transfer assembly was prepared according to the 
manufacturer’s instruction. Briefly, a sandwich of the provided fiber pad-filter 
paper-the membrane- the gel-filter paper-fiber pad (all soaked in transfer 
buffer) was placed in the transfer cell filled with chilled transfer buffer. A 
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cooling element (called "ice bucket") was also placed in the transfer cell. The 
transfer of the proteins from the gel to the membrane occurred under 350 mA 
constant electric current from the negative to the positive pole at for 1.5 hours.  
After the transfer, the membranes were incubated in blocking solution (5 % 
nonfat dried milk in TBST) for 1 hr at RT (alternatively, O/N at 4°C) to block 
nonspecific binding sites. Immunoblotting was carried out with specific 
antibodies diluted in 5 % nonfat dried milk in TBST. The dilution of the primary 
antibody varied depending on the antibodies used (2.1.14). The incubation 
with the primary antibody was carried out for 1 hr at RT (alternatively, O/N at 
4°C) in most cases and was followed by extensive washing with TBST 
washing buffer (2.1.3.4) (rinsed twice, wash 3 x 5 min at RT). Secondary 
antibodies conjugated to horseradish peroxidase (HPR) were used for the 
detection of the primary antibody. The membranes were incubated for 1 hour 
at RT followed by extensive washing with TBST buffer as described above. 
Finally, the secondary antibodies were detected by incubating the membrane 
with enhanced chemiluminescence reagent for 3- 5 min at RT (ECL, 
Amersham Pharmacia biotech). The membranes were then placed in an X-ray 
film cassette and autoradiography films were exposed for 5 sec to 10 min. In 
order to probe the same membrane with a different antibody, the immunoblots 
were stripped. Immunoblots were stripped by incubating in stripping solution 
at 56° C for 30 min, followed by two washes in TBST buffer for 10 min at RT. 
The membranes were then blocked again and probed with a different primary 
antibody.   
2.2.5 Cytogenetic Techniques 
2.2.5.1 Conventional Cytogenetics 
Conventional cytogenetic techniques are mainly used for the preparation of 
chromosomes from different tissues and the study of genetic aberrations at 
the chromosome level. 
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2.2.5.1.1 Short-term culture of human bone marrow and blood 
samples 
An appropriate amount of  blood or bone marrow sample containing  0.4 -1.0 
x 107 lymphocytes was added to 5 ml of RPMI-1640 medium with 20% FBS 
and 1% antibiotic-antimycotic solution (Gibco, Invitrogen: 10,000 U/ml 
Penicillin G sodium, 10,000 µg/ml Streptomycin sulphate, 25 µg/ ml 
Amphotericin B in 0.85% saline). The cells were allowed to grow for 24 hours 
in a closed culture system at 37° C. After 24 hrs of incubation, colcemid 
(stock: 10 µg/ml) was added to the cultures to a final concentration of 300 
ng/ml and the cells were harvested after 2 more hours of incubation. To obtain 
a high mitotic index, the cells could also be harvested 24 hrs after the addition 
of colcemid. 
2.2.5.1.2 Harvesting and fixation 
After the incubation with colcemid, the cells were pelleted down at 700 x g for 
10 min at RT. The cell pellet was gently resuspended with 6 ml of pre-warmed 
hypotonic solution (0.075 M KCl) and incubated at 37° C for 15-20 min. The 
cells were centrifuged at 600 x g for 10 min at RT and resuspended very 
gently by drop wise addition of Carnoy’s fixative (1:3; acetic acid:methanol). 
The fixed cells were incubated at 4° C or -20° C for 30 minutes followed by 
several washing steps with the fixative to remove cell debris. The 
centrifugation for the washing was done at 700 x g for 7 min at 4° C.  
2.2.5.1.3 Preparation of metaphase spreads 
After the last wash, the cell pellet was resuspended in about 1 ml of fixative 
and mixed gently. The fixed cell suspension was then dropped (4-6 drops) 
onto a clean-chilled- wet slide held at an angle of about 45°. The cells were 
allowed to roll over the surface of the slide. The cell suspension was then 
allowed to dry evenly by keeping the slide horizontal, thus the cells burst and 
the metaphase spreads were obtained by surface tension. Optimum 
spreading of the chromosomes can be obtained by controlling the speed of 
the drying by using a hot plate or a humidified chamber. For fluorescence in 
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situ hybridization (FISH), the slides were aged at least for 1 day and then 
stored at -20° C if not used immediately.  
Cytogenetic preparations were obtained from cultured cell lines in a similar 
way with slight modifications in the protocol. 
2.2.5.2 Fluorescence in-situ hybridization 
Fluorescence In-Situ hybridization (FISH) allows the localization of specific 
fluorescently labeled DNA sequence in interphase nuclei or on metaphase 
chromosomes. Among other things, this technique is used to characterize and 
analyze chromosomal aberrations and fine map translocation breakpoints. 
2.2.5.2.1 Probe preparation 
We prepared “dual color dual fusion” (DCDF) FISH probes (Figure 2.27 A, B) 
for the detection of the SHIP1/ABL1 rearrangement. The FISH probes were 
prepared from selected Bacterial Artificial Chromosome (BACs) from the 
SHIP1 and ABL1 locus (2.1.15 )by “Sequence independent amplification” 
(SIA).  
2.2.5.2.1.1 Sequence independent amplification (SIA) of BACs-DNA. 
To generate sufficient quantities of BAC DNA for the preparation of FISH 
probes, we used the technique of Sequence Independent Amplification (SIA) 
(Bohlander et al., 1992). By SIA, we converted the small amounts of BAC 
DNA that were obtained from mini preparations (3 to 6 ml culture volume of 
the low copy BACs) into PCR amplifiable DNA fragments that could be 
labeled conveniently. 
The SIA technique was originally developed to amplify extremely small 
amounts of DNA from micro dissected chromosome fragments to generate 
chromosomal band specific DNA libraries or chromosome band specific FISH 
painting probes (Bohlander et al., 1992). 
In this method, short random DNA fragments (200 to 1500 bp in length) from 
the input DNA are flanked by a known primer (Primer A) sequence (2.1.13). 
This is called “preamplification”. The random DNA fragments flanked by the 
known 5’ sequence introduced by primer A are then amplified with a normal 
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PCR using Primer B (2.1.13). Primer B has the defined sequence of Primer A 
at its 3’ end and additionally 5 nucleotides at the 5’ end (Figure 2.2). 
 
Figure 2.2: Diagram of SIA principle 
The flanking of the DNA fragments with the primer sequences and the 
subsequent PCR amplification are performed in a single Eppendorf tube. The 
procedure is described in detail in the following paragraphs. 
After an initial denaturation, a special primer (primer A) (2.1.13) is annealed to 
the single stranded template DNA. Primer A has a random pentanucleotide 
sequence at its 3’ end and is capable to anneal in a sequence independent 
fashion to single stranded DNA with this 3’ end. The 5’ end of Primer A is a 
defined 15 bp long sequence. In the initial denaturation step, 0.5 µl of the 
BAC DNA template (2.2.2.1.1) is added to the a 4µl of reaction buffer A (50 
mM NaCl, 40 mM Tris-HCl pH 7.5, 10 mM MgCl2, 50 ng/µl BSA, 300 µM of 
each dNTP, 5 mM DTT, and 0.625 µM of Primer A) and denatured at 94°C for 
4 min.  
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After the denaturation, 0.5 µl of reaction buffer A containing 0.5 U of the T7 
DNA polymerase Sequenase 2.0 (United States Biochemical, USB) are added 
to the tube (denatured template) and the polymerase is allowed to work by 
slow increase in the temperature from 13°C to 37°C over a period of 3 
minutes, followed by an incubation at 37°C for an additional 2 minutes. In this 
so-called preamplification cycle, DNA fragments containing the defined 
sequence introduced by Primer A at their 5’ ends are generated. This 
preamplification cycle is stopped by another denaturation step at 94°C for 1 
minute. Then a fresh aliquot of buffer A (0.5µl) containing 0.5 U of Sequenase 
2.0 is added for another preamplification cycle with the same temperature 
profile as the first preamplification cycle. After this second preamplification 
step and the denaturation, single-stranded DNA fragments are produced that 
have the known sequence of Primer A at their 5’ end and the reverse 
complement of this sequence at their 3’ end.  These DNA fragments could 
now be amplified in PCR reaction with a primer (Primer B) (2.1.13) that has 
the known sequence of Primer A and additional 5 nucleotides at the 5’ end.  
However, to increase the yield of the sequence-independent amplification, the 
preamplification cycle is repeated two more times for a total of four 
preamplification rounds, each time adding fresh 0.5 µl aliquot of buffer A 
containing Sequenase 2.0 enzyme. Thus, the final reaction volume after 4 
preamplification cycles would be 6 µl.  
After the 4th preamplification round, the 6 µl preamplification reaction is added 
to 54 µl of buffer B (55 mM KCl, 6.6 mM Tris-HCl pH 9.0, 11 ng/µl gelatin, 133 
µM of each dNTP, 1.25 µM of Primer B, and 0.03 U/µl Taq Polymerase) to 
attain the total reaction volume of 60 µl. The addition of buffer B adjusts the 
reaction conditions to PCR conditions suitable for Taq polymerase. Primer B 
has the defined sequence of Primer A at its 3’ end and additional 5 
nucleotides at the 5’ end. Then a normal PCR reaction is performed with an 
initial 5 cycles of low stringency annealing (from 44°C to 70°C; ramp 
0.2°C/sec) followed by 22 cycles of high stringency annealing (56°C) 
The detailed protocol for the sequence independent amplification is given 
below. 
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1. Initial denaturation of the template DNA:  
• The reaction buffer A was pipetted as follows and 4 µl of the mix 
was mixed with 0.5 µl BAC-DNA template and incubated at 94° 
C for 90 seconds. 
Buffer A 
Reagents Amount 
(µl) 
Final concentration 
10x MAP 0.600 1x 
1 mg/ml BSA 0.300 50 µg/ml 
3 mM each dNTP 0.600 300 µM 
10 µM Primer A 0.375 0.625 mM 
ddH2O 3.985 up to 5.860 µl  
Sequenase 2.0  
(13 U/µl) 
Added later (Step 2) 
0.140 0.3 U/µl 
Total  6.000  
2. Pre-amplification: 
• To the rest of the buffer mix A (1.860 µl), 0.140 µl Sequenase 
was added and  
• From the above mix 0.5 µl was added to the reaction tube (step 
1) after denaturation and a sequenase cycle was run as given in 
the following table.  
• The sequenase cycle was repeated three more times preceded 
by the addition of 0.5 µl of the Buffer A with Sequenase. The 
reaction volume was 6 µl after the 4th preamplification cycle. 
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Preamplification Cycle (Sequenase Cycle) 
Steps Temperature (°C) Time (min) 
1 13°C 1 
2 13-37°C 2 min, ramp with 0.2° C/ sec 
3 37°C 2 
4 94°C 1 
5 4°C soak 
3. PCR amplification using specific primers 
• After the preamplification, 54 µl of buffer B was added to each 
tube to bring the volume to 60 µl and the reactions were cycled 
through the temperature profile as shown below (SIA PCR 
cycles). 
• Buffer B 
Reagents Amount (µl) Final concentration 
10x BP buffer 5.400 1x 
3 mM each dNTP 2.400 133 µM 
20 µM Primer B 3.375 1.25 mM 
ddH2O 42.525 to 54 µl total 
Taq Pol (5 U/µl) 0.300  
Total 54.000  
The products of the SIA procedure are examined on a 1.5% agarose gel. The 
procedure yields a smear of fragments ranging from 200 bp to 1500 bp from 1 
ng of BAC DNA as template. The BAC clones contained inserts ranging in 
size from 100 kbp to 200 kbp. 
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SIA PCR cycles 
Steps Temperature 
(°C) 
Time 
(min:sec) 
No. of cycles 
Initial denaturation 94 3:00 1 
Denaturation 94 0:45 
Initial annealing 44 1:00 
Annealing 44-72 2:00 
Elongation 72 2:00 
5 cycles, 
Ramp 0.2° C/s 
Denaturation 94 0:45 
Annealing 56 0:45 
Elongation 72 2:00 
Final elongation 72 7:00 
22 cycles 
Soak 4  1 
2.2.5.2.1.2 PCR labeling of SIA products 
After the initial SIA amplification from a BAC, the DNA fragments were 
fluorescently labeled in a second PCR by the incorporation of nucleotides that 
were chemically modified with fluorochromes. We used dATP  and dCTP  
labeled with FITC or Texas Red and Spectrum Orange or FITC conjugated 
dUTPs. 
In this secondary labeling PCR (usually 50 µl in volume), primer B was used 
at 1 µM concentration. Depending on which fluorescently-labeled nucleotide 
was used the concentration of the same non-labeled nucleotide was reduced 
accordingly. Typically we used the labeled nucleotide at a final concentration 
of 40 µM, eg. 40 µM of Spectrum Orange dUTP. Then the concentration of 
dTTP was reduced to 110 µM so that the total concentration of dUTP and 
dTTP would be 150 µM. The individual concentration of the other three 
nucleotides would also be 150 µM. 1 µl from the final SIA product (2.2.5.2.1.1) 
containing the fragments from a specific BAC was used as template. 
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The following cycle profile was used to label SIA products: 
Steps Temperature 
(°C) 
Time 
(min:sec) 
No. of cycles 
Denaturation 94 1:00 
Annealing 56 1:00 
Elongation 72 3:00 
20 cycles 
 
2.2.5.2.1.3 DNase treatment of labeled SIA products 
In order to achieve the right size range (300-500 bp) of DNA fragments for 
optimum hybridization kinetics and results, the labeled SIA products were 
mildly treated with DNase I. 
The DNase I stock solution was diluted in DNase dilution buffer at an 
empirically determined ratio (usually 1:1000). Then 1/10 volume of the labeled 
PCR reaction (2.2.5.2.1.2) was removed for later analysis and 1/10 volume of 
diluted DNase I solution was added. The reaction was incubated at RT for 10 
minutes and then the DNase was inactivated at 65°C for 10 minutes. To 
monitor the efficiency of the DNase digestion, the aliquot (1/10 of the labeled 
PCR reaction) removed before the digestion and an aliquot of the sample 
after the digestion were run side by side on a 1.8% agarose gel. Typically a 
distinct reduction in the average size of the DNA fragments should be visible. 
However, since DNase I introduces single stranded nicks into the DNA, even 
a slight reduction in the average molecular weight of the smear indicated 
substantial digestion of the DNA. 
2.2.5.2.1.4 Precipitation of labeled probes 
After labeling and DNase treatment (in the case of the SIA products), the 
FISH probes were precipitated in order to remove un-incorporated labeled 
nucleotides, to concentrate the probe and to add non-labeled highly repetitive 
human DNA (Cot-1-DNA). Cot-1-DNA, which would hybridizes to the labeled 
repeat DNA, was used to reduce non-specific background hybridization 
signals. For precipitation, 3 µg Cot-1 DNA (1 µg/l), 0.1 v/v 3 M sodium acetate 
and 2.5 v/v of 100% ethanol were added to the labeled probes in an 
Eppendorf tube. After vortexing, the tube was put at -80°C for 20 min to allow 
Materials and Methods 
76 
the DNA to precipitate. The precipitated DNA was pelleted at 16000 x g, 4°C 
for 20 min. After air drying the pellet was resuspended in 7 µl hybridization 
buffer (Abbott, Germany) and 3 µl d2H2O. This mix was used for the 
hybridization.  
2.2.5.2.2 Protein digesting pre-treatment and hybridization 
The cytoplasmic proteins of the cells may obstruct the denaturation of the 
chromosomal DNA and interfere with hybridization. This may result in a high 
background fluorescence and poor quality fluorescence signals. To improve 
hybridization results, we pretreated the chromosomal preparations (2.2.5.1.3) 
with pepsin to digest the cytoplasmic proteins, when required. 
For pepsin treatment, the slides were immersed in working pepsin solution 
(2.1.3.5) at 37° C for 3-5 min and washed with 1x PBS for 3 minutes at RT. 
After the wash, 100 µl of the post fixation (2.1.3.5) solution was applied onto 
the slide, overlaid with a coverslip and incubated for 10 min at RT. The slides 
were washed by 1x PBS for 3 min, RT and subjected to dehydration in 70%, 
90% and 100% ethanol baths for 2 min each. When the protein digestion was 
not required, the slides were directly dehydrated through the ethanol series 
before hybridization. 
The slides were air dried and 8-10 µl of the probe mix was applied for a 24x24 
mm2 area, covered with a coverslip and sealed with rubber cement. 
Alternatively for a 9x9 mm2 area 1-1.5 µl of probe mix was applied. The slides 
were subjected to denaturation at 76°C for 3 min followed by hybridization at 
37° C for 12-16 hrs using an automated FISH hybridization chamber 
(HybriteTM, Vysis, Germany)  
2.2.5.2.3 Post-hybridization washes, staining and microscopy 
After hybridization, the slides were washed in Wash solution I (2.1.3.5) at 
75°C for 2 min (high stringency wash), followed by an additional wash in 
Wash solution II (2.1.3.5) for 1 min at RT (low stringency wash). The slides 
were mounted with DAPI (1000 ng/ml in antifade solution) for counter staining 
and the fluorescent signals were visualized with an epi-fluorescence 
microscope (Axioplan2 imaging system; Carl Zeiss, Jena, Germany), 
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equipped with a CCD camera. The images were captured and processed 
using the Isis software (Metasystems, Altlussheim, Germany). 
2.2.5.2.4 Fluorescent signal amplification 
If the fluorescent signals were weak, the signals were amplified with a 
sandwich technique employing fluorescently labeled antibodies. For the 
amplification, the slide was washed in wash solution II for 1 min at RT to 
remove the DAPI counter stain, followed by an additional wash in Wash 
solution III (2.1.3.5) for 3 min at RT. The slide was then incubated in freshly 
prepared blocking solution (2.1.3.5) for 10-20 min at RT and washed with 
Wash solution III for 3 min at RT. The slides were then incubated with 100 µl 
of appropriate antibody (e.g., anti-FITC, Rabbit IgG, Alexa Fluor 488 
conjugated antibody) diluted in blocking solution, at 37° C in a moist chamber 
for 30 min. The slides were washed in Wash solution III for 3 min, 4 times at 
RT. When stronger signals amplification was required, an additional round of 
amplification was performed using appropriate secondary and tertiary 
antibodies, followed by washing with wash solution III as described earlier. 
The slides were then washed twice with PBS for 5 min at RT, dehydrated 
through a 70-80-90-100% ethanol series, air-dried and mounted with the DAPI 
counter stain (2.1.3.5). 
2.2.6 Statistical methods 
Standard statistical parameters (eg. mean, median and standard deviation) 
were calculated using the built in statistics functions of spreadsheet programs 
like Excel (Microsoft). The IC50 (inhibition cell growth by 50%) concentration, 
the concentration of a drug at which 50% of the cells die, was derived 
manually by performing a standard Probit analysis using Finney’s table 
(Finney 1952) (Finney, 1952).  
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3 Results 
3.1 DISCOVERY OF A NOVEL FUSION PARTNER OF ABL1 
3.1.1 Case History 
An 18-year-old female patient was admitted to the University of Munich 
hospital because of anemia, thrombocytopenia and general weakness and 
was diagnosed with Acute Lymphoblastic Leukemia (ALL). The peripheral 
blood showed the presence of 23% of small lymphoid blasts with narrow 
cytoplasm (white blood cell count: 7000/µl). In the bone marrow (BM) about 
70% of the cells were blasts. The flow cytometry analysis of the BM sample 
revealed an immature lymphoid blast population, which was positive for 
CD19, CD10, HLA-DR, CD34 as well as the cytoplasmic markers TdT and 
CD22. There was no expression of IgM and no co-expression of myeloid 
markers (CD13, CD33, CD65, CD15, CD14, CD64, CD61 or 
myeloperoxidase), which was compatible with the diagnosis of common Acute 
Lymphoblastic Leukemia (cALL). 
As a part of the routine diagnostic procedure for ALL patients, the samples 
were screened for the presence of the BCR-ABL1 fusion gene. An RT-PCR 
was performed to detect the BCR/ABL1 fusion transcript, and fluorescence in 
situ hybridization (FISH) was performed for the detection of the BCR/ABL1 
fusion gene at the genomic level. In addition, routine cytogenetic techniques 
revealed a normal female karyotype of 46,XX at the 250 band resolution level 
in standard GAG-banding.  
The patient was treated according to the GMALL 07/2003 protocol in the very 
high risk arm. She was given Imatinib, since our FISH results suggested an 
ABL1 rearrangement (3.1.6). The treatment was uneventful, and she achieved 
a complete remission within 11 days of the start of therapy. She was 
transplanted with the bone marrow from an unrelated male donor 5 months 
after the initial diagnosis and continues to be in complete remission (follow-up 
15 months). 
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3.1.2 Detection of unexpected products after RT-PCR to 
detect BCR/ABL1 
For the detection of the BCR/ABL1 fusion transcript, RT-PCR (2.2.2.4.3) with 
the mRNA derived from the patient’s BM and peripheral blood samples was 
performed using primer pairs (2.1.13) specific for the p190 and p210 BCR-
ABL1 fusion transcripts.  These PCRs did not result in the amplification of 
DNA fragments of the expected sizes corresponding to the p190 or p210 
fusion transcripts. However, in both the RT-PCR reactions unexpectedly weak 
bands of higher molecular weight were seen after agarose gel electrophoresis 
(Figure 3.1). To characterize these bands further, we excised them from the 
agarose gels and sequenced them with the primers used for amplification. 
 
Figure 3.1:  Detection of higher molecular weight PCR bands after RT-
PCR for the BCR-ABL1 fusion transcripts: (A) PCR with primers specific for 
the p190 BCR/ABL fusion: Lane 1: Negative control (no template); lane 2: 
positive control (template: cDNA of the patient with the p190 fusion transcript); 
lane 3: patient sample. (B) PCR with primers specific for the p210 BCR/ABL 
fusion: Lane 1: Negative control; lane 2: positive control; lane 3: patient 
sample. 
3.1.3 Sequence analysis of the unexpected PCR fragment 
To sequence the higher molecular weight bands, the following primers were 
used: for the p190 product the P190 F70 and p190 R20 primers and for the 
p210 product the P210 F60 and the p210 R40 primers (2.1.13). A BLAST 
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(Basic Local Alignment Search Tool; http://blast.ncbi.nlm.nih.gov) analysis of 
the sequences showed homologies to ABL1 and, unexpectedly, to the 
INPP5D gene (inositol polyphosphate-5-phosphatase) from chromosome 2 
band q37. A detailed analysis revealed a fusion of the INPP5D 
(NM_001017915.1) gene at nucleotide 1183 to the ABL1 gene 
(NM_007313.2) at position 576. The fusion conserved the open reading frame 
of both genes, with an in-frame fusion between the 9th exon of the INPP5D 
gene and the 2nd exon of the ABL1 gene (Figure 3.2). This initial sequence 
covered INPP5D from nt 1035 to 1183 and ABL1 from nt 576 to 701. Since  
 
Figure 3.2: Sequence of the in-frame fusion between the 5’-INPP5D and 
3’-ABL1 genes: The sequence was obtained by sequencing the unexpected 
higher molecular weight RT-PCR product amplified by the BCR-ABL fusion 
transcript specific primers. The underlined sequences in the individual 
sequences of INPP5D and ABL1 fuse to form an INPP5D/ABL1 fusion gene.  
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there was no proper intron-exon annotation of the INPP5D at the time of our 
analysis due to a gap in the NCBI reference genome assembly in the middle 
of the INPP5D gene, we determined the exon-intron boundaries of the 
INPP5D gene ourselves using the NCBI-BLAST tool and the Celera genome 
assembly. 
3.1.4 Confirmation of the presence of the INPP5D/ABL1 fusion 
transcript in the patient sample. 
To confirm the presence of an INPP5D/ABL1 fusion transcript in the patient 
sample, a putative INPP5D/ABL1 fusion sequence was constructed using 
INPP5D (Genbank accession no: NM_001017915) and ABL1 (NM_007313.2) 
sequences, based on the breakpoint identified from the PCR product (Figure 
3.2, Appendix I). Corresponding to this putative INPP5D/ABL1 sequence, a 
specific primer pair (INPP5D-ABL1F997-1015 and INPP5D-ABL1B1474-
1454) (2.1.13) flanking a 477 bp region spanning the breakpoint (nt 1183 of 
NM_001017915) was designed (Figure 3.3A). Using this primer pair, we were 
able to amplify a specific 477 bps fragment from the patient’s cDNA sample, 
thus confirming the presence of the INPP5D/ABL1 fusion transcript in the 
patient sample (Figure 3.3B). The identity of this INPP5D/ABL1 fusion 
transcript was verified by sequence analysis. 
 
Figure 3.3: Confirmation of the presence of the INPP5D/ABL1 fusion 
transcript in the patient sample: (A) Diagrammatic representation of the 
position of the breakpoint spanning primer pair in the putative INPP5D/ABL1 
fusion transcript. The primer pair covers a breakpoint spanning region of 477 
nucleotides. (B) Detection of the specific INPP5D/ABL1 fusion transcript (477 
bp fragment) in the patient sample: M: size marker; lane 1: negative control; 
lane 2: patient sample. 
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3.1.5 Absence of the reciprocal ABL1/INPP5D fusion 
transcript in the patient sample. 
To detect the presence of the reciprocal ABL1/INPP5D fusion, a hypothetical 
ABL1/INPP5D sequence was generated. A primer pair (ABL1-INPP5D402-
421F and ABL1-INPP5D741-721B), flanking a 339 bps region of the 
hypothetical ABL1/INPP5D sequence spanning the breakpoint of the 
reciprocal fusion transcript was designed (2.1.13). Using this primer pair we 
were unable to amplify an ABL1/INPP5D fusion transcript from the patient 
sample. Taken together with our data from the FISH experiments (see below: 
3.1.6), this negative result strongly suggests that there is no reciprocal 
ABL1/INPP5D transcript in the patient sample  
3.1.6 Analysis of the genomic rearrangement using BCR and 
ABL Fluorescence In-situ Hybridization (FISH) probes 
Considering the presence of the 5’INPP5D/3’ABL1 in the patient’s sample and 
that the transcriptional direction of both the ABL1 and SHIP1 genes is 
centromere to telomere (3.2), we expected that a simple balanced 
translocation had occurred between chromosome 9 (with the breakpoint in 
ABL1 at 9q34) and chromosome 2 (with the breakpoint in INPP5D at 2q37) 
(Figure 3.4). The fact that we were unable to amplify the reciprocal fusion 
transcript might have been due to alternative splicing or the presence of a 
small deletion at the breakpoint. To confirm the presence of this translocation 
we performed a fluorescence in-situ hybridization (FISH) experiment on the 
patient’s interphase and metaphase cells using a commercially available 
BCR/ABL-dual-color-dual-fusion (DCDF) probe (2.2.5). To better understand 
the FISH results, the BCR/ABL-DCDF probe is described in Figure 3.5 A and 
the results of the hybridization for interphase and metaphases in the case of 
the classical t(9;22)(q34;q11) translocation, which generates the BCR/ABL1 
fusion, is described in Figure 3.5 B. The expected hybridization results for this 
probe for both metaphase and interphase cells in the case of a balanced 
t(2;9)(q37;q34) is shown in Figure 3.5 C.  We would expect three orange 
signals for the ABL1 probes: one signal for the intact ABL1 locus, and one 
signal each for the 5’ and 3’ portion of the rearranged ABL1 allele. 
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Unexpectedly, the patient’s metaphase cells showed a normal signal pattern 
for the BCR/ABL-DCDF probe with 2 green signals for the BCR gene, one on 
each chromosome 22, and 2 orange signals for ABL1 gene, one on each 
chromosome 9, without any indication of any rearrangements involving BCR 
or ABL1 (Figure 3.6 A). However, when the same probe was hybridized on 
the interphase cells from the patient, the orange signals for both the ABL1 loci 
were split (Figure 3.6 B) resulting in two pairs of closely spaced orange 
signals.  
Based on the RT-PCR and FISH results, we speculate that the INPP5D/ABL1 
fusion was generated by an insertion of the 5’ part of INPP5D into the first 
intron of the ABL1 gene (Figure 3.6 C). In addition, to explain the fact that 
both ABL1 signals appear split in the interphase FISH analysis, we have to 
assume that the normal chromosome 9 was lost and that the chromosome 9 
with the insertion of the INPP5D sequences in the ABL1 locus was duplicated. 
 
Figure 3.4: Putative genomic rearrangement leading to the SHIP1/ABL1 
fusion: Diagram of the chromosomal location of SHIP1 and ABL1 and the 
balanced translocation resulting in the formation of the 5’SHIP1/3’ABL1 fusion 
on the derivative chromosome 2 and the reciprocal fusion 5’ABL1/3’SHIP1 on 
the derivative chromosome 9.  
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Figure 3.5: The BCR/ABL1-DCDF probe: (A) Design of the BCR/ABL1 DCDF 
FISH probe: BCR is labeled with FITC (green signals) and ABL1 is labeled with 
Spectrum Orange (orange signals) (B) Possible BCR/ABL DCDF FISH signal 
patterns: (i) Signal pattern indicating absence of the BCR/ABL1 fusion: 2 
orange and 2 green signals corresponding to the normal ABL1 and BCR loci 
both in interphase (IP) cell and in metaphase (MP) cells (ii) Signal pattern 
indicating a classical translocation t(9;22)(q34;q11), on metaphase (MP) 
chromosomes and in interphase (IP) cells: The resulting two reciprocal fusions, 
BCR/ABL1 and ABL1/BCR, give rise to two yellow signals in addition to 1 
orange and 1 green signal for the normal ABL1 and BCR loci, respectively. (C) 
Expected signal pattern with the BCR/ABL1 DCDF FISH probes in cells with 
the t(2;9)(q37;q34). In metaphase cells: 2 green signals on the two 
chromosomes 22 for the normal BCR loci, 1 orange signal on the normal ABL1 
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loci, 1 orange signal for the 3’ABL1 portion on the long arm of chromosome 2 
and one orange signal on the other chromosome 9 for the 5’ABL1 portion; In 
interphase nuclei: two green signals and 3 orange signals would be expected. 
 
 
Figure 3.6: FISH assays performed on the patient’s sample: (A) 
Hybridization of the BCR/ABL1 DCDF FISH probes. (i) Representative 
metaphase cell showing the absence of the BCR/ABL1 fusion: 2 orange signals 
corresponding to the two ABL1 loci, 2 green signals corresponding to the two 
BCR loci and no yellow signal; (ii) Representative interphase cells showing the 
absence of BCR/ABL1 fusion (no yellow signal), two normal BCR loci (2 green 
signals) and split ABL1 at both the ABL1 loci (two split orange signals). (B) 
Diagrammatic explanation of the ABL1 split signal pattern in the FISH assays: 
An insertion of the 5’ portion of INPP5D within the ABL1 genomic locus could 
generate an INPP5D/ABL1 fusion and the observed signal pattern.  
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3.2 INPP5D (SHIP1): THE NEW FUSION PARTNER OF ABL1 
The inositol polyphosphate-5 phosphatase (INPP5D) gene, the novel fusion 
partner of ABL1, is also known as SH2 containing inositol phosphatase 1 
(SHIP1). INPP5D (SHIP1) is located in the telomeric region of the long arm of 
chromosome 2 (2q37) and is transcribed 5’ to 3’ in a centromere to telomere 
direction. The SHIP1 gene encodes a protein of 1188 amino acids (aa) (145 
kDa molecular weight) with an N-terminal SH2 (scr-homology) domain, an 
inositol phosphatase domain, and a C-terminal proline rich region containing 
two protein interaction motifs. These motifs, INPNY and ENPLY, are target 
sequences for the phosphotyrosine binding domains of several other proteins 
(Figure 3.7). The expression of the SHIP1 protein is restricted to 
haematopoietic cells where its movement from the cytosol to the plasma 
membrane is controlled by tyrosine phosphorylation (Damen et al., 1996; 
Ware et al., 1996). SHIP1 functions as a negative regulator of myeloid cell 
proliferation and survival (Helgason et al., 1998). Mice with a targeted 
disruption of the SHIP1 locus develop a myeloproliferative syndrome and 
show an increased number of NK cells and increased rate of mast cell 
degranulation (Helgason et al., 1998). The hematopoietic specific expression 
of SHIP1 and its negative regulatory role in important signaling pathways 
made the SHIP1/ABL1 fusion a very interesting subject for further 
characterization. 
 
Figure 3.7: Defined protein domains within the SHIP1 protein. SH2: Src 
homology-2 domain; 5-ptase: Inositol 5-phosphatase domain; INPNY and 
ENPLY: Target sequences for the phospho tyrosine binding domains of other 
proteins. (Derived from Damen et al., 1996) 
Results 
88 
3.3 THE PUTATIVE SHIP1/ABL1 FUSION PROTEIN 
As mentioned earlier (3.1.3), in the SHIP1/ABL1 fusion, the breakpoint in 
ABL1 is in the 1st intron, in the same location where it is observed in all the 
other known ABL1 fusions. The resulting SHIP1/ABL1 fusion protein 
comprises the first 343 amino acids of the INPP5D protein and the whole 
ABL1 protein except for the first 27 amino acids (in the case of ABL1a: 
NP_005148.2) or the first 46 aa (in the case of ABL1b: NP_009297.2) (Figure 
3.8). Thus, the putative INPP5D/ABL1 fusion protein is predicted to contain 
the SH2 domain SHIP1 (amino acids 2 to 102) and the SH3, SH2, tyrosine 
kinase and the actin-binding domain of the ABL1 protein. 
 
Figure 3.8: Diagram of the SHIP1, ABL1 and SHIP1/ABL1 proteins with 
their relevant protein domains. SH2: Src homology-2 domain; SH3: Src 
homology-3 domain; 5-ptase: Inositol 5-phosphatase domain; INPNY and 
ENPLY: Target sequences for the phospho tyrosine binding domains of other 
proteins; TK: Tyrosine kinase domain; DB: DNA binding domain; AD: Actin-
binding domain. The upper two boxes show the SHIP1 and the ABL1 proteins 
and the lower box shows the protein domains of SHIP1/ABL1 fusion protein. 
The arrows indicate  the breakpoints in the individual proteins; numbers 
indicate amino acid positions. 
3.4 CLONING OF THE FULL LENGTH SHIP1/ABL1 
To characterize and study the function of the SHIP1/ABL1 fusion protein in 
detail, we cloned the full length SHIP1/ABL1 fusion coding sequence into 
eukaryotic expression vectors. For this, we first amplified the 5’ portion of the 
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SHIP1/ABL1 fusion from the patient’s cDNA with a nested PCR using the 
primers SHIP-ABL-F20-38 and SHIP-ABL-B1520-1502 for the first PCR and 
SHIP-ABL1-F38-57 and SHIP-ABL1-B1508-1489 (2.1.13) in the second PCR. 
The amplified fragment contained nucleotides 39 to 1508 of the hypothetical 
SHIP1/ABL1 sequence (Figure 3.9). At the 5’ end of this 1470 bps long 
fragment, a HindIII and a Mun1 site were introduced by PCR using the 
primers SHIP-ABL1-HindIII-Mun1-F39-59 and SHIP-ABL1-B1508-1489 
(2.1.13). The PCR product was then cloned into the pGEM-Teasy vector. 
Several recombinant pGEM-Teasy clones were sequenced, and a clone with 
the correct sequence of the 5’ SHIP1/ABL1 fusion, pGEM-Teasy-SA(39-
1508)-CLN9, was used in the subsequent cloning steps. The insert sequence 
of the pGEM-Teasy-SA(39-1508)-CLN9 clone had two single nucleotide 
substitutions compared to the reference SHIP1/ABL1 sequence: one at 
position 642 in the SHIP1 and another at position 1236 in the ABL1 portion. 
Neither one of these substitutions led to a change in the amino acid 
sequence. 
For the cloning of the full length SHIP1/ABL1 into the eukaryotic expression 
vector, the 5’ SHIP1/ABL1 fragment (nucleotides 39-1488 of the SHIP1/ABL1 
sequence) was excised from the pGEM-Teasy-SA(39-1508)-CLN9 clone 
using the 5’ HindIII site,  which had been introduced by the primer, and the 
Kpn1 site at position 1488 in the ABL1 portion of the fragment (Figure 3.9). A 
pcDNA3-BCR/ABL1 construct was linearized with a HindIII and Kpn1 digest. 
This resulted in the removal of the 5’ portion of the BCR/ABL1 fusion 
(including the whole BCR portion) from the HindIII site of the vector back bone 
until the Kpn1 site within the ABL1 sequence. Then the HindIII-Mun1-
5’SHIP1-ABL1-Kpn1 fragment was inserted into the HindIII-pcDNA3-ABL-
Kpn1 vector to generate a full length SHIP1-ABL1 fusion cDNA in the pcDNA3 
vector.  
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Figure 3.9: Strategy for the cloning of the full length SHIP1/ABL1 fusion into the eukaryotic expression vector pcDNA3 and 
the retroviral expression vector pMSCV-IRES-GFP.
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The full length SHIP1/ABL1 sequence was then cloned into a retroviral 
expression vector. For this, the whole SHIP1/ABL1 insert was excised from 
the pcDNA3-SHIP1/ABL1 construct by a Mun1/Xho1 double digest. The insert 
was then ligated into  EcoRI and Xho1 sites of the pMSCV-IRES-GFP (pMIG) 
vector. The resulting pMIG-SHIP1/ABL1 construct would lead to the 
expression of both a SHIP1/ABL1 and a green fluorescent protein (GFP) 
because of the internal ribosome entry site (IRES) between the coding region 
of SHIP1/ABL1 and GFP. The cloning strategy is summarized in figure 3.9. 
3.5 VERIFICATION OF SHIP1/ABL1 EXPRESSION 
CONSTRUCTS 
The completeness and integrity of the full length SHIP1/ABL1 clones were 
confirmed by analyzing the expression of the SHIP1/ABL1 protein and by 
sequencing the complete coding region of SHIP1/ABL1.  
3.5.1 Expression of the SHIP1/ABL1 clones in 293T cells 
HEK293T cells were transiently transfected (2.2.3.3) with the pcDNA3-
SHIP1/ABL1 construct and allowed to express the protein for 48 hours. In 
parallel, the HEK293T cells were also transfected with the pcDNA3-
BCR/ABL1 plasmid to serve as a positive control for the efficiency of the anti 
ABL1 antibody used in the Western analysis. After 48 hours, total cell lysates 
were prepared (2.2.4.1) from the transfected cells and non-transfected 
HEK293T cells, which were to be used as a control for the endogenous 
expression of the ABL1 protein. The proteins in the cell lysates were then 
resolved by SDS-PAGE and analyzed by Western blotting. The blot was 
probed with an antibody against the ABL1 protein and the expression of the 
SHIP1/ABL1 (estimated size ~158 kD) and the BCR/ABL1 (p210) proteins 
could be confirmed (Figure 3.10). The endogenous ABL1 protein was not 
detected in the non-transfected HEK293T cells. 
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Figure 3.10: Expression of SHIP1/ABL1 in HEK293T cells detected by an 
antibody against c-ABL1: Lane 1: Lysate from non-transfected HEK293T cell 
lysate; Lane 2:  Lysate from BCR/ABL1 transfected cells; Lane2: Lysates from 
SHIP1/ABL1 transfected cells.  
3.5.2 Sequencing of the retroviral SHIP1/ABL1 expression 
constructs 
The complete SHIP1/ABL1 insert in the pMIG-SHIP1/ABL1 construct was 
sequenced using the “pMIG-5’SHIP/3’ABL1 sequencing primers” listed in 
section 2.1.13. The individual sequence reads were assembled into a contig 
of the complete SHIP1/ABL1 sequence with the help of the program 
“Sequencher 4.7”. The sequence showed a near 100% identity to the 
sequences of SHIP1 and ABL1 deposited in Genbank with the exception of 
two silent nucleotide substitutions; one at position 642 in the SHIP1 portion 
and one at position 1236 in the ABL1 portion of the hypothetical SHIP1/ABL1 
sequence. In addition, we found a nucleotide change in the ABL1 portion at 
position 4297 in the hypothetical SHIP1/ABL1 sequence, which led to a 
threonine (T) to serine (S) substitution close to the C-terminal end of ABL1.  
The nucleotide that led to a threonine to serine substitution is at position 3689 
of the ABL1 sequence with accession number NM_007313.2. Although this 
threonine to serine amino acid substitution is not present in any of the ABL1 
sequences deposited in Genbank, we chose to ignore it, since the 
transforming activity of our BCR/ABL1 and SHIP1/ABL1 constructs was not 
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compromised by this mutation. The positions of the single nucleotide changes 
are indicated in the sequence of SHIP1/ABL1 fusion (Appendix I). 
3.5.3 Expression of SHIP1/ABL1 in Ba/F3 cells 
To confirm the expression from the retroviral pMIG-SHIP1/ABL1 construct, 
Ba/F3 cells were retrovirally transduced with the empty pMIG vector, pMIG-
SHIP1/ABL1 or pMIY-BCR/ABL1 and Ba/F3- cell lines stably expressing the 
green fluorescent protein (GFP) only, GFP and SHIP1/ABL1 or Yellow 
fluorescence protein (YFP) and BCR/ABL1 were established (2.2.3.4). The 
Ba/F3 cell line expressing the well studied BCR/ABL1 protein was used for 
positive control experiments. For negative control experiments (as a control 
for integration effects of the retroviral vector), the Ba/F3 cell line expressing 
GFP only was used. Total protein lysates were prepared from all three cell 
lines and the expression of SHIP1/ABL1 and BCR/ABL1 was confirmed in the 
appropriate cell lines (Figure: 3.11). 
 
Figure 3.11: Western blot analysis of Ba/F3 cell lines expressing the 
SHIP1/ABL1 or BCR/ABL1 fusion proteins using an c-ABL1 specific 
antibody. Lane 1: Lysate from non-transfected Ba/F3 cells; Lane 2: Lysates 
from BCR/ABL1 transduced Ba/F3 cells; Lane 3: Lysates from SHIP1/ABL1 
transduced Ba/F3 cells.  
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3.6 SHIP1/ABL1 CONFERS GROWTH FACTOR INDEPENDENT 
GROWTH TO BA/F3 CELLS 
The Ba/F3 cell line is an IL3 dependent murine pro B cell line. This cell line is 
an important biological system for the study of tyrosine kinases. The 
constitutively activated forms of tyrosine kinases like ABL1, JAK2, PDGFR-
alpha, FLT3, and cKIT induce IL3 independent growth in Ba/F3 cells. 
Therefore we used the Ba/F3 cell line system to study the transformation 
potential of the SHIP1/ABL1 fusion. We performed cell proliferation assays in 
presence and absence of IL3 (2.2.3.6) using the trypan blue exclusion method 
(2.2.3.5.1) for the assessment of the cell viability. Each experiment was done 
three times in triplicates resulting in 9 individual data points for each 
experimental condition. The assays showed that SHIP1/ABL1 induces IL3 
independence in Ba/F3 cells, suggesting that the ABL1 tyrosine kinase is 
constitutively active in the SHIP1/ABL1 fusion. Interestingly, the SHIP1/ABL1 
fusion expressing Ba/F3 cells consistently showed a faster growth rate than 
BA/F3 cells expressing the BCR/ABL1 fusion (Figure: 3.12). 
 
Figure 3.12: Transformation of Ba/F3 cells to IL3 independent 
proliferation: Ba/F3 cells retrovirally transduced with the indicated constructs 
were grown in the absence or presence of IL3 and their growth was recorded 
Results 
95 
over a period of 3 days. Proliferation curves were prepared by plotting the 
mean ± SD values derived from three individual assays. 
3.7 THE PROLIFERATIVE EFFECT OF THE SHIP1/ABL1 FUSION 
PROTEIN CAN BE INHIBITED BY IMATINIB 
Imatinib is a competitive inhibitor of the tyrosine kinases ABL1, c-Kit and 
PDGFRβ. Imatinib is used as a targeted therapeutic agent to treat 
malignancies which are caused by constitutively active forms of the ABL1, c-
Kit or PDGFR tyrosine kinases. To study and compare the Imatinib sensitivity 
of  the SHIP1/ABL1 and the BCR/ABL1 fusion proteins, SHIP1/ABL1 and 
BCR/ABL1 expressing Ba/F3 cell lines were treated with different 
concentrations of Imatinib (STI571) in the absence or presence of IL3 
(2.2.3.6).  The experiments without IL3 were used to determine the effect of 
Imatinib on the activity of the constitutively activated ABL1 tyrosine kinases. 
To control for a possible unspecific cytotoxic effect of Imatinib,  the same 
experiments were also performed in the presence of IL3. The cell viability was 
estimated using the MTT method (2.2.3.5.2). The experiments clearly showed 
that the Ba/F3 cells expressing the SHIP1/ABL1 fusion are more sensitive to 
the effects of Imatinib than the BCR/ABL1 expressing Ba/F3 cells (Figure 
3.13).  
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Figure 3.13: Sensitivity of Ba/F3 cells expressing SHIP1/ABL1 to Imatinib: 
Ba/F3 cells retrovirally transduced with SHIP1/ABL1 or BCR/ABL1 were treated 
with different concentrations of Imatinib for 3 days and the % viability of the 
cells was calculated at each concentration with reference to the cell viability of 
untreated cells at the same time point.  
From these experiments we also determined the IC50IMATINIB (the 
concentration of imatinib at which 50% of the cells are dead) both for the 
SHIP1/ABL1 and BCR/ABL1 fusion (Figure 3.14, Table: 3.1). The IC50IMATINIB 
for Ba/F3 cells expressing SHIP1/ABL1 was about 0.15 µM, whereas the 
IC50IMATINIB for BCR/ABL1 expressing cells was about 0.79 µM. Thus, 
SHIP1/ABL1 is more than 4 times more sensitive to Imatinib than BCR/ABL1 
in our Ba/F3 cell line system.  
 
Figure 3.14: Determination of the IC50IMATINIB: Probit values corresponding to 
the % cell viability at different Imatinib concentration were derived using 
Finney’s table (Finney, 1952). The probits were plotted on the Y-axis against 
the Log10 values of the Imatinib (nM) concentrations on the X-axis. For each 
fusion protein, the concentration at which 50% of the cells were dead was 
defined as the IC50IMATINIB value. 
Corresponding Log concentration “X” for 
Probit "5" from Finney’s table  
IC50 (nM) IC50 (µM) 
BCR/ABL1 2.95 891.25094 0.89 
SHIP1/ABL1 2.17 147.9108388 0.15 
Table 3.1: The IC50IMATINIB of SHIP1/ABL1 and BCR/ABL1 derived from figure 3.14 
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These results clearly demonstrate that the proliferative effect of the 
SHIP1/ABL1 fusion protein in Ba/F3 cells is due to the constitutive activation 
of the ABL1 tyrosine kinase activity in the fusion protein. 
3.8 MECHANISM OF TRANSFORMATION USED BY THE 
SHIP1/ABL1 FUSION 
As explained earlier, in all the ABL1 fusions proteins examined so far the 
constitutive activation the ABL1 tyrosine kinase is due to a dimerization or 
oligomerization of the fusion protein mediated by a protein domain contributed 
by the fusion partner. Therefore, we asked the question whether the novel 
SHIP1/ABL1 fusion protein would also follow the same mechanism of 
activation: namely dimerization or oligomerization of the SHIP1/ABL1 
mediated by the SHIP1 protein domain. To prove homo-dimerization of the 
SHIP1/ABL1 protein we constructed two SHIP1/ABL1 fusions bearing 
different 5’-epitope tags in eukaryotic expression vectors and performed co-
immunoprecipitation experiments.  
3.8.1 Cloning of epitope tagged full length SHIP1/ABL1 into 
eukaryotic expression vectors 
A FLAG or HA epitope tag was introduced in frame at the 5’ end of the 
SHIP1/ABL1 fusion by PCR using the pGEM-Teasy-SA(39-1508)-CLN9 clone 
as template. Three consecutive PCRs were performed in order to introduce 
the epitope tags and the necessary restriction enzyme sites at the 5’ end of 
the SHIP1/ABL1(38-1508) fragment. For the generation of Flag-
SHIP1/ABL1(154-1508) fragments, the forward primers Hind3-Mun1-Flag-
SHIP1No1 (for PCR no 1), Hind3-Mun1-Flag-SHIP1No2  (for PCR no 2) and 
Hind3-Mun1-Flag-SHIP1No3  (for PCR no 3) and the reverse primer SHIP-
ABL1-B1508-1489  (PCR no 1, 2 and 3) (2.1.13) were used (Figure 3.15). 
One microliter of a 1:100 dilution of PCR no 1 was used as template for PCR 
no 2, and similarly 1 µl of a 1:100 dilution of PCR no 2 was used as template 
in the third PCR. With each PCR, about 15 additional nucleotides were added 
to the 5’ end of the fragment, thus building up the sequence for the Flag 
epitope and the HindIII and Mun1 restriction sites.  The HA-SHIP1/ABL1 
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fragments were obtained in a similar fashion in three consecutive PCRs by 
using the forward primers Hind3-Mun1-HA-SHIP1No1, Hind3-Mun1-HA-
SHIP1No2 and Hind3-Mun1-HA-SHIP1No3 and the reverse primer SHIP-
ABL1-B1508-1489 (2.1.13). The epitope-tagged products were cloned into 
pGEM-Teasy vector and the clones were sequence verified. The sequence-
verified clones pGEM-Teasy-Flag-SA(154-1508)-CLN96 and pGEM-Teasy-
HA-SA(154-1508)-CLN91 (Appendix II) were used for further cloning. The 
inserts from these pGEM-Teasy clones were excised by a HindIII/Kpn1 
double-digest and inserted into the HindIII and KpnI sites of pcDNA-BCR/ABL 
replacing the BCR/ABL fusion from the HindIII site 5’ of the BCR ATG till the 
Kpn1 site within ABL1 as described in section 3.4.  
 
Figure 3.15: Introduction of epitope tags at the 5’ end of the SHIP1/ABL1 
fusion. In the upper diagram the positions of the primers are shown in the 
pGEM-Teasy-S/A (39-1508)-CLN9 clone, which was used for the introduction 
of the Flag or HA epitope at the 5’ end of the SHIP1/ABL1 fusion by PCR. The 
lower diagram shows the resulting PCR products, which were cloned into the 
pGEM-Teasy vector.  
The pcDNA clones with the tagged full-length SHIP1/ABL1 fusion, pcDNA-
Flag-SA-96E and pcDNA-HA-SA-91E, were transiently transfected into 
HEK293T cells. The expression of the epitope-tagged SHIP1/ABL1 proteins 
was confirmed by Western blot analysis using antibodies against the Flag and 
HA (2.1.14) epitopes as well as against the ABL1 protein (Figure 3.16). As 
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controls for the anti Flag and anti HA antibodies plasmids expressing Flag-
tagged AF10 protein and HA-tagged Ikaros protein were also transiently 
transfected into HEK293T cells.  
 
Figure 3.16: Western blot analysis of the total cell lysates of the HEK293T 
cells transiently over-expressing SHIP1/ABL1, Flag-SHIP1/ABL1 or HA-
SHIP1/ABL1. Blot1: Immunoblotting with an antibody against c-ABL1: All the 
ABL1 fusion proteins are detected; Blot 2: Immunoblotting with an anti-body 
against the Flag tag: Flag tagged AF10 and SHIP1/ABL1 are detected but HA-
SHIP1/ABL1 is not detected; Blot 3: Immunoblotting with an antibody against 
the HA epitope: HA tagged IKAROS and SHIP1/ABL1 are detected but Flag-
SHIP1/ABL1 is not detected. 
3.8.2 Homo di- or oligomerization of the SHIP1/ABL1 fusion 
protein 
To demonstrate the dimerization or oligomerization of the SHIP1/ABL1 fusion 
protein, HEK293T cells were co-transfected (2.2.3.3) with the pcDNA-Flag-
SA-96E and pcDNA-HA-SA-91E plasmids. For controls, HEK293T cells were 
also transfected with pcDNA-Flag-SA-CLN96E or pcDNA-HA-SA-CLN91E 
alone. After 48 hrs, total cell lysates were prepared (2.2.4.1) from transfected 
and non-transfected cultures. The lysates were then subjected to co-
immunoprecipitation (CoIP) (2.2.4.4).  During the CoIPs, protein complexes 
were precipitated with an anti–FLAG antibody, followed by immunoblotting 
with anti-HA antibodies. These CoIP experiments revealed that protein 
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complexes containing Flag-SHIP1/ABL1 (i.e., complexes precipitated with the 
anti-FLAG antibody) could also be detected with the anti–HA antibody, 
demonstrating the interaction between FLAG-tagged SHIP1/ABL1 proteins 
and HA-tagged SHIP1/ABL1 proteins (Figure 3.17). These results showed 
that the SHIP1/ABL1 fusion protein is present as a dimer or multimer in the 
cells, and strongly suggests that the activation of the ABL1 tyrosine kinase 
activity in SHIP1/ABL1 is mediated via homo di- or oligomerization. 
Homodimerization or oligomerization has also been demonstrated for the 
BCR/ABL1, ETV6/ABL1 and EML1/ABL1 fusions (McWhirter et al., 1993; 
Golub et al., 1996; De Keersmaecker et al., 2005).  
 
Figure 3.17: Detection of a homotypic interaction of the SHIP1/ABL1 
protein: (A) Diagram showing important domains of the SHIP1/ABL1 protein 
with the two different N-terminal epitope tags used in the co-
immunoprecipitation experiments: Flag and HA indicates the Flag and HA 
epitope tags, SH2: Src homology 2, SH3: Src homology 3, TK: Tyrosine kinase 
domain, DB: DNA binding domain, AB: Actin binding domain; (B) Co-
immunoprecipitation of Flag-SHIP1/ABL1 and HA-SHIP1/ABL1: The indicated 
Flag-tagged SHIP1/ABL1 and HA-tagged SHIP1/ABL1 proteins were 
transiently expressed in the HEK293T cells and immunoprecipitated with 
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antibody against the Flag epitope (lane 1-3). As a control, the protein lysates 
obtained from the Flag-SHIP1/ABL1+HA-SHIP1/ABL1 cotransfected cells, 
were immunoprecipitated with antibody against normal IGg (lane 4). The 
immunoprecipitates were separated by SDS-PAGE and immunoblotted with 
anti-HA antibody (lane 1-4). In addition, 5% amount of the total cell lysates 
were subjected to SDS-PAGE and immunoblotted with anti-HA antibody (lane 
5-7). 
3.9 IDENTIFICATION OF THE HOMO DIMERIZATION DOMAIN 
OF SHIP1/ABL1 
As mentioned in the Introduction (1.4), in all ABL1 fusion proteins analyzed so 
far the tyrosine kinase activity of ABL1 is activated via  homo di- or 
oligomerization of the fusion protein. In all of these ABL1 fusion proteins, the 
protein domain which mediates the homo di or oligomerization is supplied by 
the fusion partner of ABL1. As observed in the Co-IP experiments (3.8.2), the 
SHIP1/ABL1 fusion also forms di- or multimers, implying that there should be 
a di- or oligomerization domain within the SHIP1 portion of the SHIP1/ABL1 
fusion. Based on these results, we decided to map the di- or oligomerization 
domain within the SHIP1 portion of the SHIP1/ABL1 fusion protein. To 
approach this problem, we decided to divide the amino terminal 343 amino 
acids of SHIP1 into putative protein domains and to assay their dimerization 
potential in the Yeast-Two Hybrid (Y2H) system. 
3.9.1 Mapping of putative protein domains within the 5’ SHIP1 
portion  
To identify putative protein domains within the amino terminal 343 amino 
acids of SHIP1 contained in the SHIP1/ABL1 fusion protein, we first examined 
the already described conserved domains of SHIP1 in Genbank 
(http://www.ncbi.nlm.nih.gov).  The only conserved domain described in the 
first 343 amino acids of SHIP1 is an SH2 (src-homology 2) domain from aa 5 
to 102. Next, we sought to explore whether the remaining 240 amino acids 
(aa 103 to 343) of the N-terminal SHIP1 portion could be subdivided into 
structural domains. For this we analyzed the sequence with the “scratch 
protein predictor” (http://www.ics.uci.edu/~baldig/scratch/) from the University 
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of California at Irvine. The output of this query predicted two protein domains: 
the first roughly from aa 100 to 260 and the second from aa 260 to 340. Since 
these prediction are inherently uncertain, we decided to subdivide the aa 100 
to 340 region of SHIP1 into two more equally-sized domain which we named 
D1 (aa 100 to 220; nt 451-813) and D2 (aa 220 to 340; nt 811-1173) (Figure 
3.18 and 3.19). 
 
Figure 3.18: Putative protein domains within the N-terminal SHIP1 portion 
contained in the SHIP1/ABL1 fusion protein: SH2: Src homology-2 domain, 
D1: putative domain 1, D2: putative domain 2. The amino acids at the domain 
borders are designated below/above each domain.  
10        20        30        40        50        60 
   AAACAGGAAGTCAGTCAGTTAAGCTGGTGGCAGCAGCCGAGGCCACCAAGAGGCAACGGG 
 
           70        80        90       100       110       120 
   CGGCAGGTTGCAGTGGAGGGGCCTCCGCTCCCCTCGGTGGTGTGTGGGTCCTGGGGGTGC 
 
          130       140       150       160       170       180 
   CTGCCGGCCCGGCCGAGGAGGCCCACGCCCACCATGGTCCCCTGCTGGAACCATGGCAAC 
                                     M  V  P  C  W  N  H  G  N>  10 
 
          190       200       210       220       230       240 
   ATCACCCGCTCCAAGGCGGAGGAGCTGCTTTCCAGGACAGGCAAGGACGGGAGCTTCCTC 
    I  T  R  S  K  A  E  E  L  L  S  R  T  G  K  D  G  S  F  L>  30 
 
          250       260       270       280       290       300 
   GTGCGTGCCAGCGAGTCCATCTCCCGGGCATACGCGCTCTGCGTGCTGTATCGGAATTGC 
    V  R  A  S  E  S  I  S  R  A  Y  A  L  C  V  L  Y  R  N  C>  50  
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          310       320       330       340       350       360 
   GTTTACACTTACAGAATTCTGCCCAATGAAGATGATAAATTCACTGTTCAGGCATCCGAA 
    V  Y  T  Y  R  I  L  P  N  E  D  D  K  F  T  V  Q  A  S  E>  70 
 
          370       380       390       400       410       420 
   GGCGTCTCCATGAGGTTCTTCACCAAGCTGGACCAGCTCATCGAGTTTTACAAGAAGGAA 
    G  V  S  M  R  F  F  T  K  L  D  Q  L  I  E  F  Y  K  K  E>  90 
 
          430       440       450       460       470       480 
   AACATGGGGCTGGTGACCCATCTGCAATACCCTGTGCCGCTGGAGGAAGAGGACACAGGC 
    N  M  G  L  V  T  H  L  Q  Y  P  V  P  L  E  E  E  D  T  G> 110 
 
          490       500       510       520       530       540 
   GACGACCCTGAGGAGGACACAGTAGAAAGTGTCGTGTCTCCACCCGAGCTGCCCCCAAGA 
    D  D  P  E  E  D  T  V  E  S  V  V  S  P  P  E  L  P  P  R> 130 
 
          550       560       570       580       590       600 
   AACATCCCGCTGACTGCCAGCTCCTGTGAGGCCAAGGAGGTTCCTTTTTCAAACGAGAAT 
    N  I  P  L  T  A  S  S  C  E  A  K  E  V  P  F  S  N  E  N> 150 
 
          610       620       630       640       650       660 
   CCCCGAGCGACCGAGACCAGCCGGCCGAGCCTCTCCGAGACATTGTTCCAGCGACTGCAA 
    P  R  A  T  E  T  S  R  P  S  L  S  E  T  L  F  Q  R  L  Q> 170 
 
          670       680       690       700       710       720 
   AGCATGGACACCAGTGGGCTTCCAGAAGAGCATCTTAAGGCCATCCAAGATTATTTAAGC 
    S  M  D  T  S  G  L  P  E  E  H  L  K  A  I  Q  D  Y  L  S> 190 
 
          730       740       750       760       770       780 
   ACTCAGCTCGCCCAGGACTCTGAATTTGTGAAGACAGGGTCCAGCAGTCTTCCTCACCTG 
    T  Q  L  A  Q  D  S  E  F  V  K  T  G  S  S  S  L  P  H  L> 210 
 
          790       800       810       820       830       840 
   AAGAAACTGACCACACTGCTCTGCAAGGAGCTCTATGGAGAAGTCATCCGGACCCTCCCA 
    K  K  L  T  T  L  L  C  K  E  L  Y  G  E  V  I  R  T  L  P> 230 
 
          850       860       870       880       890       900 
   TCCCTGGAGTCTCTGCAGAGGTTATTTGACCAGCAGCTCTCCCCGGGCCTCCGTCCACGT 
    S  L  E  S  L  Q  R  L  F  D  Q  Q  L  S  P  G  L  R  P  R> 250 
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          910       920       930       940       950       960 
   CCTCAGGTTCCTGGTGAGGCCAATCCCATCAACATGGTGTCCAAGCTCAGCCAACTGACA 270 
    P  Q  V  P  G  E  A  N  P  I  N  M  V  S  K  L  S  Q  L  T> 
 
          970       980       990      1000      1010      1020 
   AGCCTGTTGTCATCCATTGAAGACAAGGTCAAGGCCTTGCTGCACGAGGGTCCTGAGTCT 
    S  L  L  S  S  I  E  D  K  V  K  A  L  L  H  E  G  P  E  S> 290 
 
         1030      1040      1050      1060      1070      1080 
   CCGCACCGGCCCTCCCTTATCCCTCCAGTCACCTTTGAGGTGAAGGCAGAGTCTCTGGGG 
    P  H  R  P  S  L  I  P  P  V  T  F  E  V  K  A  E  S  L  G> 310 
 
         1090      1100      1110      1120      1130      1140 
   ATTCCTCAGAAAATGCAGCTCAAAGTCGACGTTGAGTCTGGGAAACTGATCATTAAGAAG 
    I  P  Q  K  M  Q  L  K  V  D  V  E  S  G  K  L  I  I  K  K> 330 
 
         1150      1160      1170      1180      1190      1200 
   TCCAAGGATGGTTCTGAGGACAAGTTCTACAGCCACAAGAAAAAAGCCCTTCAGCGGCCA 
    S  K  D  G  S  E  D  K  F  Y  S  H  K  K  K> 
               SHIP1                         > 
                                                 A  L  Q  R  P> 350 
                                              >      ABL1     > 
 
Figure 3.19: Sequence of the 5’SHIP1 portion contained in the 
SHIP1/ABL1 fusion, showing the putative protein domains:  The SH2 
domain is indicated by bold letters, domain D1 is indicated by underlined letters 
and domain D2 is indicated by blue letters. The highlighted sequence shows 
the Eco81I sites flanking the D1 domain, which were used for the construction 
of the delta-D1 mutants. The nucleotide numbers are given above the 
sequence, the amino acids are numbered to the right of the sequence. 
3.9.2 Mapping of putative interacting domains within the 5’ 
SHIP1 portion using the Yeast Two Hybrid system 
For the mapping of the di- or oligomerization domain within the SHIP1 portion 
of the SHIP1/ABL1 fusion, the SH2, D1, and the D2 domains were cloned into 
appropriate bacterial/yeast shuttle vectors (Y2H vectors) and yeast-two-hybrid 
(Y2H) assays were performed. 
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3.9.2.1 Cloning of different regions of  the 5’ SHIP1 portion for 
Y2H assays 
For the Y2H assays, the coding regions of the whole SHIP1 portion of the 
fusion (5’SHIP) containing the SH2, D1 and D2 domains as well as the coding 
sequences for the D1, D2 and SH2 domains individually were cloned into the 
bacterial/yeast shuttle vectors (Y2H vectors) pGBKT7 and pGADT7, to 
generate GAL4-DBD-fusion and GAL4-AD-fusion proteins, respectively. In 
addition, a sequence coding for SH2-D2 (also called 5’SHIP-deltaD1) was 
cloned into both Y2H vectors.  
For the cloning of SH2-D1-D2, and the individual domains SH2, D1 and D2 
domains, the coding sequences of the these domains were amplified from the 
pGEM-Teasy-SA(39-1508)-CLN9 plasmid. Along with the amplification, 
appropriate linkers (restriction enzyme sites) were introduced at the ends of 
fragments (Figure 3.20) by using the appropriate primers listed in section 
2.1.13. The PCR fragments were then cloned into pGEM-Teasy, the 
sequence of the inserts was verified and the fragments were then cloned into 
pGBKT7 or into pGADT7 using appropriate restriction enzymes (Figure 3.20). 
The pGBKT7 and pGADT7 clones are shown diagrammatically in Figure 3.20. 
The pGEM-Teasy, pGBKT7 and pGADT7 clones containing SH2-D1-D2, 
SH2, D1 and D2 are listed in Appendix II 
To clone the 5’ portion of SHIP1 without the D1 domain (SH2-D2) into the 
bacterial-yeast shuttle vectors for the Y2H assay, the pGEM-Teasy-BamH1-
SH2-D1-D2-Xho1-CLN(6-5) (also called as pGEM-Teasy-BamH1-5’SHIP1-
Xho1-CLN(6-5)) and the pGEM-Teasy-S/A(39-1508)-CLN9 constructs were 
used (Appendix II). In short, the D1-D2 coding sequence in the pGEM-Teasy-
BamH1-SH2-D1-D2-Xho1-CLN(6-5) construct was replaced by D2 coding 
sequence. For this, the D1-D2 region was removed from the plasmid pGEM-
Teasy-BamH1-SH2-D1-D2-Xho1-CLN(6-5) by a Eco81I and Xho1 double 
digestion. Then the D2 region of SHIP1 (nt 904-1182) was amplified from the 
plasmid pGEM-Teasy-S/A(39-1508)-CLN9 along with the introduction of a 5’ 
Bpu10I site and a 3’ Xho1 to obtain the 5’Bpu10I-D2-3’Xho1 fragment using 
the primers Bpu10I-SHIP-D2 F(904-921) and SHIP-D2-Xho1R(1182-1164) 
(2.1.13). This fragment was cloned into the pGEM-Teasy vector. Then the 
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Bpu10I-D2-Xho1 fragment was excised from a pGEM-Teasy clone with the 
correct sequence  (pGEM-Teasy-Bpu10I-D2-Xho1-CLN(1-5)) and inserted 3’ 
to the SH2 coding sequence into the plasmid pGEM-Teasy-BamH1-SH2-D1-
D2-Xho1-CLN(6-5), from which the D1-D2 region had been excised (see 
above). The construct was named pGEM-Teasy-BamH1-5’SHIP1-deltaD1-
Xho1-CLN(6-5). Then using a BamH1-XhoI or a BamH1-Not1 double digest 
the fragments BamH1-SH2-D2-Xho1 or BamH1-SH2-D2-Not1 were excised 
from the plasmid pGEM-Teasy-BamH1-5’SHIP1-deltaD1-Xho1-CLN(6-5) and 
inserted into pGADT7 and into pGBKT7, respectively (Figure 3.21). The Not1 
site used for cloning the fragment into the pGBKT7 plasmid was derived from 
the pGEM-Teasy backbone. The Eco81I recognition sequences in the D1-D2 
region of 5’SHIP1 are indicated in Figure 3.19. The Bpu10I recognition 
sequence introduced at the 5’ end of the D2 fragment by PCR was compatible 
with the Eco81I site at the 3’ end of SH2 region (nt 488) (Figure 3.19). All 
clones were verified by sequencing. In addition, the expression of the 
individual GAL4DBD and GALAD fusion proteins with the various SHIP1 
domains in the yeast cells was verified by Western analysis (data not shown). 
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Figure 3.20: Diagrammatic representation of the Y2H clones: The pGADT7 
constructs are shown as GAL4-AD (activation domain) fusion proteins and the 
pGBKT7 constructs are shown as GAL4-DBD (DNA binding domain) fusion 
proteins. SH2: Src homology-2 domain, D1: domain 1, D2: domain 2. 
Restriction enzyme sites used for cloning (linkers) are indicated. 
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Figure 3.21: Cloning scheme for pGADT7-5’SHIP1-deltaD1 and pGBKT7-5’SHIP1-deltaD1
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3.9.2.2 The domains D1 and D2 are critical for SHIP1/ABL1 
dimerization 
The Yeast-two-hybrid (Y2H) assays were performed (2.2.2.5.3) by co-
transforming the yeast strain AH109 with the pGBKT7 and the pGADT7 
clones with the different domains of 5’SHIP in all possible combinations 
(Figure 3.22 A). The transformed cells were streaked out on high stringency 
SD/-Trp, -Leu, -His plates supplemented with 15 mM 3AT (Figure 3.22 B) and 
the growth of the different yeast clones was recorded after 5 days (Figure 
3.22 A). We also assayed the interactions on SD/-Trp, -Leu, -His plates 
supplemented with other concentrations of 3 AT (0, 3, 5, 10 and 30 mM) but 
found that the most representative read-out was obtained at 15 mM 3AT. The 
assays showed a strong interaction between D1 and D2 (Figure 3.22, 
Experiment 9, 14) and a weak interaction of D1 with itself (Figure 3.22, 
Experiment 8). Surprisingly, there was no interaction between the complete 
5'SHIP domain (consisting of SH2-D1-D2), which contained all the necessary 
interaction domains. The assays showed that SH2-D1-D2 can only interact 
with an isolated D1 domain (Figure 3.22, Experiment 11, 26) and not with the 
D2 domain, regardless of whether D2 is isolated or expressed together with 
the SH2 domain (SH2-D2) (Figure 3.22, Experiment 17, 23, 27, 28, 29).  In 
contrast, an isolated D1 domain can interact with D2, no matter if D2 is 
isolated or together with the SH2 domain (as SH2-D2) or part of the whole 
5'SHIP domain (SH2-D2-D1) (Figure 3.22, Experiment 10, 11, 20, 26). From 
these results we conclude that when D1 is flanked by SH2 and D2, it is unable 
to interact with the D2. One possible explanation could be that D1 engages in 
an intra-molecular interaction with the neighboring D2 domain, and is unable 
to form inter-molecular interactions with other D2 domains. Experiment 33 
(Figure 3.22) shows a surprising interaction of the GAL4-DBD protein with the 
D2 domain when fused to the GAL4-AD. We do not have an explanation for 
this interaction, and we did not pursue it any further. 
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A. 
 
B. 
 
Figure 3.22:  Identification of D1 and D2 as putative interacting domains 
within the SHIP1 portion of the SHIP1/ABL1 fusion protein by Y2H 
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assays: (A) Overview of the Y2H assays: Each interaction assay is assigned a 
number from 1 to 36. The size of the red circles corresponds to the strength of 
the interaction observed on the high stringent SD, -Tr, -Leu, -His, +15mM 3AT 
selection plates; (B) Plates showing the interaction assays: Yeast strain AH109 
was co-transformed with different combinations of pGBKT7 and pGADT7 
constructs (see 3.9.2.1). Each combination of co-transformed Y2H constructs 
(interaction) are described and designated by a number in figure 3.22B. Plates 
1 and 2 show  the growth of the co-transformants on SD, -Tr, -Leu selection 
medium. The co-transformants were then streaked out on high stringency SD, -
Tr, -Leu, -His, +15mM 3AT selection plates (Plates 3 & 4).  The numbers 1-36 
in the figure correspond to the number assigned to each interaction assay as 
described in Figure 3.22A. Visible yeast colonies wre recorded as an 
interaction between the two corresponding proteins. The strength of the 
interaction was determined by scoring the density and size of the yeast 
colonies.  
3.9.3 Verification of SHIP1 interaction domains in mammalian 
cells  
As observed in the Y2H assays (3.9.2.2), there was a strong interaction 
between D1 and D2 and a weak interaction of D1 with itself. However, the 
yeast assays were performed without the ABL1 portion of the fusion protein. 
To validate our hypothesis that both the D1 and the D2 domain of the 5’SHIP 
region are required for SHIP1/ABL1 dimerization in mammalian cells, we 
performed co-immunoprecipitation experiments using different mutants of the 
SHIP1/ABL1 fusion protein with deletions in the SHIP1 portion.  
3.9.3.1 Cloning of SHIP1/ABL1 deletion mutants in eukaryotic 
expression vectors for co-immunoprecipitation 
experiments 
For the co-immunoprecipitation experiments we cloned 4 different variants of 
SHIP1/ABL1 carrying deletion of  the SH2, D1, or the D2 domain of SHIP1 
into the pcDNA3 vector. These mutant variants are SHIP1-deltaD1/ABL1, 
D1(SHIP1)/ABL1, D1-D2(SHIP1)/ABL1 and D2(SHIP1)/ABL1. 
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For the cloning of SHIP1-deltaD1/ABL1 fusion with and without the FLAG 
and HA epitope tags, the fragment coding for the D1-D2-ABL1 up to the Kpn1 
site of ABL1 (nt 1488) was removed from the plasmid pGEM-Teasy-SA(39-
1508)-CLN9 and its tagged derivatives, pGEMTeasy-Flag-SA(154-1508)-
CLN96 and pGEMTeasy-HA-SA(154-1508)-CLN91 (Figure 3.23 A) by an 
Eco81I and Kpn1 double digest to obtain linearized tagged or untagged 
pGEM-Teasy-SH2, flanked by Eco81I and Kpn1 sites. A Bpu10I-D2-ABL1 (nt 
904-1508) fragment was generated by PCR using the primers Bpu10I-SHIP-
D2 F904-921 and SHIP-ABL1-B1508-1489 (2.1.13) and cloned into pGEM-
Teasy generating the plasmid pGEM-Teasy-Bpu10I-D2/ABL(904-1508)-
CLN(3-4). From this plasmid, the Bpu10I-D2/ABL1-Kpn1 (nt 904-1488) 
fragment was obtained by a Bpu10I and Kpn1 double digest and inserted 3’ to 
the SH2 region in the linearized pGEM-Teasy-SH2-Eco81I-Kpn1 vectors (see 
above), to generate the untagged or tagged versions of  SHIP1/ABL1 till nt 
1508 lacking the D1 domain. These pGEM-Teasy plasmids were named 
pGEM-Teasy-S/A-deltaD1-1508-9(5), pGEM-Teasy-Flag-S/A-deltaD1-1508-
96(2) and pGEM-Teasy-HA-S/A-deltaD1-1508-91(3) (Appendix II). The 
pcDNA3 clones of the complete SHIP1-deltaD1/ABL1 with or without tags 
were obtained following the same strategy as described in section 3.4 (Figure 
3.9). The structure of the tagged and untagged SHIP1-deltaD1/ABL1 inserts 
of the pcDNA3 clones as well as the important restriction enzyme sites are 
shown in figure 3.23 B. 
For the cloning of D1(SHIP1)/ABL1 fusion, the coding sequence of the D1 
domain of SHIP1 (nt 460-898 of the SHIP1/ABL1 sequence) and that of ABL1 
(nt 1184-1508 of the SHIP1/ABL1 sequence) were amplified separately. 
During the amplification of the D1 coding sequence, a HindIII-Mun1-Kozak-
ATG sequences with or without 5’ tags (Flag or HA) were introduced 5’ to the 
D1 sequence and at the 3’ end of the D1 sequence a Bcl1 linker was 
introduced using appropriate primers listed in section 2.1.13. These HindIII-
Mun1-D1-Bcl1 fragments were cloned into the pGEM-Teasy vector. A Bcl1 
linker was also introduced to the 5’ end of the ABL1 (1184-1508) fragment by 
PCR and the fragment was cloned into pGEM-Teasy vector. The primers 
used to obtain the HindIII-Mun1-D1(460-898)-Bcl1 and Bcl1-ABL1(1184-1508)  
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Figure 3.23: Diagrams of the pcDNA3 constructs of the deletion mutants 
of SHIP1/ABL1; SHIP1/ABL-delta D1 and the D1/ABL1 (Not to the scale): 
(A) Diagram of pGEM–Teasy-SA(39-1508)-CLN9 and its Flag and HA-tagged 
derivatives; (B) Schematic diagram of the SHIP1-deltaD1/ABL1 insert in the 
pcDNA3 vector; (C) Schematic diagram of the D1/ABL1 insert in the pcDNA3 
vector.  
fragments are listed in the section 2.1.13 (Primer no. 18, 19, 21, 22, 49, 50 
and 55 for D1 and no. 51, 16 for ABL1 fragment). The sequence verified 
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pGEM-Teasy clones of ABL1 and D1 with or without tags (Appendix II) were 
later used for further cloning step. The Bcl1-ABL1 (1184-1488) (Appendix II) 
fragments were linked 3’ to the tagged or untagged D1-Bcl1 fragments in the 
pGEM-Teasy clones of D1 to generate tagged and untagged versions of 
incomplete D1/ABL1 fusions (till nt 1508). For this cloning step, in addition to 
the Bcl1 site of the insert, either Apa1 or Sal1 site from the pGEM-Teasy 
vector were used depending on the direction of the insert. The in-frame fusion 
of the D1 and ABL1 was confirmed by sequencing. Finally, the full length 
D1/ABL1 fusions were assembled in the pcDNA3 vector as described in 
section 3.4 (Figure 3.9). The tagged or untagged full length D1/ABL1 inserts 
of the pcDNA3 clones and the important restriction enzyme sites are shown in 
figure 3.23 C. The pcDNA-SA-deltaD1 and pcDNA-D1/ABL1 constructs were 
used for co-immunoprecipitation experiments in order to confirm the 
interactions discovered by Y2H assays (3.9.3.2). 
3.9.3.2 Confirmation of the interaction between the D1 and D2 
domains of SHIP1 by co-immunoprecipitation  
HEK293T cells were co-transfected (2.2.3.3) with the plasmids pcDNA-Flag-
D1/ABL1-CLN(3-1) and pcDNA-HA-D1/ABL1-CLN(4-1) to analyze the homo-
dimerization potential of the D1 domain of SHIP1 in the context of the 
SHIP1/ABL1 fusion. To confirm the hetero-dimerization of the D1 and the D2 
domains of SHIP1 in the context of the SHIP1/ABL1 fusion, HEK293T cells 
were co-transfected (2.2.3.3) with the plasmids pcDNA-Flag-SA-deltaD1-
CLN(6-3) and pcDNA-HA-D1/ABL1-CLN(4-1). The structure of the SHIP1-
deltaD1/ABL1 and D1/ABL1 proteins are shown in figure 3.24 A. Total cell 
protein lysates from the co-transfected HEK293T cells were subjected to 
immuno-precipitation using an anti-FLAG antibody, separated on an SDS-
PAGE gel and immunoblotted with an anti-HA antibody (Figure 3.24 B). The 
immunoblots showed that the HA-D1/ABL1 protein was strongly co-
precipitated with the Flag-SHIP1-deltaD1/ABL protein. (Figure: 3.24 A; Blot 1). 
This finding confirmed the strong interaction between the D1 and the D2 
domains of SHIP1 in mammalian cells, which we had observed in the Y2H 
system (3.9.2.2, Figure: 3.22). However, this conclusion is only valid under 
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the assumption that the SH2 domain does not interact with the D1 domain, 
which was shown in the Y2H assays (3.9.2.2, Figure: 3.22).  
 
 
Figure 3.24: Interaction between different deletion mutants of the 
SHIP1/ABL1 fusion protein assayed by co-immunoprecipitation: (A) 
Structure of the proteins used in the co-precipitation experiments: SH2: Src 
homology-2 domain, D1: domain 1, D2: domain 2, SH3: Src homology -3 
domain, TK: tyrosine kinase domain, AB: actin binding domain. These proteins 
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were either Flag or HA tagged. (B) Co-immunoprecipitation experiments 
showing that domains D1 and D2 in the N-terminal SHIP1 portion interact 
strongly with each other. Blot 1: Flag-SHIP1-deltaD1/ABL1 and HA-D1/ABL1 
can be co-immunoprecipitated; Blot 2: Flag-D1/ABL1 and HA-D1/ABL1 show a 
very weak interaction visible upon long exposure indacting an interaction 
between the D1 domains; Blot 3: a shorter exposure of Blot 2; Blot 4: Flag-
SHIP1-deltaD1/ABL1 and HA-SHIP1-deltaD1/ABL1 cannot be co-precipitated 
indicating that the D1 domain is crucial for dimerization. All experiments were 
performed in transiently transfected HEK293T cells. The protein lysates of the 
HEK293T cells were subjected to immunoprecipitation with an antibody against 
the Flag epitope (lanes 1-3). As a control, the protein lysates were also 
immunoprecipitated with IgG isotype control (lane 4). The immunoprecipitates 
were separated by SDS-PAGE and immunoblotted with an anti-HA antibody 
(lanes 1- 4). 5% of the total cell lysates, used for the Co-IPs were also 
subjected to SDS-PAGE and immunoblotted with anti-HA antibody (lanes 5-7). 
Protein lysates from untransfected HEK293T cells were used as negative 
controls (lane 8). 
The weak interaction of the D1 domain with itself, which we found in the Y2H 
assays (3.9.2.2, Figure: 3.22), was also observed in the co-
immunoprecipitation experiments, when the immuno-blot was exposed for a 
longer time  (Figure 3.24 B; Blot 2). At shorter exposure times, the band 
indicating interaction of D1 with itself could hardly be seen (Figure 3.24 B; Blot 
3). As positive and negative controls, Co-IPs of Flag-SHIP1/ABL1 with HA-
SHIP1/ABL1 (see Figure 3.17) and Flag-SHIP1-deltaD1/ABL1 with HA-
SHIP1-deltaD1/ABl1 (Figure 3.24 B; Blot 4) were performed, respectively. In 
summary, these results clearly demonstrate that the D1 and D2 domains are 
the critical domains within the SHIP1 portion of the SHIP1/ABL1 fusion gene 
which mediate the dimerization or oligomerization of the SHIP1/ABL1 fusion 
protein and thereby lead to the constitutive activation of the ABL1 tyrosine 
kinase portion of the SHIP1/ABL1 fusion protein. 
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3.10 THE PROLIFERATION POTENTIAL OF DIFFERENT 
SHIP1/ABL1 DELETION MUTANTS 
Since we had identified the domains D1 and D2 as strongly interacting protein 
domains, and the D1 domain as a weakly self-interacting domain, we wanted 
to determine the role of these domains in inducing factor independent growth 
in BA/F3 cells. For this, we cloned 4 different SHIP1/ABL1 mutants with 
deletions of different parts of the SHIP1 portion into the MSCV-IRES-GFP 
(pMIG) retroviral expression vector.  
3.10.1 Cloning of additional SHIP1/ABL1 deletion mutants 
In addition to the SHIP1-deltaD1/ABL1 and D1(SHIP1)/ABL1 expressing 
constructs we cloned D2(SHIP1)/ABL1 and D1-D2(SHIP1)/ABL1 expressing 
plasmids. 
To obtain a pcDNA3-D2/ABL1 construct, we generated the D2(SHIP1)/ABL1 
fusion (nt 829-1508) (Appendix I) with a HindIII-Mun1–KOZAK-ATG sequence 
at the 5’ end of the fragment by PCR. This fragment was amplified from the 
pGEM-Teasy-SA(39-1508)-CLN9 clone using the primers HindIII-Mun1-D2-
F(829-844) and SHIP-ABL1-B1508-1489 (2.1.13) and cloned into pGEM-
Teasy. A sequence verified pGEM-Teasy-D2/ABL(829-1508)-CLN(2-2) clone 
was used to obtain a full length D2/ABL1 fusion (Figure: 3.25 A) in pcDNA3. 
For this, the same cloning strategy, as explained in section 3.4 (Figure 3.9) 
was followed in which the 5’ BCR/ABL1 portion of the pcDNA-BCR/ABL1 
construct was replaced with the D2(SHIP1)/ABL(829-1508) using the HindIII 
and Kpn1 sites. 
In the same way, a pGEM-Teasy clone for the D1-D2(SHIP1)/ABL1 (nt 463-
1508) (Appendix I) fragment was obtained from the pGEM-Teasy-SA(39-
1508)-CLN9 clone using the primers HindIII-Mun1-SHIPD1 (463-478)F and 
SHIP-ABL1-B1508-1489 (2.1.13). The complete D1-D2(SHIP1)/ABL1 fusion 
(Figure: 2.25 B) was assembled in the pcDNA3 vector as described in the 
preceding paragraph using the HindIII and KpnI sites (3.4). We also cloned 
the epitope-tagged versions of D1-D2(SHIP1)/ABL1 and D2(SHIP1)/ABL1 into 
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pcDNA3, but we have not done any further experiments with these two 
constructs yet. 
Finally, to establish the stable Ba/F3 cell lines expressing the SHIP1-
deltaD1/ABL1, D1(SHIP1)/ABL1, D1-D2(SHIP1)/ABL1 and D2(SHIP1)/ABL1 
fusions, the corresponding coding regions were cloned into the retroviral 
expression vector pMSCV-IRES-GFP (pMIG) from the pcDNA3 constructs. 
This was achieved by using the strategy described in section 3.4 (Figure 3.9).  
 
Figure 3.25: Diagrams of the D2/ABL1 (A) and D1-D2/ABL1 (B) inserts in 
pcDNA3 with relevant restriction enzymes. Numbers denote nucleotide 
positions. 
3.10.2 Cell proliferation assays for the SHIP1/ABL1 
deletion mutants: The D1-D2(SHIP1)/ABL1 fusion 
induces IL3 independence in Ba/F3 cells  
Ba/F3 cells were stably transduced (2.2.3.4) with the different pMIG 
constructs expressing the SHIP1-deltaD1/ABL1, D1(SHIP1)/ABL1, 
D2(SHIP1)/ABL1 and D1-D2(SHIP1)/ABL1 mutants. To assay growth factor 
independent growth of Ba/F3 cell lines carrying different mutants of the 
SHIP1/ABL1, the cell lines were cultured in the presence and absence of IL3 
and the number of viable cells was counted on three consecutive days with 
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the trypan blue exclusion method. In addition, the proliferation potential of the 
Ba/F3 cells expressing BCR/ABL1 and the SHIP1/ABL1 fusions, in presence 
and absence of IL3 was also assayed as positive control experiment. As 
negative controls, non- transduced Ba/F3 cells and the stably transduced 
Ba/F3 cells with the pMIG empty vectors were used. The assays were 
performed three times in triplicate for a total of 9 individual assays for each 
mutant and culture condition.  
The assays showed that among all the mutants of SHIP1/ABL1 fusion, only 
the D1-D2(SHIP1)/ABL1 fusion induces IL3 independent growth of the Ba/F3 
cells. However, the proliferation potential of D1-D2(SHIP1)/ABL1 was slightly 
weaker than that of BCR/ABL1 and the complete SHIP1/ABL1 fusions (Figure 
3.26).   
 
Figure 3.26:  Assessment of the proliferation potential of different 
deletion mutants of the SHIP1/ABL1 fusion protein in Ba/F3 cells. Ba/F3 
cells retrovirally transduced with the indicated constructs were grown in the 
absence or presence of IL3 and their growth was recorded over a period of 3 
days. Proliferation curves were prepared by plotting the mean ± SD derived 
from three individual assays. 
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3.11 LOCALIZATION OF THE SHIP1/ABL1 FUSION ON 
METAPHASE CHROMOSOMES BY FISH 
In order to analyze the genomic rearrangement that led to the SHIP1/ABL1 
fusion, we performed fluorescence in-situ hybridization (FISH) assays. We 
prepared dual color dual fusion (DCDF)-FISH probes for the detection of the  
 
Figure 3.27: Fluorescent in-situ hybridization for the analysis of genomic 
SHIP1/ABL1 fusion: (A) Position of the selected BAC clones in the genome 
browser view from www.ensembl.org ; BP is breakpoint region (B) SHIP1/ABL1 
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DCDF FISH probe design for the detection of the SHIP1/ABL1 fusion and the 
resulting signal pattern in normal cell. (C) The SHIP1/ABL1 DCDF probe set 
hybridized to a metaphase cell of a normal male. 
SHIP1/ABL1 fusion from selected bacterial artificial chromosome (BAC) 
clones corresponding to the genomic locus of the SHIP1 and ABL1 genes 
flanking the breakpoints (Figure 2.27 A)(2.1.15). The SHIP1 specific FISH 
probes were labeled with Spectrum Green (FITC) and the ABL1 specific FISH 
probes were labeled with Spectrum Orange (Texas Red, TR) fluorophores. 
The BAC DNA was amplified by SIA (Sequence independent amplification) 
before PCR-labelling (2.2.5.2.1.1). The SHIP1/ABL1 DCDF-FISH probe set 
contained two FITC labelled BACs corresponding to the 5’ and the 3’ region of 
the SHIP1 locus and two TR labelled BACs corresponding to the 5’ and the 3’ 
region flanking the breakpoint in the ABL1 locus. With this probe set, normal 
cells should show 2 green signals on the two SHIP1 loci on 2q37 and 2 
orange signals on the two ABL1 loci on 9q34 (a so-called 2G2O signal 
pattern) (Figure 2.27 B). As hypothesized in chapter 3.1.6 (Figure 3.6), in our 
patient sample the insertion of the 3’ portion of SHIP1 into the ABL1 locus 
should result in at least one yellow signal on chromosome 9. The specificity 
and quality of the DCDF-SHIP1/ABL1 FISH probe set was confirmed by 
hybridizations on the metaphase cells obtained from the peripheral blood 
sample of a normal male (Figure 2.27 C). Unfortunately, we were unable to 
achieve good hybridization results with the DCDF-SHIP1/ABL1 FISH probe 
set in our patient sample. This could be due to the poor quality of the patient 
sample. We are attempting to improve the hybridization conditions and to 
optimize the pretreatment of our patient sample, and will hopefully be able to 
obtain adequate hybridization results in the future.  
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4 Discussion 
4.1 SHIP1/ABL1: A NEW ABL1 FUSION GENE  
The study of chromosomal translocations, which lead to the formation of 
fusion genes has provided us with fundamental insights into the basic 
mechanisms of malignant transformation not only in leukemias but also in 
solid tumors. The genes that are found at the translocation breakpoints and 
are part of the fusion genes occupy central positions in key regulatory 
pathways in the cells, which control, among other things, proliferation, 
differentiation and programmed cell death. Despite the cloning of more than a 
hundred different gene fusions in hematological malignancies and solid 
tumors, we are still very far from a comprehensive understanding of the 
cellular pathways that are altered in the many different tumor types. For this 
reason the identification of each new gene fusions will help us in our quest to 
understand the formation of tumors. 
We identified a new fusion gene involving the ABL1 tyrosine kinase gene in 
the leukemic cells of an 18-year old female patient diagnosed with common 
ALL. The fusion was found through the sequence analysis of an aberrant PCR 
band from an RT-PCR reaction designed to detect a BCR/ABL fusion 
transcript. The sequence of this band revealed an in-frame fusion between the 
ABL1 (Abelson 1) and the SHIP1 (SH2 containing Inositol phosphatase-1) 
gene located on chromosome 2 band q37. Interestingly, the reciprocal 
ABL1/SHIP1 fusion transcript was not detectable by RT-PCR.  
The first ABL1 gene fusion, the BCR/ABL1 fusion, was the first fusion gene in 
leukemia characterized at the molecular level in 1985 (Shtivelman et al., 
1985), and is the hallmark of Chronic Myeloid Leukemia (CML) (>95% of all 
CML cases are BCR/ABL positive). The BCR/ABL1 fusion is also the most 
common known genetic lesion in ALL (25% of adult B-ALL, and 2-4% of 
childhood B-ALL cases are BCR/ABL1 positive), but is rarely seen in AML 
(Borowitz and Chan, 2008). Though the constitutive activation of the tyrosine 
kinase activity of ABL1 through the BCR moiety in the BCR/ABL fusion is 
such a common event in leukemia, ABL1 fusion partners other than BCR are 
exceedingly rare. Up to now, only 5 additional ABL1 fusion partners have 
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been identified. This includes the ETV6/ABL1 fusion, which was the second 
ABL1 fusion, discovered 10 years after the identification of the BCR/ABL1 
fusion (Papadopoulos et al., 1995). The other four ABL1 fusions, EML1/ABL1, 
NUP214/ABL1, RCSD1/ABL1 and ZMIZ1/ABL1 were described almost 10 
years after the identification of the ETV6/ABL1 fusion (Graux et al., 2004; De 
Keersmaecker et al., 2005; De Braekeleer et al., 2007; Soler et al., 2008). It is 
remarkable that even though BCR/ABL1 was the first fusion gene found and 
is the most common fusion gene, up to now only five additional fusion 
partners of ABL1 could be identified. This is very different from the situation of 
several other genes, some of which are much less frequently rearranged than 
ABL1, like MLL, NUP98, ETV6 or ALK. As an example, even though the first 
MLL fusion genes were characterized 10 years after the identification of the 
BCR/ABL1 fusion, there are now over 50 different fusion partners of MLL 
described (Meyer et al., 2006) (http://atlasgeneticsoncology.org/Genes/MLL. 
html). Thus, comparing the two most common fusion gene subgroups, the 
MLL fusions and the ABL1 fusions, the identification of a novel ABL1 fusion 
partner is a comparatively rare event and should lead to valuable insights into 
the pathways important in ABL1-mediated leukemogenesis. For this reason 
we found it very important and interesting to characterize the SHIP1/ABL1 
fusion in more detail. 
As mentioned above, in contrast to the BCR/ABL1 fusion, which is the most 
common genetic aberration in leukemia, all the other ABL1 fusions are 
extremely rare. There are only single case reports of the EML1/ABL1, 
RCSD1/ABL1 and ZMIZ1/ABL1 fusions, and just 6 cases of ETV6/ABL1 have 
been described (http://atlasgeneticsoncology.org//Indexbychrom/idxa_9.html). 
The NUP214/ABL1 fusion is slightly more common and found in 6% of T-ALLs 
(Graux et al., 2004).  
If one compares the different ABL1 fusion partners, it should be possible to 
learn more about the requirements for ABL1-mediated leukemogenesis. The 
common denominator of all the ABL1 fusion partners is that they are all 
expressed in haematopoietic tissues and they all contribute a di- or 
oligomerization domain to the fusion protein. The di- or oligomerization 
domains are required for the constitutive activation of the ABL1 kinase 
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activity. However, in that respect the NUP214/ABL1 fusion differs from the 
other ABL1 fusion, in that the coiled-coil motifs of NUP214 do not mediate the 
oligomerization of the NUP214/ABL1 protein, but mediate the interaction of 
NUP214/ABL1 with other nuclear pore proteins. This NUP214/ABL1 nucleo 
pore interaction is required to achieve the full NUP214/ABL1 transforming 
potential (De Keersmaecker et al., 2008). Neverthless, considering these two 
basic requirements for an ABL1 fusion partner, one would expect many genes 
in the cell to fulfil these two requirements. Thus, it is very surprising that there 
have only been 6 fusion partners of ABL1 identified till now.  This indicates, 
that the fusion partners of ABL1 are required to have some other unknown 
important properties. It could be that they have to be able to activate some 
specific signalling pathways. For example, in addition to the coiled-coil 
domain, BCR contains a GRB2 binding site (Tyr177), which is required for the 
maximal transformation potential of BCR/ABL1 by activating the RAS and the 
GAB2/PI3K/AKT signalling pathways (Pendergast et al., 1993; Puil et al., 
1994; Goga et al., 1995; He et al., 2002; Sattler et al., 2002). The ability of 
NUP214 to localize at the nuclear pore complex via its coiled-coil domains 
and its interaction with other nuclear pore proteins is a prerequisite to achieve 
the full transforming potential of NUP214/ABL1 (De Keersmaecker et al., 
2008). There is also evidence that some of the fusion partners of ABL1 have 
tumor suppressor gene functions. This is known for example for the ETV6 
gene and, as explained below, might also be the case for SHIP1. 
The ABL1 breakpoint in the SHIP1/ABL1 fusion is 5’ of exon 2 of ABL1. This 
is the same location as in all the other known ABL1 fusions like BCR/ABL1, 
ETV6/ABL1, or NUP214/ABL1. These facts make the SHIP1/ABL1 fusion a 
good model to study the requirements for the constitutive activation of ABL1 
and ABL1-mediated malignant transformation of hematopoietic cells. It should 
be noted that ours is the first report that SHIP1 has been found altered in a 
malignancy and suggests that the possible tumor suppressor function of 
SHIP1 might play an important role in leukemogenesis. 
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4.2 SHIP1: THE NOVEL FUSION PARTNER OF ABL1 IS A 
PUTATIVE TUMOR SUPPRESSOR GENE 
What is known about the normal function of SHIP1 makes it an extremely 
attractive target for genetic alterations that would facilitate tumor formation. 
SHIP1 (SH2-containing inositol phosphatase-1), which is also known as 
INPP5D (Inositol polyphosphate 5-phosphatase), is widely and specifically 
expressed in haematopoietic cells. SHIP1 was cloned in 1996. SHIP1 was 
originally identified as the major 145 kD tyrosine phosphorylated protein that 
became associated with SHC (SH2 domain containing transforming protein 1) 
after cytokine stimulation (Damen et al., 1996). At the same time, SHIP1 was 
observed as the major tyrosine phosphorylated protein, which bound to the C-
terminal SH3 domain of the adaptor protein GRB2 (growth factor receptor-
bound protein 2) (Damen et al., 1996; Ware et al., 1996). Thus SHIP1 
interacts with both SHC and GRB2, which are adapter proteins known to be 
involved in cytokine signaling and the activation of the Ras pathway (Damen 
et al., 1996).  
SHIP1 contains a central phosphatase domain, an N-terminal SH2 domain 
and a C-terminal terminal domain containing NPXY (Asn-Pro-Xaa-Tyr) sites, 
which can be tyrosine phosphorylated, and proline-rich sequences, which can 
provide the binding sites for the SH3 domains of other proteins. SHIP1 is a 
phosphatase, which hydrolyzes the 5-phosphates from phosphatidylinositol 
(3,4,5)–trisphosphate(Ptdins(3,4,5)P3;PIP3) and inositol-1,3,4,5 tetrakis-
phosphate (Ins(1,3,4,5)P4) (Damen et al., 1996), thereby negatively regulating 
the PI3K (phosphoinositide 3-kinase) pathway. The PI3K pathway is part of 
many important signalling pathways and regulates key cellular functions such 
as survival, proliferation, cell activation and cell migration (Krystal, 2000; Ward 
and Cantrell, 2001; Ward, 2006). SHIP1 regulates these important cellular 
functions by controlling PIP3 levels and Ras activity following cytokine 
stimulation (Batty et al., 1985; Damen et al., 1996).  
A murine SHIP1 knockout model has provided us with additional information 
about the function of SHIP1 in the hematopoietic system.  SHIP1 knockout 
mice fail to thrive and show an increased number of neutrophils and 
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monocytes/macrophages due to enhanced survival and proliferation of their 
progenitors. For this reason, the SHIP1 knockout mice develop a 
myeloproliferative-like disease with massive infiltration of myeloid cells in their 
lungs. The bone marrow progenitor cells of the SHIP1 knockout mice are 
hypersensitive to hematopoietic growth factors. SHIP1 knockout mice exhibit 
a reduction in the number of pre-B and immature B cells in the bone marrow, 
but an increased number of hypermature B cells in the spleen (Helgason et 
al., 1998). The B cells from SHIP1 knockout mice are hypersensitive to B cell 
receptor stimulation, and less sensitive to apoptotic stimuli (Brauweiler et al., 
2000a; Brauweiler et al., 2000b; Helgason et al., 2000). It was shown that 
SHIP1 plays a different role in T cells compared to myeloid or B cells (Gloire 
et al., 2007). SHIP1 does not seem to inhibit T cell proliferation, but instead its 
absence creates an anergy to T cell receptor stimulation. Whereas SHIP1 
clearly has pro-apoptotic functions in myeloid and, under certain conditions, in 
B cells, it appears to play an anti-apoptotic role in T cells (Gloire et al., 2007). 
In cell line models it could be shown that SHIP1 negatively regulates cellular 
growth, differentiation or migration, and that it may play an important role in 
apoptosis (Lioubin et al., 1996; Ono et al., 1996; Liu et al., 1997; Sattler et al., 
2001). 
Interestingly, it has been observed that SHIP1 is reversibly down regulated in 
BCR/ABL transformed Ba/F3 cells (Sattler et al., 1999). In this murine pro-B 
cell line, SHIP1 was found to form a signaling complex with BCR/ABL that 
includes DOK1 (Downstream of tyrosine kinase 1), phosphatidylinositol 3-
kinase (PI3K) and CRKL (v-crk sarcoma virus CT10 oncogene homolog 
(avian)-like), each of of these proteins is known to regulate cell migration. 
SHIP1 interacts directly with the PTB (phosphotryrosine binding) domain of 
DOK1 and with the SH2 domain of CRKL. The association of PI3K with this 
complex is thought to occur via CRKL (Sattler et al., 2001).  
Thus, SHIP1 is found to be involved in multiple important hematopoietic 
signaling pathways in myeloid cells and in B cells but also in T cells. Most 
importantly, considering the phenotype of the SHIP1 knockout mice, SHIP1 is 
an excellent candidate for a tumor suppressor gene.  
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4.3 THE GENOMIC REARRANGEMENT LEADING TO THE 
SHIP1/ABL1 FUSION  
Interestingly, the cytogenetic analysis of the leukemic cells from the patient 
with the SHIP1/ABL1 fusion showed a normal karyotype. At first sight, this 
finding is not surprising considering the location and direction of transcription 
of the SHIP1 and ABL1 genes. Both genes located close to the telomeres of 
their chromosomes and are transcribed 5’ to 3’, centromere to telomere. Thus 
a SHIP1/ABL1 fusion gene can be generated by a simple balanced 
t(2;9)(q37;q34) translocation (Figure 3.4 A). Given the sub-telomeric genomic 
locations of SHIP1 and ABL1, this translocation could be easily overlooked by 
conventional cytogenetics, but should be easily detectable upon FISH 
analysis using a BCR/ABL dual color dual fusion (DCDF) FISH probe on 
metaphase chromosomes (Figure 3.5). In this analysis one would expect to 
see two signals for the BCR loci on chromosome 22, and three ABL1 signals: 
one signal on the normal chromosome 9, a smaller signal  (5’ABL1) on the 
derivative chromosome 9, and a third ABL1 signal (3’ABL1) on the derivative 
chromosome 2 (Figure 3.4 B). But unexpectedly, we observed only two ABL1 
signals, both on chromosome 9 and no ABL1 signal on chromosome 2. 
However, in about 50% of the interphase nuclei, we saw a peculiar ABL1 
signal pattern with four ABL1 signals in a pair wise arrangement with a small 
gap equivalent to the size of 1-2 signals separating the signals of each pair. 
These observations led us to speculate that there might be an insertion of the 
5’SHIP1 portion into the ABL1 genomic locus, forming a 5’SHIP1-3’ABL1 
fusion on chromososme 9. The explanation for the observation of the signal 
pairs of the ABL1 loci in the interphase nuclei but not on metaphase 
chromosomes, is the decondensed chromatin in the interphase nuclei. In the 
metaphase chromosomes, the chromatin is so condensed that the gap 
between the 5’ and the 3’ ABL1 signals cannot be resolved.  It is interesting to 
note that, even though the 3’ portion of ABL1 can easily form a fusion with 
5’SHIP1 by a simple translocation, apparently a more complex rearrangement 
took place. 
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4.4 GENOMIC CONSEQUENCES OF THE SHIP1/ABL1 FUSION 
The FISH analysis on interphase nuclei revealed rearrangements involving 
both ABL1 loci, resulting in the absence of a normal ABL1 allele. The possible 
mechanism for the generation of the two identically aberrant ABL1 loci can be 
explained as follows. Initially, an insertion of a 5’SHIP1 fragment within one of 
the ABL1 loci occurred. Then, possibly through a mitotic non-disjuntion event, 
this derivative chromosome 9 was duplicated while the normal copy of 
chromosome 9 was lost from the cell. Thus, it can be speculated that this 
rearrangement should have led to a LOH (Loss Of Heterozygosity) covering 
all of chromosome 9.  
4.5 ASSAYING THE TRANSFORMATION POTENTIAL OF 
ONCOGENES  
One of the key questions that arise during the study of leukemia-associated 
rearrangements and especially during the analysis of fusion genes is whether 
the fusion gene is capable of causing leukemia. The question whether a given 
(fusion) oncogene is actually able to transform hematopoietic cells is not easy 
to answer. The transforming potential of a fusion gene can be analyzed in cell 
line systems or in animal models. 
The murine pro-B cell line Ba/F3 and fibroblast cell lines like NIH-3T3 or Rat-1 
are some of the cellular systems used for the study of the oncogenic potential 
of fusion genes or mutated genes, especially in the case of constitutively 
activated tyrosine kinases. Ba/F3 cells are interleukin-3 (IL3) dependent and 
can only proliferate in the presence of IL3. The fibroblast cell lines (eg. 
NIH3T3) are anchorage dependent and need to attach to the surface of the 
culture flask to proliferate. As an indication of its transformation potential the 
expression of a putative oncogene can induce IL3 independent proliferation of 
Ba/F3 cells or anchorage independent growth of the fibroblasts in soft agar.  
As mentioned above, these two cellular systems are especially suitable to test 
the activity of activated tyrosine kinases. However, these cell line systems are 
not sufficient to accurately measure the transformation potential of all types of 
fusion genes or oncogenes, and they can not recapitulate the complexity of 
tumor development in the organism. To obtain a more complete 
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understanding of the true tumorogenic potential of a given oncogene whole 
animal models like bone marrow transplantation (BMT) models, transgenic 
animals and knock-in models are available. Bone marrow transplantation 
models, in which the oncogene is retrovirally transduced into primary bone 
marrow cells which are then transplanted into lethally irradiated syngeneic 
mice, are especially useful to assay the potential of an oncogene to induce 
tumors in the hematopoietic systems. 
It should be kept in mind that in many cases the read outs obtained in the cell 
line systems do not match the read outs obtained from the animal model 
systems. For example, the transformation potentials of the BCR/ABL1 and the 
ETV6/ABL1 fusiongenes are more or less similar in the Ba/F3 cell line system, 
but in the bone marrow transplant (BMT) mouse models these two ABL1 
fusions induce different diseases with different latency periods. The recipients 
(Balb-c mice) of BCR/ABL1 transduced bone marrow develop a CML-like 
disease, whereas the recipients of ETV6/ABL1 expressing bone marrow cells 
did not develop leukemia but rather a myeloproliferative syndrome or a small 
bowel syndrome (Golub et al., 1996; Million et al., 2002). These differences 
were also observed for the NUP214/ABL1 fusion. The NUP214/ABL1 fusion 
induces very weak IL3 independent growth of the Ba/F3 cells compared to the 
BCR/ABL1 fusion. However, in the BM transplanted mice a strong ALL 
phenotype is seen (De Keersmaecker et al., 2008).  
Thus, for the study of the oncogenic potential of particular genetic lesion, 
animal models are more realistic. However, these model systems also have 
their limitations. For example, in BMT models, the gene, which is retrovirally 
transduced in the bone marrow cells, randomly integrates in the genome of 
these cells. These random integrations may disrupt or activate neighboring 
tumor suppressor gene or oncogene, respectively, thereby altering the 
phenotype. In addition, animal models are very expensive and time 
consuming to establish and to evaluate. This is especially true for the 
transgenic and knock-in models.   
4.5.1 Behavior of SHIP1/ABL1 in Ba/F3 cells: SHIP1/ABL1 
induces IL3 independent proliferation in a murine pro-B 
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cell line, which is inhibited by the tyrosine kinase 
inhibitor Imatinib 
To obtain an initial cellular read out of the oncogenic potential of the 
SHIP1/ABL1 fusion, we used the IL3-dependent Ba/F3 cell line system. We 
expressed the SHIP1/ABL1 and the BCR/ABL1 fusion in IL3 dependent Ba/F3 
cells. The expression of SHIP1/ABL1 induced IL3 independent proliferation of 
Ba/F3 cells, which was comparable with that induced by the BCR/ABL1 
fusion. The IL3 independent growth induced by the SHIP1/ABL1 fusion and 
the fact that the SHIP1/ABL1 protein contains the same portion of ABL1 as 
the other ABL1 fusions, suggested that the ABL1 tyrosine kinase is 
constitutively activated in the SHIP1/ABL1 fusion protein. To assess this 
possibility, we analyzed the sensitivity of the SHIP1/ABL1 fusion to the 
tyrosine kinase inhibitor STI571 (Imatinib). 
STI571, also known as Imatinib, is an ABL1 specific tyrosine kinase inhibitor 
as described in the introduction. All ABL1 fusions are sensitive to Imatinib. We 
assessed the sensitivity of SHIP1/ABL1 and BCR/ABL1 by proliferation 
assays using the Ba/F3 cell line. As expected, the IL3-independent 
proliferation of SHIP1/ABL1 expressing Ba/F3 cells could be inhibited by 
Imatinib treatment. Interestingly, SHIP1/ABL1 expressing Ba/F3 cells were 
significantly more sensitive to Imatinib than BCR/ABL1 expressing cells. The 
rate of proliferation was much lower in the SHIP1/ABL1 expressing Ba/F3 
cells compared to that in the Ba/F3 cells expressing BCR/ABL1 at a particular 
concentration of Imatinib. The Imatinib concentrations required to inhibit the 
proliferation of SHIP1/ABL1 expressing Ba/F3 cells by 50% (inhibitory 
concentration 50, IC50) was less than one-fourth of that required in case of 
the BCR/ABL1-transduced Ba/F3 cells. The IC50 IMATNIB for SHIP1/ABL1 was 
0.16 µM and that for BCR/ABL1 was 0.71 µM. These results clearly 
demonstrated that the ABL1 tyrosine kinase is constitutively active in the 
SHIP1/ABL1 fusion.  
This higher sensitivity of SHIP1/ABL1 to Imatinib compared to that of 
BCR/ABL1 is surprising and difficult to explain. One explanation could be that, 
because of the strong tetramerization domain of BCR, the tyrosine activity of 
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the BCR/ABL1 fusion protein is more strongly activated than that of the 
SHIP1/ABL1 fusion protein.   
To better understand these results and the leukemogenic mechanisms used 
by the SHIP1/ABL1 fusion, it might be helpful to look at the mechanism of 
ABL1 tyrosine kinase activation in the other ABL1 fusions and to examine 
more closely the protein domains in the SHIP1 portion of the SHIP1/ABL1 
fusion.   
4.6 THE N-TERMINAL PORTION OF SHIP1 CONTAINS TWO 
PROTEIN INTERACTION DOMAINS 
The common mechanism of the activation of the ABL1 tyrosine kinase used 
by almost all the other ABL1 fusions is oligo or dimerization of the fusion 
protein. The oligo- or dimerization of the fusion protein is mediated by protein 
domains in the ABL1 fusion partner. As expected, we could see a clear 
interaction between the full-length SHIP1/ABL1 fusion proteins in co-
immunoprecipitation experiments using Flag and HA-tagged versions of the 
SHIP1/ABL1 fusion protein. This suggested the presence of an oligo- or 
dimerization domain in the SHIP1 portion of the fusion protein.  
To dissect the protein interaction domain within the N-terminal portion of 
SHIP1, we first performed an in silico protein domain homology search. The 
SH2 domain (aa 5-102) of SHIP1 was the only conserved domain that was 
detected in this region. Based on the calculations of a protein structure 
prediction program, we defined two additional putative protein domains 
(roughly aa 100-220 and aa 220-340) in the N-terminal portion of SHIP1. We 
called these two domains domain 1 (D1) and domain 2 (D2). To further 
characterize the protein interaction domains, we used the Yeast-two-hybrid 
system (Y2H).  
In the Y2H assays, we discovered a strong heterotypic interaction between 
domain D1 and domain D2, when these domains were fused individually to 
the GAL4-DNA-binding protein and to the GAL4-activation domain. But 
unexpectedly, we could not detect any interaction between the complete N-
terminal portions (SH2-D1-D2) of SHIP1 in the Y2H assays, even though the 
D1 and the D2 domain were contained in these proteins. There was also no 
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interaction between an isolated D2 domain and the N-terminal portion (SH2-
D1-D2) of SHIP1. This was very surprising, because in the co-
immunoprecipitation experiments with the full-length SHIP1/ABL1 fusion 
proteins a strong homotypic interaction between the SHIP1/ABL1 fusion 
proteins was detected. The Y2H assays suggested that when the D1 domain 
is flanked by the SH2 and D2 domains, it can not interact with an isolated D2 
domain or with a D2 domain flanked by a D1 and an SH2 domain. The 
possible explanation for this observation is the inhibition of intramolecular 
interactions by intermolecular interactions combined with differences in the 
posttranslational modifications in different species.  
4.6.1 Inhibition of intermolecular interaction by intramolecular 
interaction in the Y2H system 
As shown in the Y2H assays, D1 and D2 interact strongly with each other. 
This interaction might also occur within the SH2-D1-D2 protein as an 
intramolecular interaction. The intramolecular interaction between D1 and D2 
in the SH2-D1-D2 protein would result in a closed conformation of this protein. 
In this closed conformation of the SH2-D1-D2 protein, the protein interaction 
sites of D1 and D2 are occupied and embedded within the SH2-D1-D2 protein 
(Figure 4.1 A). This model can explain why the intermolecular interaction 
between the SH2-D1-D2 proteins could not be observed in the Y2H assays. 
4.6.2 Difference in the post-translational modifications 
between yeast and mammals 
The difference between the Y2H and the co-immunoprecipitation results can 
be explained by differences in the post-translational modifications (PTM) 
between yeast and mammalian cells. It could be that a specific PTM, like a 
phosphorylation or acetylation, of the N-terminal SHIP1 portion (SH2-D1-D2) 
is required to prevent this protein region from forming the intramolecular 
interaction between the D1 and D2 domains (Figure 4.1B, C). It is conceivable 
that the enzymes required for this PTM are not present in the yeast and thus 
the SH2-D1-D2 region would mainly be in its closed conformation in yeast. 
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Figure 4.1:  Protein interaction model explaining the difference between 
the Y2H and co-immunoprecipitation results: (A) model showing the 
intramolecular interaction within the isolated 5’SHIP1 protein, which would 
explain the absence of intermolecular interaction between the 5’SHIP1(SH2-
D1-D2) proteins observed in the Y2H assays (B) Schematic representation of a 
possible post translational modification (PTM) of the N- terminal SHIP1 portion 
(SH2-D1-D2) regulating the intermolecular interaction between the full length 
SHIP1/ABL1 proteins in the mammalian system. (C) A model showing the 
interaction between the full-length SHIP1/ABL1 proteins, as observed in the co-
immunoprecipitation experiments. 
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Figure 4.2: Models explaining possible protein interactions lead by the D1 
and D2 domains within the N-terminal SHIP1 portion. Models showing (A) 
the homo-oligomerisation of the SHIP1/ABL1 fusion proteins, (B) the homo-
dimerisation of SHIP1, (C) the hetero dimerisation and (D) the hetero-
oligomerisation of the SHIP1-SHIP1/ABL1 proteins. 
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The interaction between the D1 and the D2 domains of SHIP1 was confirmed 
by co-immunoprecipitations in mammalian cells by co-expressing the Flag-
tagged SHIP1-deltaD1/ABL1 and the HA-tagged SHIP1(D1)/ABL1 proteins 
(3.9.3.2, Figure 3.24 B). Thus, we demonstrated that, in addition to the SH2 
domain, the SHIP1 portion of the SHIP1/ABL1 protein contains two other 
domains, which interact with each other and which are crucial for the 
dimerization/oligomerization of the SHIP1/ABL1 fusion protein.  
The two protein domains D1 and D2 in the N-terminal SHIP1 portion would 
not only allow for the dimerization of the fusion protein (Figure 4.1 C) but also 
for an oligo- or multimerization (Figure 4.2).  
In addition to the formation of the homo-dimers of the SHIP1/ABL1 fusion 
proteins (Figure 4.1 C), the two protein domains D1 and D2 in the N-terminal 
SHIP1 portion might also allow for an oligo- or multimerization of the 
SHIP1/ABL1 protein (Figure 4.2 A), homodimerisation of the wild type SHIP1 
(Figure 4.2 B) and hetero di- or oligomers of the wild type SHIP1 and 
SHIP1/ABL1 proteins (Figure 4.2 C, D). 
4.7 D1 AND D2 ARE REQUIRED FOR IL3 INDEPENDENT 
PROLIFERATION OF BA/F3 CELLS  
The importance of the domain 1 (D1) and the domain 2 (D2) was also 
demonstrated by in vivo assays in Ba/F3 cells using different deletion mutants 
of the SHIP1/ABL1 fusion protein. This included the deletion mutants lacking 
D1 or D2 or the SH2 domain. Among all the deletion mutants, only the 
SHIP1(D1-D2)/ABL1 fusion lacking the SH2 domain of SHIP1 was able to 
induce IL3 independent proliferation of Ba/F3 cells. Whereas Ba/F3 cells 
carrying the SHIP1(D1)/ABL1 or SHIP1(D2)/ABL1 fusions died after IL3 
withdrawal. However, the SHIP1(D1-D2)/ABL1 showed lower proliferation 
potential compared to the BCR/ABL1 and SHIP1/ABL1 fusions. These results 
indicate that the SH2 domain does not contribute to the activation of the ABL1 
kinase activity and that the domains D1 and D2 are necessary for the 
activation of the ABL1 kinase activity. However, we cannot exclude the 
possibility that the SH2 domain of SHIP1 also contributes in a certain way to 
factor independent growth in Ba/F3 cells. 
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In addition to the importance of D1 and D2 in the activation of the tyrosine 
kinase activity of ABL1, the interaction between the domains D1 and D2 in the 
N-terminal portion of SHIP1 suggests two interesting hypotheses for 
additional leukemogenic effects of the SHIP1/ABL1 fusion protein.   
4.7.1 Hypothesis I: The SHIP1/ABL1 fusion acts as a dominant 
negative regulator of normal SHIP1 function 
As discussed earlier, SHIP1 functions as a negative regulator of myeloid cell 
proliferation and differentiation. The formation of the SHIP1/ABL1 fusion gene, 
disrupts one of the SHIP1 alleles resulting in a condition similar to SHIP1 
heterozygosity (+/-). The mouse models of SHIP1 have shown that SHIP1 
heterozygosity is not associated with a disease phenotype. However, mice 
with a homozygous loss of SHIP1 (-/-) failed to thrive and developed a 
myeloproliferative syndrome-like condition.  As we demonstrate here that 
SHIP1 contains two protein interaction domains, it can be speculated that the 
interaction between different SHIP1 molecules in the form of di- or oligomers 
might be necessary for the regulation of SHIP1 function itself. On the other 
hand, the domains D1 and D2 are also important for the 
dimerization/oligomerization of the SHIP1/ABL1 fusion protein and thereby for 
the constitutive activation of the ABL1 kinase. Based on this background, it 
can be speculated that in addition to the formation of the SHIP1/ABL1 homo-
dimers or homo-oligomers (Figure 4.1 C, 4.2 A) and SHIP1 homo-dimers 
(Figure 4.2 B) or homo-oligomers, the D1-D2 interaction could also result in 
the formation of the SHIP1/ABL1 - SHIP1 hetero-dimers or hetero-oligomers 
(Figure 4.2 C and D). The formation of the SHIP1/ABL1 - SHIP1 hetero di- or 
oligodimers might interfere with the proper function of the SHIP1 protein 
(Figure 4.3). Thus, the formation of the SHIP1/ABL1 fusion, in addition to the 
induction of the factor independent growth in the hematopoietic cells, disrupts 
not only one of the SHIP1 alleles, but may also interfere with the activity of the 
normal SHIP1 protein through a dominant negative mechanism. Therefore, it 
is tempting to speculate that the SHIP1/ABL1 fusion has two leukemogenic 
consequences: (1) activation of the ABL1 tyrosine kinase and (2) down 
regulation of normal SHIP1 function (Figure 4.3). 
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Figure 4.3: Pathways affected by the SHIP1/ABL1 fusion protein. 
Activation of an oncogene and interference with a tumor suppressor gene 
function by the SHIP1/ABL1 fusion.  
4.7.2 Hypothesis II: D1 and D2 mediated inhibition of the ABL1 
kinase activity of SHIP1/ABL1 by normal SHIP1 
Considering the above hypothesis proposing a dominant negative effect of 
SHIP1/ABL1 over SHIP1, the inverse mechanism might also be possible. The 
wild-type SHIP1 protein might have a negative effect on the function of the 
SHIP1/ABL1 fusion protein. In this scenario, the normal SHIP1 protein would 
interfere with the formation of SHIP1/ABL1 di- or oligomers which are 
necessary for the activation of the tyrosine kinase function of the fusion 
protein. In this situation, the loss of the remaining non-rearranged SHIP1 
allele might provide the cells with an additional growth advantage.  
This situation is reminiscent of the cases with ETV6/ABL1 or ETV6/AML1 
fusion genes. In these cases, in addition to the disruption of one ETV6 allele 
by the generation of the fusion gene, the other ETV6 allele was found to be 
deleted, resulting in the loss of wild-type ETV6 function in the majority of 
cases with these fusion genes (Golub et al., 1995; Romana et al., 1995; 
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Golub et al., 1996). In addition, in the T-ALL cell line MT-ALL, which carries 
an ETV6/ABL2 fusion, the non-rearranged ETV6 allele has a point mutation in 
the DNA-binding domain (Griesinger et al., 2002). It should be noted however, 
that in the cases of ETV6/ABL1, ETV6/ABL2 and ETV6/AML1, the reason for 
the loss or inactivation of the non-rearranged ETV6 allele is believed to be the 
inactivation of the tumor suppressor function of ETV6 and not the interference 
of the wild-type ETV6 protein with the function of the ETV6 fusion proteins. 
But as noted earlier: there is even more evidence from the phenotype of the 
SHIP1 knockout mice than from the ETV6 knock-out mice that SHIP1 is a 
good candidate tumor suppressor gene.  
To support the hypothesis of the dominant negative effect of SHIP1 over 
SHIP1/ABL1 or the dominant negative effect of SHIP1/ABL1 over SHIP1, 
further experiments are required. The second hypothesis would be supported 
by the detection of a deletion of the SHIP1 locus in our patients. For this we 
performed FISH assays using SHIP1/ABL1-DCDF probes. The specificity of 
the FISH probes was confirmed by the hybridization on metaphase 
chromosomes from a normal male, but unfortunately, we could not obtain 
satisfactory hybridization results from the patient sample.  
4.8 THE SHIP1/ABL1 FUSION IN CONTEXT OF OTHER 
GENETIC ABERRATIONS IN ALL 
It is well known that almost always several genetic alterations are required to 
transform a normal cell into a cancer cell. There are, to our knowledge, no 
mutational events described that will transform on their own a normal cell into 
a cancer cell. Constitutively activated tyrosine kinases can confer a 
proliferative and survival advantage to hematopoietic progenitors and are 
sufficient to induce myeloproliferative disease, but usually require the co-
operative effect of other mutations to induce acute leukemia (Kelly and 
Gilliland, 2002; Kelly et al., 2002). There are several well-studied recurring 
genetic lesions, like chromosomal translocations that lead to fusion genes or 
gene deregulation but also gene specific mutations, described in ALL. In B 
lineage ALL, which is the more common form of ALL, these include alteration 
of transcription factors such ETV6, AML1, EBF1, PAX5, E2A and Ikaros, 
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translocations affecting the MLL gene or tyrosine kinases like the activation of 
ABL1 in the BCR/ABL1 fusion protein. In T lineage ALL these recurring 
alterations include gain-of-function mutations of NOTCH1, which is a 
transmembrane receptor playing an essential role in T cell development, 
rearrangements of the TAL1 gene (Teitell and Pandolfi, 2008), or the 
NUP214/ABL1 fusion (Graux et al., 2004). It is very obvious that several, if not 
all of the genes we find altered in ALL play important roles in lineage 
determination, differentiation, and growth of lymphoid cells. These genes are 
thus part of critical cellular pathways in lymphoid development. The 
establishment of murine models of leukemia with these alteration has also 
taught us, as mentioned above, that a single mutation (eg. like the 
ETV6/AML1 fusion) is frequently inadequate to initiate a full-blown leukemia, 
but rather that additional, so-called cooperating mutations are required (Teitell 
and Pandolfi, 2008). In this context it is important to note, that more than 80% 
of B-ALL with a BCR/ABL fusion have a deletion within the IKZF1(IKAROS) 
genes (Mullighan et al., 2008). However, cooperating mutations are not easy 
to find. It is therefore tempting to speculate that rare mutational events, like 
the rare SHIP1/ABL1 fusion, give important hints to pathways that are critical 
for leukemogenesis.  
The available evidence indicates that activating mutations in the tyrosine 
kinases confer proliferative advantage to hematopoietic progenitors and 
cooperate with loss-of-function mutations in hematopoietic transcription 
factors to cause acute leukemia which is characterized by proliferation and 
impaired differentiation.  
Let us take a closer look at the other known ABL1 fusion in B cell ALL. About 
20% of B-ALLs have the BCR/ABL1 fusion gene. However, it is well known 
that additional mutations are required to synergize with the BCR/ABL1 for ALL 
to develop. For example, deletions of CDKN2A (INK4A-ARF, p16), a 
tumorsuppressor gene at 9p21, are found in 30% of the BCR-ABL1 positive 
ALLs (Heerema et al., 2004; Primo et al., 2005). Another frequent additional 
lesion in BCR/ABL1 positive ALL are affecting the IKZF1 locus, which 
encodes the nuclear protein IKAROS (Mullighan et al., 2008). It has been 
shown that haploinsufficiency, homozygous loss, or expression of a dominant 
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negative IKAROS isoform occurs in about 84% of the pediatric BCR-ABL1 
positive ALL. Both, CDKN2 and IKAROS are tumor suppressor genes. Mice 
with reduced IKAROS expression have a partial block at the pro-B cell stage 
in B cell development (Kirstetter et al., 2002).  
It is quite obvious that the activation of the tyrosine kinase ABL1 in early B 
cells is not sufficient to cause an acute leukemia phenotype. 
 
Figure 4.4: Summary of the potential mechanism of the SHIP1/ABL1 
fusion to promote leukemogenesis. 
While the activation of the ABL1 tyrosine kinase activity in the SHIP1/ABL1 
fusion, as explained earlier, induces IL3 independent growth in BaF3 cells, 
this alone is, with all likelihood, not sufficient to cause a full-blown leukemia. In 
this context, the interference with the tumor suppressor properties of SHIP1 
might play a crucial role in collaborating with tyrosine kinase activation of 
ABL1. As explained earlier, the formation of the SHIP1/ABL1 fusion results in 
the inactivation of one SHIP1 allele through the genomic rearrangement. 
Considering the down regulation of SHIP1 expression by BCR/ABL (Sattler et 
al., 1999), which was described in Ba/F3 cells, one can also speculate that it 
is advantages for a BCR/ABL1 transformed cell to reduce SHIP1 expression. 
In addition, it is very likely that SHIP1/ABL1 can also reduce the expression of 
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SHIP1. Thus taking into account the potential dominant negative effects of the 
SHIP1/ABL1 fusion protein on the normal SHIP1 protein and the loss of one 
SHIP1 allele during the formation of the SHIP1/ABL1 fusion gene, it can be 
hypothesized that the formation of the SHIP1/ABL1 fusion might not only 
activate important signaling pathways downstream of ABL1, but would also 
reduce the negative regulation which is normally exerted by SHIP1 on multiple 
cytokine and growth factor signaling pathways. The combination of both 
effects could be an extremely powerful force to cause leukemia (Figure 4.4). 
It is important to stress that with the SHIP1/ABL1 fusion an alteration of the 
SHIP1 gene has been reported for the first time in a malignancy. We believe 
that the tumor suppressor gene function of SHIP1 in B cell malignancy has 
not been recognized fully up to now. 
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5 Summary 
In the past four decades, the study of chromosomal translocations in leukemia 
has given us tremendous insight into the mechanisms responsible for 
leukemogenesis. One of the most dramatic consequences of a chromosomal 
translocation is the formation of a fusion gene. BCR/ABL1 is the most 
common fusion gene observed in leukemia. The BCR/ABL1 fusion is the 
hallmark of Chronic Myeloid Leukemia (CML) and is frequently found in B-
lineage Acute Lymphoblastic Leukemia (ALL). As a consequence of the 
BCR/ABL1 fusion, the ABL1 tyrosine kinase is constitutively activated through 
the oligomerization of the fusion protein mediated by the coiled-coil domain of 
BCR. While the BCR gene is by far the most common fusion partner of ABL, 
there are 5 other, very rare fusion partners of ABL1: ETV6, RCSD1, EML1, 
NUP214 and ZMIZ1. ETV6, EML1 and NUP214, like BCR, contribute a 
dimerization/oligomerization domain for the constitutive activation of the ABL1 
tyrosine kinase of their respective fusion proteins.  
In this doctoral thesis, we describe a novel fusion of ABL1 to the Inositol 
Polyphosphate-5 Phosphatase gene (INPP5D or SHIP1 for SH2 containing 
inositol phosphatase), which we discovered in the leukemic cells of an 18-
year-old woman with c-ALL. This SHIP1/ABL1 fusion was detected as an 
unexpected PCR amplification product during a routine RT-PCR diagnostic 
screening for BCR/ABL fusion transcripts. Sequence analysis of the 
amplification product revealed an in-frame fusion of the first 343 amino acids 
of SHIP1 to the second exon of the ABL1. The presence of the SHIP1/ABL1 
fusion transcript in the patient’s bone marrow cells was confirmed by RT-PCR 
using primers specific for the SHIP1/ABL1 fusion transcript. The putative 
SHIP1/ABL1 fusion protein is predicted to contain an SH2 domain in the 
SHIP1 portion (amino acids 5 to 102) and an SH3, SH2, tyrosine kinase and 
an actin binding domain in the ABL1 portion. Of note, the SHIP1/ABL1 fusion 
has the same protein domains of ABL1 like the other ABL1 fusions.  
In order to anlyze this novel fusion in more detail, we cloned the full length 
SHIP1/ABL1 fusion open reading frame without tag or with HA or FLAG 
epitope tags into eukaryotic expression vectors. For this, the 5’ portion of 
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SHIP1/ABL1 fusion till the Kpn1 site in ABL1 was amplified from the patient 
sample and then insertd into a pcDNA3-BCR/ABL construct replacing the 
BCR/ABL fusion up to the the Kpn1 site of ABL1. The expression of the 
SHIP1/ABL1 fusion protein was confirmed in transiently transfected HEK293T 
cells by Western blotting. To analyze the dimerization/oligomerization of the 
SHIP1/ABL1 fusion protein, HA-tagged and Flag-tagged versions of the 
SHIP1/ABL1 fusion protein were co-expressed in HEK293T cells. We were 
able to coimmunoprecipitate the HA-tagged SHIP1/ABL1 protein with the 
Flag-tagged SHIP1/ABL1 protein, confirming the dimerization/oligomerization 
kinase activation mechanism used by the SHIP1/ABL1 fusion. In addition, like 
the BCR/ABL1 fusion, the SHIP1/ABL1 fusion protein induces IL3 
independent proliferation in a stably transduced murine pro-B cell line (Ba/F3). 
The IL3 independent growth induced in the Ba/F3 cells expressing the 
SHIP1/ABL1 fusion was inhibited by the ABL1-specific tyrosine kinase 
inhibitor Imatinib in a dose dependent fashion, confirming that the ABL 
tyrosine kinase is activated in the SHIP/ABL1 fusion. Furthermore, we were 
able to map two protein domains  (domain D1: aa 100 to 220 and domain D2: 
aa 220 to 343) in SHIP1 which are critical for the dimerization of the fusion 
protein and for the induction of the IL3 independent proliferation in the Ba/F3 
cells.  
As the SHIP1 gene is located on 2q37 and transcribed from the centromere to 
the telomere like the ABL1 gene on 9q34, we predicted that a simple 
balanced translocation generated the SHIP1/ABL1 fusion gene on a 
derivative chromosome 2. But surprisingly, FISH analysis using a commercial 
BCR/ABL dual color dual fusion probe on metaphase chromosomes did not 
show an ABL1 signal on chromosome 2. However, the same FISH probe, 
when hybridized to interphase nuclei, revealed two pairs of closely spaced 
ABL1 signals. These findings suggest that an insertion of the 5’ portion of 
SHIP1 into both ABL1 loci generated the SHIP1/ABL1 fusion gene, possibly 
disrupting both SHIP1 alleles. However, since we were unable to achieve 
adequate FISH signals with a SHIP1 probe, the true nature of the genomic 
rearrangement leading to the SHIP1/ABL1 fusion still needs to be elucidated 
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SHIP1 removes the 5' phosphate from phosphatidylinositol (3,4,5)-
trisphosphate and inositol-1,3,4,5-tetrakisphosphate, thereby negatively 
regulating multiple cellular signaling pathways. Interestingly, the expression of 
SHIP1 is restricted to hematopoietic cells and it functions among other things 
as a negative regulator of myeloid cell proliferation and survival. SHIP1 knock-
out mice develop a myeloproliferative syndrome-like disease. Thus, it is 
tempting to speculate that the formation of the SHIP1/ABL1 fusion, in addition 
to the activation of the ABL1 tyrosine kinase function, also results in a haplo-
insufficiency of SHIP1, which might contribute to cellular transformation by 
relieving proliferative pathways from negative regulation. Thus the 
SHIP1/ABL1 fusion would not only generate an oncogene but would also 
compromise the function of the putative tumor suppressor gene SHIP1. Since 
our protein interaction studies have a revealed a previously unknown strong 
dimerization or oligomerization domain in SHIP1, it is also conceivable that 
the SHIP1/ABL1 fusion protein can function as a dominant negative protein 
for SHIP1. Of note, this is the first time that a mutation or alteration of the 
SHIP1 gene has been described in a malignancy. 
The discovery of the SHIP1/ABL1 fusion gene will enable us to dissect the 
pathways that lead to B-cell acute lymphoblastic leukemia in greater detail 
and will also give us the opportunity to understand better the mechanisms that 
underlie BCR/ABL1 mediated leukemogenesis.  
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6 Zusammenfassung 
In den letzten vier Jahrzehnten haben wir durch das Studium von 
Chromosomentranslokationen große Erkenntnisse über die Mechanismen 
gewonnen, die für die Leukämogeneses verantwortlich sind. Eine der 
dramatischsten Folgen einer Chromosomentranslokation ist die Bildung eines 
Fusionsgens. BCR/ABL ist das häufigste Fusionsgen, das bei Leukämien 
beobachtet wird. Die BCR/ABL1-Fusion ist typisch für the Chronisch 
Myeloische Leukämie (CML) und wird auch sehr häufig bei der Akuten B-Zell 
lymphoblastischen Leukämie (ALL) beobachtet.  Als Folge der BCR/ABL1-
Fusion kommte es zu einer konstitutiven Aktivierung der ABL1 
Tyrosinekinaseaktivität durch die Oligomerisierung des Fusionsproteins, die 
durch die Coiled-coil Domäne von BCR bewirkt wird. BCR ist der häufigste 
Fusionspartner von ABL1. Es gibt jedoch noch 5 andere, sehr seltene 
Fusionspartner von ABL1: ETV6, RCSD1, EML1, NUP214 und ZMIZ1. ETV6, 
EML1 und NUP214 tragen, wie BCR, durch eine Dimerisierungs- oder 
Oligomerisierungsdomäne zur konstitutiven Aktivierung der ABL1 
Tyrosinkinaseaktivität in den jeweiligen Fusionsproteinen bei. 
In dieser Doktorarbeit beschreiben wir eine neue ABL1-Fusion zum Inositol 
Polyphospate-5 Phosphastase Gen (INPP5D oder SHIP1 für SH2-Domäne 
enthaltende Inositol Phosphatase), die wir in den Leukämiezellen einer 18 
Jahre alten Frau mit c-ALL entdeckten. Diese SHIP1/ABL1-Fusion wurde bei 
einer Routine RT-PCR-Untersuchung für BCR/ABL1-Fusionstranskripte als 
unerwartetes Amplifikationsprodukt entdeckt. Die Sequenzierung dieses 
Amplifikationsprodukt zeigte eine im-Leserahmen Fusion der ersten 343 
Aminosäuren von SHIP1 mit dem zweiten Exon von ABL1. Das 
Vorhandensein des SHIP1/ABL1 Fusionstranskripts in den 
Knochenmarkszellen der Patientin konnte durch eine RT-PCR mit für 
SHIP1/ABL1 spezifischen Primern bestätigt werden. Das putative 
SHIP1/ABL1-Fusionsprotein enthält eine SH2-Domäne im SHIP1-Anteil 
(Aminosäuren (As) 5 bis 102) sowie eine SH3-, eine SH2-, eine 
Tyrosinkinase- und eine Actinbindungsdomäne im ABL1-Anteil.  Es ist zu 
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beachten, dass das SHIP1/ABL1-Fusionsprotein dieselben Proteindomänen 
im ABL1-Anteil hat wie die anderen ABL1-Fusionen. 
Um die neue Fusion im Detail zu untersuchen, klonierten wir den gesamten 
offenen Leserahmen von sowohl mit als auch ohne HA- oder Flag-Epitoptags 
in eukaryontische Expressionsvektoren. Hierfür wurde der 5’-Anteil von 
SHIP1/ABL1 bis zur Kpn1 Schnittstelle in ABL1 aus der Patientenprobe 
amplifiziert und dann in ein pcDNA1-BCR/ABL Konstrukt inseriert, wobei es 
die BCR/ABL-Fusion bis zur Kpn1 Schnittstelle in ABL1 ersetzte. Die 
Proteinexpression der SHIP1/ABL1-Fusion wurde mittels Westernblotanalyse 
in transient transfizierten HEK293T Zellen bestätigt. Um die Dimerisierung 
bzw. Oligmerisierung des SHIP1/ABL1-Fusionsproteins zu analysieren, wurde 
die HA- und die Flag-markierten Versionen des SHIP1/ABL1-Fusionsproteins 
zusammen in HEK293T Zellen exprimiert. Wir waren dann in der Lage das 
HA-markierte SHIP1/ABL1-Fusionsprotein zusammen mit dem Flag-
markierten SHIP1/ABL1-Fusionsprotein zu präzipitieren. Dieses Experiment 
bestätigte, dass auch bei SHIP1/ABL1-Fusion die Kinase durch einen 
Dimerisierungs- bzw. Oligomerisierungsmechanisms aktiviert wird. Weiterhin 
konnten wir zeigen, dass, genauso wie die BCR/ABL1-Fusion, die 
SHIP1/ABL1-Fusion IL3-unabhängiges Wachstum in einer stabil 
transduzierten murinen Pro-B Zelllinie (Ba/F3) induziert. Das IL3-unabhängige 
Wachstum, das in den SHIP1/ABL1 exprimierenden Ba/F3-Zellen induziert 
wurde, konnte durch den ABL1-spezifischen Tyrosinkinaseinhibitor Imatinib in 
einer Dosis-abhängigen Weise gehemmt werden. Zusätzlich waren wir in der 
Lage zwei Proteindomänen in SHIP1 zu kartieren (Domäne D1: As 100 bis 
220 und Domäne D2: As 220 bis 343), die essentiell für die Dimerisierung des 
Fusionsprotein und für die Induktion von IL3-unabhängigem Wachstum sind. 
Da das SHIP1-Gen in der Chromosomenbande 2q37 liegt und genauso wie 
das ABL1-Gen auf 9q34 vom Zentromer zum Telomer abgelesen wird, gingen 
wir davon aus, dass eine einfache balanzierte Translokation zur Bildung des 
SHIP1/ABL1-Fusionsgen auf dem derivativen Chromosom 2 führte. 
Überraschenderweise zeigte sich jedoch bei der FISH-Analyse auf 
Metaphasechromosomen mit einer kommerziell erhältlichen BCR/ABL-Dual 
Color Dual Fusion-Sonde kein   -Signal auf einem Chromosom 2. Jedoch 
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ergab dieselbe FISH-Sonde, als sie auf Interphasekerne hybridisiert wurde, 
zwei Paare von dicht beeinanderliegenden ABL1-Signalen. Diese Ergebnisse 
legten den Schluss nahe, dass das SHIP1/ABL1-Fusionsgen durch eine 
Insertion des 5’-Anteils des SHIP1-Gens in beide ABL1-Loci zustande 
gekommen war, was möglicherweise zu einer Veränderung oder Inaktivierung 
beider SHIP1-Loci geführt hat. Da wir jedoch nicht in der Lage waren 
adäquate FISH-Signale mit eine SHIP1-Sonde bei den Zellen unserer 
Patientin zu erzeugen, muß die genaue Art des genomischen 
Rearrangements, die zur SHIP1/ABL1-Fusion führte noch genauer untersucht 
werden. 
Dadurch dass das SHIP1-Enzym 5’ Phosphatreste von 
Phoshpoinositol(3,4,5)-triphosphat und Inositol-(1,2,4,5)-tetrakisphosphate 
entfernt, reguliert es negative viele zelluläre Signaltransduktionswege. 
Interessanterweise ist die Expression von SHIP1 auf hämatopoetisches 
Gewebe beschränkt. Hier fungiert SHIP1 unter anderem als ein negativer 
Regulator der Proliferation und der Überlebens von myeloischen Zellen. 
SHIP1 knock-out Mäuse enwickeln eine Erkrankung, die an ein 
myeloproliferatives Syndrom erinnert. Es ist somit naheliegend anzunehmen, 
dass die Bildung der SHIP1/ABL1-Fusion zusätzlich zur  konstitutiven 
Aktivierung der Tyrosinkinaseaktivität von ABL1, auch zu einer 
Haploinsuffizienz von SHIP1 führt, die ebenfalls zur malignen Transformation 
durch eine verminderte Hemmung von proliferativen Signalwegen beiträgt. In 
diesem Sinne würde die SHIP1/ABL1-Fusion nicht nur zur Bildung eines 
Onkogens führen, sondern würde zusätzlich die Funktion des mutmaßlichen 
Tumorsuppressorgens SHIP1 beeinträchtigen. Da unsere 
Proteininteraktionsstudien bisher unbekannte starke Dimerisierungs- oder 
Oligomerisierungsdomänen in SHIP1 selbst identifizierten, ist es ebenfalls 
denkbar, dass das SHIP1/ABL1-Fusionprotein zusätzlich als dominant-
negativer Regulator der normalen SHIP1-Funktion fungiert. Es muß betont 
werden, dass unsere Arbeit zum ersten Mal eine Mutation oder Veränderung 
des SHIP1-Gens bei einer Tumorerkrankung beschreibt. 
Die Entdeckung des SHIP1/ABL1-Fusionsgens wird es uns nicht nur 
ermöglichen, die Mechanismen, die zur Entstehung der B-Zell ALL führen 
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detailliert zu analysieren, sondern wird uns zusätzlich die Möglichkeit 
eröffnen, die BCR/ABL-mediierte Leukämogenese besser zu verstehen. 
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APPENDIX I: Sequence of the SHIP1/ABL1 fusion 
The nucleotides highlighted in yellow denote the (genbank sequence) and that 
highlighted in blue denote the sequence used in this work (as per the  sequencing of the 
pMIG-SA-9A6a)  at the place of nucleotide differences. The green highlight denotes the 
Kpn1(1488) site. The red highlight indicated the single amino acid change found in the 
ABL1 sequence. The breakpoint is indicated by an arrow. nt no.: nucleotide position; nt 
seq:nucleotide sequence; aa: amino acids; ‘*’: STOP codon 
 
          10         20         30         40         50         60 ? nt no. 
  AAACAGGAAG TCAGTCAGTT AAGCTGGTGG CAGCAGCCGA GGCCACCAAG AGGCAACGGG ? nt seq 
 
          70         80         90        100        110        120 
  CGGCAGGTTG CAGTGGAGGG GCCTCCGCTC CCCTCGGTGG TGTGTGGGTC CTGGGGGTGC 
 
         130        140        150           160          170      
  CTGCCGGCCC GGCCGAGGAG GCCCACGCCC ACC ATG GTC CCC TGC TGG AAC CAT 
                                        M   V   P   C   W   N   H>  ? aa 
 
      180           190          200          210           220   
  GGC AAC ATC ACC CGC TCC AAG GCG GAG GAG CTG CTT TCC AGG ACA GGC 
   G   N   I   T   R   S   K   A   E   E   L   L   S   R   T   G> 
 
         230          240           250          260          270 
  AAG GAC GGG AGC TTC CTC GTG CGT GCC AGC GAG TCC ATC TCC CGG GCA 
   K   D   G   S   F   L   V   R   A   S   E   S   I   S   R   A> 
 
            280          290          300           310           
  TAC GCG CTC TGC GTG CTG TAT CGG AAT TGC GTT TAC ACT TAC AGA ATT 
   Y   A   L   C   V   L   Y   R   N   C   V   Y   T   Y   R   I> 
 
 320          330           340          350          360         
  CTG CCC AAT GAA GAT GAT AAA TTC ACT GTT CAG GCA TCC GAA GGC GTC 
   L   P   N   E   D   D   K   F   T   V   Q   A   S   E   G   V> 
 
    370          380          390           400          410      
  TCC ATG AGG TTC TTC ACC AAG CTG GAC CAG CTC ATC GAG TTT TAC AAG 
   S   M   R   F   F   T   K   L   D   Q   L   I   E   F   Y   K> 
 
      420           430          440          450           460   
  AAG GAA AAC ATG GGG CTG GTG ACC CAT CTG CAA TAC CCT GTG CCG CTG 
   K   E   N   M   G   L   V   T   H   L   Q   Y   P   V   P   L> 
 
         470          480           490          500          510 
  GAG GAA GAG GAC ACA GGC GAC GAC CCT GAG GAG GAC ACA GTA GAA AGT 
   E   E   E   D   T   G   D   D   P   E   E   D   T   V   E   S> 
 
            520          530          540           550           
  GTC GTG TCT CCA CCC GAG CTG CCC CCA AGA AAC ATC CCG CTG ACT GCC 
   V   V   S   P   P   E   L   P   P   R   N   I   P   L   T   A> 
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 560          570           580          590          600         
  AGC TCC TGT GAG GCC AAG GAG GTT CCT TTT TCA AAC GAG AAT CCC CGA 
   S   S   C   E   A   K   E   V   P   F   S   N   E   N   P   R> 
 
                                                G 
    610          620          630           640          650      
  GCG ACC GAG ACC AGC CGG CCG AGC CTC TCC GAG ACA TTG TTC CAG CGA 
   A   T   E   T   S   R   P   S   L   S   E   T   L   F   Q   R> 
 
      660           670          680          690           700   
  CTG CAA AGC ATG GAC ACC AGT GGG CTT CCA GAA GAG CAT CTT AAG GCC 
   L   Q   S   M   D   T   S   G   L   P   E   E   H   L   K   A> 
 
         710          720           730          740          750 
  ATC CAA GAT TAT TTA AGC ACT CAG CTC GCC CAG GAC TCT GAA TTT GTG 
   I   Q   D   Y   L   S   T   Q   L   A   Q   D   S   E   F   V> 
 
            760          770          780           790           
  AAG ACA GGG TCC AGC AGT CTT CCT CAC CTG AAG AAA CTG ACC ACA CTG 
   K   T   G   S   S   S   L   P   H   L   K   K   L   T   T   L> 
 
 800          810           820          830          840         
  CTC TGC AAG GAG CTC TAT GGA GAA GTC ATC CGG ACC CTC CCA TCC CTG 
   L   C   K   E   L   Y   G   E   V   I   R   T   L   P   S   L> 
 
    850          860          870           880          890      
  GAG TCT CTG CAG AGG TTA TTT GAC CAG CAG CTC TCC CCG GGC CTC CGT 
   E   S   L   Q   R   L   F   D   Q   Q   L   S   P   G   L   R> 
 
      900           910          920          930           940   
  CCA CGT CCT CAG GTT CCT GGT GAG GCC AAT CCC ATC AAC ATG GTG TCC 
   P   R   P   Q   V   P   G   E   A   N   P   I   N   M   V   S> 
 
         950          960           970          980          990 
  AAG CTC AGC CAA CTG ACA AGC CTG TTG TCA TCC ATT GAA GAC AAG GTC 
   K   L   S   Q   L   T   S   L   L   S   S   I   E   D   K   V> 
 
           1000         1010         1020          1030           
  AAG GCC TTG CTG CAC GAG GGT CCT GAG TCT CCG CAC CGG CCC TCC CTT 
   K   A   L   L   H   E   G   P   E   S   P   H   R   P   S   L> 
 
1040         1050          1060         1070         1080         
  ATC CCT CCA GTC ACC TTT GAG GTG AAG GCA GAG TCT CTG GGG ATT CCT 
   I   P   P   V   T   F   E   V   K   A   E   S   L   G   I   P> 
 
   1090         1100         1110          1120         1130      
  CAG AAA ATG CAG CTC AAA GTC GAC GTT GAG TCT GGG AAA CTG ATC ATT 
   Q   K   M   Q   L   K   V   D   V   E   S   G   K   L   I   I> 
1140          1150         1160         1170          1180   
  AAG AAG TCC AAG GAT GGT TCT GAG GAC AAG TTC TAC AGC CAC AAG AAA 
   K   K   S   K   D   G   S   E   D   K   F   Y   S   H   K   K> 
  <____________1 to 1183 of SHIP1 (NM001017915)_________________> 
 
Breakpoint 
   ↓ 
 1183      1190         1200          1210         1220         1230 
  A AA GCC CTT CAG CGG CCA GTA GCA TCT GAC TTT GAG CCT CAG GGT CTG 
   K> 
        A   L   Q   R   P   V   A   S   D   F   E   P   Q   G   L> 
    ___________576 to 5881 of ABL1B  (NM_0073132)________________> 
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        G 
           1240         1250         1260          1270           
  AGT GAA GCC GCT CGT TGG AAC TCC AAG GAA AAC CTT CTC GCT GGA CCC 
   S   E   A   A   R   W   N   S   K   E   N   L   L   A   G   P> 
 
1280         1290          1300         1310         1320         
  AGT GAA AAT GAC CCC AAC CTT TTC GTT GCA CTG TAT GAT TTT GTG GCC 
   S   E   N   D   P   N   L   F   V   A   L   Y   D   F   V   A> 
 
   1330         1340         1350          1360         1370      
  AGT GGA GAT AAC ACT CTA AGC ATA ACT AAA GGT GAA AAG CTC CGG GTC 
   S   G   D   N   T   L   S   I   T   K   G   E   K   L   R   V> 
 
     1380          1390         1400         1410          1420   
  TTA GGC TAT AAT CAC AAT GGG GAA TGG TGT GAA GCC CAA ACC AAA AAT 
   L   G   Y   N   H   N   G   E   W   C   E   A   Q   T   K   N> 
 
        1430         1440          1450         1460         1470 
  GGC CAA GGC TGG GTC CCA AGC AAC TAC ATC ACG CCA GTC AAC AGT CTG 
   G   Q   G   W   V   P   S   N   Y   I   T   P   V   N   S   L> 
 
           1480         1490         1500          1510           
  GAG AAA CAC TCC TGG TAC CAT GGG CCT GTG TCC CGC AAT GCC GCT GAG 
   E   K   H   S   W   Y   H   G   P   V   S   R   N   A   A   E> 
 
1520         1530          1540         1550         1560         
  TAT CTG CTG AGC AGC GGG ATC AAT GGC AGC TTC TTG GTG CGT GAG AGT 
   Y   L   L   S   S   G   I   N   G   S   F   L   V   R   E   S> 
 
   1570         1580         1590          1600         1610      
  GAG AGC AGT CCT GGC CAG AGG TCC ATC TCG CTG AGA TAC GAA GGG AGG 
   E   S   S   P   G   Q   R   S   I   S   L   R   Y   E   G   R> 
 
     1620          1630         1640         1650          1660   
  GTG TAC CAT TAC AGG ATC AAC ACT GCT TCT GAT GGC AAG CTC TAC GTC 
   V   Y   H   Y   R   I   N   T   A   S   D   G   K   L   Y   V> 
 
        1670         1680          1690         1700         1710 
  TCC TCC GAG AGC CGC TTC AAC ACC CTG GCC GAG TTG GTT CAT CAT CAT 
   S   S   E   S   R   F   N   T   L   A   E   L   V   H   H   H> 
 
1720         1730         1740          1750           
  TCA ACG GTG GCC GAC GGG CTC ATC ACC ACG CTC CAT TAT CCA GCC CCA 
   S   T   V   A   D   G   L   I   T   T   L   H   Y   P   A   P> 
 
1760         1770          1780         1790         1800         
  AAG CGC AAC AAG CCC ACT GTC TAT GGT GTG TCC CCC AAC TAC GAC AAG 
   K   R   N   K   P   T   V   Y   G   V   S   P   N   Y   D   K> 
 
   1810         1820         1830          1840         1850      
  TGG GAG ATG GAA CGC ACG GAC ATC ACC ATG AAG CAC AAG CTG GGC GGG 
   W   E   M   E   R   T   D   I   T   M   K   H   K   L   G   G> 
 
     1860          1870         1880         1890          1900   
  GGC CAG TAC GGG GAG GTG TAC GAG GGC GTG TGG AAG AAA TAC AGC CTG 
   G   Q   Y   G   E   V   Y   E   G   V   W   K   K   Y   S   L> 
 
        1910         1920          1930         1940         1950 
  ACG GTG GCC GTG AAG ACC TTG AAG GAG GAC ACC ATG GAG GTG GAA GAG 
   T   V   A   V   K   T   L   K   E   D   T   M   E   V   E   E> 
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            1960         1970         1980          1990           
  TTC TTG AAA GAA GCT GCA GTC ATG AAA GAG ATC AAA CAC CCT AAC CTG 
   F   L   K   E   A   A   V   M   K   E   I   K   H   P   N   L> 
 
2000         2010          2020         2030         2040         
  GTG CAG CTC CTT GGG GTC TGC ACC CGG GAG CCC CCG TTC TAT ATC ATC 
   V   Q   L   L   G   V   C   T   R   E   P   P   F   Y   I   I> 
 
   2050         2060         2070          2080         2090      
  ACT GAG TTC ATG ACC TAC GGG AAC CTC CTG GAC TAC CTG AGG GAG TGC 
   T   E   F   M   T   Y   G   N   L   L   D   Y   L   R   E   C> 
 
     2100          2110         2120         2130          2140   
  AAC CGG CAG GAG GTG AAC GCC GTG GTG CTG CTG TAC ATG GCC ACT CAG 
   N   R   Q   E   V   N   A   V   V   L   L   Y   M   A   T   Q> 
 
        2150         2160          2170         2180         2190 
  ATC TCG TCA GCC ATG GAG TAC CTG GAG AAG AAA AAC TTC ATC CAC AGA 
   I   S   S   A   M   E   Y   L   E   K   K   N   F   I   H   R> 
 
           2200         2210         2220          2230           
  GAT CTT GCT GCC CGA AAC TGC CTG GTA GGG GAG AAC CAC TTG GTG AAG 
   D   L   A   A   R   N   C   L   V   G   E   N   H   L   V   K> 
 
2240         2250          2260         2270         2280         
  GTA GCT GAT TTT GGC CTG AGC AGG TTG ATG ACA GGG GAC ACC TAC ACA 
   V   A   D   F   G   L   S   R   L   M   T   G   D   T   Y   T> 
 
   2290         2300         2310          2320         2330      
  GCC CAT GCT GGA GCC AAG TTC CCC ATC AAA TGG ACT GCA CCC GAG AGC 
   A   H   A   G   A   K   F   P   I   K   W   T   A   P   E   S> 
 
     2340          2350         2360         2370          2380   
  CTG GCC TAC AAC AAG TTC TCC ATC AAG TCC GAC GTC TGG GCA TTT GGA 
   L   A   Y   N   K   F   S   I   K   S   D   V   W   A   F   G> 
 
        2390         2400          2410         2420         2430 
  GTA TTG CTT TGG GAA ATT GCT ACC TAT GGC ATG TCC CCT TAC CCG GGA 
   V   L   L   W   E   I   A   T   Y   G   M   S   P   Y   P   G> 
 
           2440         2450         2460          2470           
  ATT GAC CTG TCC CAG GTG TAT GAG CTG CTA GAG AAG GAC TAC CGC ATG 
   I   D   L   S   Q   V   Y   E   L   L   E   K   D   Y   R   M> 
 
2480         2490          2500         2510         2520         
  GAG CGC CCA GAA GGC TGC CCA GAG AAG GTC TAT GAA CTC ATG CGA GCA 
   E   R   P   E   G   C   P   E   K   V   Y   E   L   M   R   A> 
 
   2530         2540         2550          2560         2570      
  TGT TGG CAG TGG AAT CCC TCT GAC CGG CCC TCC TTT GCT GAA ATC CAC 
   C   W   Q   W   N   P   S   D   R   P   S   F   A   E   I   H> 
 
     2580          2590         2600         2610          2620   
  CAA GCC TTT GAA ACA ATG TTC CAG GAA TCC AGT ATC TCA GAC GAA GTG 
   Q   A   F   E   T   M   F   Q   E   S   S   I   S   D   E   V> 
 
        2630         2640          2650         2660         2670 
  GAA AAG GAG CTG GGG AAA CAA GGC GTC CGT GGG GCT GTG AGT ACC TTG 
   E   K   E   L   G   K   Q   G   V   R   G   A   V   S   T   L> 
 
Appendix 
163 
           2680         2690         2700          2710           
  CTG CAG GCC CCA GAG CTG CCC ACC AAG ACG AGG ACC TCC AGG AGA GCT 
   L   Q   A   P   E   L   P   T   K   T   R   T   S   R   R   A> 
 
2720         2730          2740         2750         2760         
  GCA GAG CAC AGA GAC ACC ACT GAC GTG CCT GAG ATG CCT CAC TCC AAG 
   A   E   H   R   D   T   T   D   V   P   E   M   P   H   S   K> 
 
   2770         2780         2790          2800         2810      
  GGC CAG GGA GAG AGC GAT CCT CTG GAC CAT GAG CCT GCC GTG TCT CCA 
   G   Q   G   E   S   D   P   L   D   H   E   P   A   V   S   P> 
 
     2820          2830         2840         2850          2860   
  TTG CTC CCT CGA AAA GAG CGA GGT CCC CCG GAG GGC GGC CTG AAT GAA 
   L   L   P   R   K   E   R   G   P   P   E   G   G   L   N   E> 
 
        2870         2880          2890         2900         2910 
  GAT GAG CGC CTT CTC CCC AAA GAC AAA AAG ACC AAC TTG TTC AGC GCC 
   D   E   R   L   L   P   K   D   K   K   T   N   L   F   S   A> 
 
           2920         2930         2940          2950           
  TTG ATC AAG AAG AAG AAG AAG ACA GCC CCA ACC CCT CCC AAA CGC AGC 
   L   I   K   K   K   K   K   T   A   P   T   P   P   K   R   S> 
 
2960         2970          2980         2990         3000         
  AGC TCC TTC CGG GAG ATG GAC GGC CAG CCG GAG CGC AGA GGG GCC GGC 
   S   S   F   R   E   M   D   G   Q   P   E   R   R   G   A   G> 
 
   3010         3020         3030          3040         3050      
  GAG GAA GAG GGC CGA GAC ATC AGC AAC GGG GCA CTG GCT TTC ACC CCC 
   E   E   E   G   R   D   I   S   N   G   A   L   A   F   T   P> 
 
     3060          3070         3080         3090          3100   
  TTG GAC ACA GCT GAC CCA GCC AAG TCC CCA AAG CCC AGC AAT GGG GCT 
   L   D   T   A   D   P   A   K   S   P   K   P   S   N   G   A> 
 
        3110         3120          3130         3140         3150 
  GGG GTC CCC AAT GGA GCC CTC CGG GAG TCC GGG GGC TCA GGC TTC CGG 
   G   V   P   N   G   A   L   R   E   S   G   G   S   G   F   R> 
 
           3160         3170         3180          3190           
  TCT CCC CAC CTG TGG AAG AAG TCC AGC ACG CTG ACC AGC AGC CGC CTA 
   S   P   H   L   W   K   K   S   S   T   L   T   S   S   R   L> 
 
3200         3210          3220         3230         3240         
  GCC ACC GGC GAG GAG GAG GGC GGT GGC AGC TCC AGC AAG CGC TTC CTG 
   A   T   G   E   E   E   G   G   G   S   S   S   K   R   F   L> 
 
   3250         3260         3270          3280         3290      
  CGC TCT TGC TCC GCC TCC TGC GTT CCC CAT GGG GCC AAG GAC ACG GAG 
   R   S   C   S   A   S   C   V   P   H   G   A   K   D   T   E> 
 
     3300          3310         3320         3330          3340   
  TGG AGG TCA GTC ACG CTG CCT CGG GAC TTG CAG TCC ACG GGA AGA CAG 
   W   R   S   V   T   L   P   R   D   L   Q   S   T   G   R   Q> 
 
        3350         3360          3370         3380         3390 
  TTT GAC TCG TCC ACA TTT GGA GGG CAC AAA AGT GAG AAG CCG GCT CTG 
   F   D   S   S   T   F   G   G   H   K   S   E   K   P   A   L> 
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           3400         3410         3420          3430           
  CCT CGG AAG AGG GCA GGG GAG AAC AGG TCT GAC CAG GTG ACC CGA GGC 
   P   R   K   R   A   G   E   N   R   S   D   Q   V   T   R   G> 
 
3440         3450          3460         3470         3480         
  ACA GTA ACG CCT CCC CCC AGG CTG GTG AAA AAG AAT GAG GAA GCT GCT 
   T   V   T   P   P   P   R   L   V   K   K   N   E   E   A   A> 
 
   3490         3500         3510          3520         3530      
  GAT GAG GTC TTC AAA GAC ATC ATG GAG TCC AGC CCG GGC TCC AGC CCG 
   D   E   V   F   K   D   I   M   E   S   S   P   G   S   S   P> 
 
     3540          3550         3560         3570          3580   
  CCC AAC CTG ACT CCA AAA CCC CTC CGG CGG CAG GTC ACC GTG GCC CCT 
   P   N   L   T   P   K   P   L   R   R   Q   V   T   V   A   P> 
 
        3590         3600          3610         3620         3630 
  GCC TCG GGC CTC CCC CAC AAG GAA GAA GCT GGA AAG GGC AGT GCC TTA 
   A   S   G   L   P   H   K   E   E   A   G   K   G   S   A   L> 
 
           3640         3650         3660          3670           
  GGG ACC CCT GCT GCA GCT GAG CCA GTG ACC CCC ACC AGC AAA GCA GGC 
   G   T   P   A   A   A   E   P   V   T   P   T   S   K   A   G> 
 
3680         3690          3700         3710         3720         
  TCA GGT GCA CCA GGG GGC ACC AGC AAG GGC CCC GCC GAG GAG TCC AGA 
   S   G   A   P   G   G   T   S   K   G   P   A   E   E   S   R> 
 
   3730         3740         3750          3760         3770      
  GTG AGG AGG CAC AAG CAC TCC TCT GAG TCG CCA GGG AGG GAC AAG GGG 
   V   R   R   H   K   H   S   S   E   S   P   G   R   D   K   G> 
 
     3780          3790         3800         3810          3820   
  AAA TTG TCC AGG CTC AAA CCT GCC CCG CCG CCC CCA CCA GCA GCC TCT 
   K   L   S   R   L   K   P   A   P   P   P   P   P   A   A   S> 
 
        3830         3840          3850         3860         3870 
  GCA GGG AAG GCT GGA GGA AAG CCC TCG CAG AGC CCG AGC CAG GAG GCG 
   A   G   K   A   G   G   K   P   S   Q   S   P   S   Q   E   A> 
 
           3880         3890         3900          3910           
  GCC GGG GAG GCA GTC CTG GGC GCA AAG ACA AAA GCC ACG AGT CTG GTT 
   A   G   E   A   V   L   G   A   K   T   K   A   T   S   L   V> 
 
3920         3930          3940         3950         3960         
  GAT GCT GTG AAC AGT GAC GCT GCC AAG CCC AGC CAG CCG GGA GAG GGC 
   D   A   V   N   S   D   A   A   K   P   S   Q   P   G   E   G> 
 
   3970         3980         3990          4000         4010      
  CTC AAA AAG CCC GTG CTC CCG GCC ACT CCA AAG CCA CAG TCC GCC AAG 
   L   K   K   P   V   L   P   A   T   P   K   P   Q   S   A   K> 
 
     4020          4030         4040         4050          4060   
  CCG TCG GGG ACC CCC ATC AGC CCA GCC CCC GTT CCC TCC ACG TTG CCA 
   P   S   G   T   P   I   S   P   A   P   V   P   S   T   L   P> 
 
        4070         4080          4090         4100         4110 
  TCA GCA TCC TCG GCC CTG GCA GGG GAC CAG CCG TCT TCC ACC GCC TTC 
   S   A   S   S   A   L   A   G   D   Q   P   S   S   T   A   F> 
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           4120         4130         4140          4150           
  ATC CCT CTC ATA TCA ACC CGA GTG TCT CTT CGG AAA ACC CGC CAG CCT 
   I   P   L   I   S   T   R   V   S   L   R   K   T   R   Q   P> 
 
4160         4170          4180         4190         4200         
  CCA GAG CGG ATC GCC AGC GGC GCC ATC ACC AAG GGC GTG GTC CTG GAC 
   P   E   R   I   A   S   G   A   I   T   K   G   V   V   L   D> 
 
   4210         4220         4230          4240         4250      
  AGC ACC GAG GCG CTG TGC CTC GCC ATC TCT AGG AAC TCC GAG CAG ATG 
   S   T   E   A   L   C   L   A   I   S   R   N   S   E   Q   M> 
 
                                                          T 
     4260          4270         4280         4290          4300   
  GCC AGC CAC AGC GCA GTG CTG GAG GCC GGC AAA AAC CTC TAC ACG TTC 
   A   S   H   S   A   V   L   E   A   G   K   N   L   Y   T   F> 
                                                           ↓ 
                                                           S 
 
        4310         4320          4330         4340         4350 
  TGC GTG AGC TAT GTG GAT TCC ATC CAG CAA ATG AGG AAC AAG TTT GCC 
   C   V   S   Y   V   D   S   I   Q   Q   M   R   N   K   F   A> 
 
           4360         4370         4380          4390           
  TTC CGA GAG GCC ATC AAC AAA CTG GAG AAT AAT CTC CGG GAG CTT CAG 
   F   R   E   A   I   N   K   L   E   N   N   L   R   E   L   Q> 
 
4400         4410          4420         4430         4440         
  ATC TGC CCG GCG ACA GCA GGC AGT GGT CCA GCG GCC ACT CAG GAC TTC 
   I   C   P   A   T   A   G   S   G   P   A   A   T   Q   D   F> 
 
   4450         4460         4470          4480         4490      
  AGC AAG CTC CTC AGT TCG GTG AAG GAA ATC AGT GAC ATA GTG CAG AGG 
   S   K   L   L   S   S   V   K   E   I   S   D   I   V   Q   R> 
 
     4500       4510       4520       4530       4540       4550 
  TAG CAG CAGTCAGGGG TCAGGTGTCA GGCCCGTCGG AGCTGCCTGC AGCACATGCG 
   *> 
 
        4560       4570       4580       4590       4600       4610 
  GGCTCGCCCA TACCCGTGAC AGTGGCTGAC AAGGGACTAG TGAGTCAGCA CCTTGGCCCA 
 
        4620       4630       4640       4650       4660       4670 
  GGAGCTCTGC GCCAGGCAGA GCTGAGGGCC CTGTGGAGTC CAGCTCTACT ACCTACGTTT 
 
        4680       4690       4700       4710       4720       4730 
  GCACCGCCTG CCCTCCCGCA CCTTCCTCCT CCCCGCTCCG TCTCTGTCCT CGAATTTTAT 
 
        4740       4750       4760       4770       4780       4790 
  CTGTGGAGTT CCTGCTCCGT GGACTGCAGT CGGCATGCCA GGACCCGCCA GCCCCGCTCC 
 
        4800       4810       4820       4830       4840       4850 
  CACCTAGTGC CCCAGACTGA GCTCTCCAGG CCAGGTGGGA ACGGCTGATG TGGACTGTCT 
 
        4860       4870       4880       4890       4900       4910 
  TTTTCATTTT TTTCTCTCTG GAGCCCCTCC TCCCCCGGCT GGGCCTCCTT CTTCCACTTC 
 
        4920       4930       4940       4950       4960       4970 
  TCCAAGAATG GAAGCCTGAA CTGAGGCCTT GTGTGTCAGG CCCTCTGCCT GCACTCCCTG 
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        4980       4990       5000       5010       5020       5030 
  GCCTTGCCCG TCGTGTGCTG AAGACATGTT TCAAGAACCG CATTTCGGGA AGGGCATGCA 
 
        5040       5050       5060       5070       5080       5090 
  CGGGCATGCA CACGGCTGGT CACTCTGCCC TCTGCTGCTG CCCGGGGTGG GGTGCACTCG 
 
        5100       5110       5120       5130       5140       5150 
  CCATTTCCTC ACGTGCAGGA CAGCTCTTGA TTTGGGTGGA AAACAGGGTG CTAAAGCCAA 
 
        5160       5170       5180       5190       5200       5210 
  CCAGCCTTTG GGTCCTGGGC AGGTGGGAGC TGAAAAGGAT CGAGGCATGG GGCATGTCCT 
 
        5220       5230       5240       5250       5260       5270 
  TTCCATCTGT CCACATCCCC AGAGCCCAGC TCTTGCTCTC TTGTGACGTG CACTGTGAAT 
 
        5280       5290       5300       5310       5320       5330 
  CCTGGCAAGA AAGCTTGAGT CTCAAGGGTG GCAGGTCACT GTCACTGCCG ACATCCCTCC 
 
        5340       5350       5360       5370       5380       5390 
  CCCAGCAGAA TGGAGGCAGG GGACAAGGGA GGCAGTGGCT AGTGGGGTGA ACAGCTGGTG 
 
        5400       5410       5420       5430       5440       5450 
  CCAAATAGCC CCAGACTGGG CCCAGGCAGG TCTGCAAGGG CCCAGAGTGA ACCGTCCTTT 
 
        5460       5470       5480       5490       5500       5510 
  CACACATCTG GGTGCCCTGA AAGGGCCCTT CCCCTCCCCC ACTCCTCTAA GACAAAGTAG 
 
        5520       5530       5540       5550       5560       5570 
  ATTCTTACAA GGCCCTTTCC TTTGGAACAA GACAGCCTTC ACTTTTCTGA GTTCTTGAAG 
 
        5580       5590       5600       5610       5620       5630 
  CATTTCAAAG CCCTGCCTCT GTGTAGCCGC CCTGAGAGAG AATAGAGCTG CCACTGGGCA 
 
        5640       5650       5660       5670       5680       5690 
  CCTGCGCACA GGTGGGAGGA AAGGGCCTGG CCAGTCCTGG TCCTGGCTGC ACTCTTGAAC 
 
        5700       5710       5720       5730       5740       5750 
  TGGGCGAATG TCTTATTTAA TTACCGTGAG TGACATAGCC TCATGTTCTG TGGGGGTCAT 
 
        5760       5770       5780       5790       5800       5810 
  CAGGGAGGGT TAGGAAAACC ACAAACGGAG CCCCTGAAAG CCTCACGTAT TTCACAGAGC 
 
        5820       5830       5840       5850       5860       5870 
  ACGCCTGCCA TCTTCTCCCC GAGGCTGCCC CAGGCCGGAG CCCAGATACG GGGGCTGTGA 
 
        5880       5890       5900       5910       5920       5930 
  CTCTGGGCAG GGACCCGGGG TCTCCTGGAC CTTGACAGAG CAGCTAACTC CGAGAGCAGT 
 
        5940       5950       5960       5970       5980       5990 
  GGGCAGGTGG CCGCCCCTGA GGCTTCACGC CGGGAGAAGC CACCTTCCCA CCCCTTCATA 
 
        6000       6010       6020       6030       6040       6050 
  CCGCCTCGTG CCAGCAGCCT CGCACAGGCC CTAGCTTTAC GCTCATCACC TAAACTTGTA 
 
        6060       6070       6080       6090       6100       6110 
  CTTTATTTTT CTGATAGAAA TGGTTTCCTC TGGATCGTTT TATGCGGTTC TTACAGCACA 
 
        6120       6130       6140       6150       6160       6170 
  TCACCTCTTT GCCCCCGACG GCTGTGACGC AGCCGGAGGG AGGCACTAGT CACCGACAGC 
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        6180       6190       6200       6210       6220       6230 
  GGCCTTGAAG ACAGAGCAAA GCGCCCACCC AGGTCCCCCG ACTGCCTGTC TCCATGAGGT 
 
        6240       6250       6260       6270       6280       6290 
  ACTGGTCCCT TCCTTTTGTT AACGTGATGT GCCACTATAT TTTACACGTA TCTCTTGGTA 
 
        6300       6310       6320       6330       6340       6350 
  TGCATCTTTT ATAGACGCTC TTTTCTAAGT GGCGTGTGCA TAGCGTCCTG CCCTGCCCCC 
 
        6360       6370       6380       6390       6400       6410 
  TCGGGGGCCT GTGGTGGCTC CCCCTCTGCT TCTCGGGGTC CAGTGCATTT TGTTTCTGTA 
 
        6420       6430       6440       6450       6460       6470 
  TATGATTCTC TGTGGTTTTT TTTGAATCCA AATCTGTCCT CTGTAGTATT TTTTAAATAA 
 
        6480           
  ATCAGTGTTT ACATTAGAA 
  ___576 TO 5881 ____> 
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APPENDIX II: List of clones 
Clones prepared during the cloning of the full length SHIP/ABL1 fusion 
1 pGEM-Teasy-SA(39-1508)-CLN9 
2 pcDNA3-SA-9A 
3 pMIG-SA-9A6a 
  
Clones prepared to obtain the full length SHIP/ABL1 fusion with 5’ epitope tags 
4 pGEM-Teasy-Flag-SA(154-1508)-CLN96   
5 pGEM-Teasy-HA-SA(154-1508)-CLN91 
6 pcDNAFlag-SA-96E 
7 pcDNA-HA-SA-91E 
8 pMIG-FLAG-SA-96E1 
9 pMIG-HA-SA-91E2 
  
Constructs prepared during the cloning of different regions of 5’SHIP1 into the 
bacterial-yeast shuttle vectors for the Yeast-two-hybrid (Y2H) experiments 
For the deletion mutants of 5'SHIP1 
10 pGEM-T-easy-BamH1-SH2-Xho1(3-3) 
11 pGEM-T-easy-EcoR1-D1-BamH1(2-3) 
12 pGEM-T-easy-EcoR1-D2-Not1(4-2) 
13 pGEM-T-easy-EcoR1-D2-Xho1(5-1) 
14 pGBKT7-BamH1-SH2-Pst1 (1-1) 
15 pGBKT7-EcoR1-D1-BamH1(2-1) 
16 pGBKT7-EcoR1-D2-Not1(3-1) 
17 pGADT7-BamH1-SH2-Xho1(5-1) 
18 pGADT7-EcoR1-D1-BamH1(6-1) 
19 pGADT7-EcoR1-D2-Xho1(7-1) 
For the complete 5'SHIP1 portion 
20 pGEM-T-easy-BamH1-5'SHIP-Not1(7-7) 
21 pGEM-T-easy-BamH1-SH2-D1-D2-Xho1(6-5) OR  
pGEM-T-easy-BamH1-5'SHIP-Xho1(6-5) 
22 pGBKT7-BamH1-5'SHIP-Not1(6-2) 
23 pGADT7-BamH1-5'SHIP-Xho1(5-2) 
For the 5'SHIP1-deltaD1 fragment 
24 pGEM-T-easy-Bpu10I-D2-Not1(2-1) 
25 pGEM-T-easy-Bpu10I-D2-Xho1(1-3) 
26 pGEM-T-easy-BamH1-5'SHIP-deltaD1-Xho1-CLN(6-5) 
27 pGBKT7-BamH1-5'SHIPdeltaD1-Not1(3-3) 
28 pGADT7-BamH1-5'SHIPdeltaD1-Xho1(2-3) 
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Clones prepared during the construction of the deletion mutants of the SHIP1/ABL1 
fusion 
For SHIP1-deltaD1 mutants 
29 pGEM-T-easy-Bpu10I-D2/ABL(904-1508)-CLN(3-4) 
30 pGEM-T-easy-SA-deltaD1-1508-9(5) 
31 pGEM-T-easy-Flag-SA-deltaD1-1508-96(2) 
32 pGEM-T-easy-HA-SA-deltaD1-1508-91(3) 
33 pcDNA3-SA-deltaD1(5-2) 
34 pcDNA3-Flag-SA-deltaD1-CLN(6-3) 
35 pcDNA3-HA-SA-deltaD1(7-2) 
36 pMIG-SA-deltaD1(3-1) 
For SHIP1(D1)/ABL1 fusion 
37 pGEM-T-easy-D1-Bcl1-Sal1-9(1) 
38 pGEM-T-easy-Flag-D1-Bcl1-Apa1-9N2 
39 pGEM-T-easy-HA-D1-Bcl1-Apa1-9(6) 
40 pGEM-T-easy-Bcl1-ABL(1184-1508)-Apa1(4-1) 
41 pGEM-T-easy-Bcl1-ABL-(1184-1508)-Sal1(1-9) 
42 pGEM-T-easy-D1/ABL (3-4) 
43 pGEM-T-easy-Flag-D1/ABL (1-4) 
44 pGEM-T-easy-HA-D1/ABL (2-1) 
45 pcDNA3-D1/ABL(2-5) 
46 pcDNA-Flag-D1/ABL-CLN(3-1) 
47 pcDNA-HA-D1/ABL-CLN(4-1) 
48 pMIG-D1/ABL(2-3) 
For SHIP1(D1-D2)/ABL1 fusion 
49 pGEM-T-easy-D1-D2-ABL(1-2) 
50 pGEM-T-easy-Flag-D1-D2-ABL(3-5) 
51 pGEM-T-easy-HA-D1-D2-ABL(4-1) 
52 pcDNA-D1-D2-ABL(1-4) 
53 pcDNA-Flag-D1-D2-ABL(3-1) 
54 pcDNA-HA-D1-D2-ABL(4-1) 
55 pMIG-D1-D2-ABL(1-1) 
For SHIP1(D2)/ABL1 fusion 
56 pGEM-Teasy-D2/ABL(829-1508)-CLN(2-2) 
57 pGEM-T-easy-Flag-D2/ABL(5-4) 
58 pGEM-T-easy-HA-D2/ABL(6-2) 
59 pcDNA-D2/ABL(2-4)  
60 pcDNA-Flag-D2/ABL(3-2) 
61 pcDNA-HA-D2/ABL(4-1) 
62 pMIG-D2/ABL(2-1) 
 171 
ABBREVIATIONS 
 
aa  amino acids 
ab  antibody 
ALL  acute lymphoblastic leukemia 
AML  acute myeloblastic leukemia 
Amp  ampicillin 
approx.  approximately 
APS  ammonium persulfate 
BAC bacterial artificial chromosome 
B-ALL  B-cell acute lymphoblastic leukemia 
bp  base pairs 
BSA  bovine serum albumine 
cALL common accute lymphoblastic leukemia 
cDNA  complementary DNA 
CoIP  co-immunoprecipitation 
DAPI  4’,6-diamidino-2-phenylindole 
DCDF dual color dual fusion 
ddH2O  double distilled water 
DIG  digoxigenin 
DMF  N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
e.g.  example 
EDTA  ethylenediaminetetraacetic acid 
ELISA Enzyme-Linked Immunosorbant assay 
EST  expressed sequence tags 
Ex Exon 
FAB  French-American-British classification system for acute 
leukemia 
FACS  fluorescence activated cell sorting 
FISH Fluorescent In situ hybridization 
g  gram 
GAL4-AD  GAL4 transcriptional activation domain 
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GAL4-DBD  GAL4 DNA binding domain 
GAL4-UAS  GAL4 upstream activating sequence 
GFP  green fluorescent protein 
HBS Hank's balanced salt 
hr(s)  hour(s) 
HRP  horse radish peroxidase 
i.e., example 
Intr  intron 
IPTG  isopropyl beta-D-1-thiogalactopyranoside 
IRES Internal ribosome entry site 
kb  kilobases 
kD  kilodalton 
l  liter 
LacZ  E. coli gene encoding beta-galactosidase 
LB  Luria Bertani medium 
LiAc  lithium acetate 
LSI Locus specific indentifier 
M  Molar 
m-  milli (1 x 10-3) 
MCS multi cloning site 
MIC Morphologic-Immunologic-Cytogenetic 
min minute(s) 
MOPS  3-N-morpholino-propanesulfonic acid 
mRNA  messenger RNA 
n  nano (1 x 10-9) 
NaAC  sodium acetate 
NaOH  sodium hydroxide 
nt  nucleotide 
O/N  overnight 
ºC  degree Celsius 
OD  optical density 
p  pico (1 x 10-12) 
PBS  phosphate buffer saline 
PCR  polymerase chain reaction 
PEG  polyethylenglycol 
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PFA  paraformaldehyde 
PtdIns(4,5)P2  phosphatidylinositol-4,5-bisphosphate 
RNA  ribonucleic acid 
RNAse A ribonuclease A 
rpm revolutions per minute 
RT  room temperature 
RT-PCR Reverse transcriptase PCR 
SD  synthetic drop out 
SDS  sodium dodecylsulfate 
sec  second(s) 
SSC  saline sodium citrate buffer 
TBE Tris-borate-EDTA 
TBS tris-buffered saline 
TCA Tris-chloro-acetate 
TE  tris-EDTA buffer 
Tm  melting temperature 
U  unit 
V  volts 
VCM Viral conditioned medium 
vol.  volume 
w/v  weight per volume 
WB  western blot 
WCP whole chromosome paint 
x g  gravity (9.81 m/s2) 
X-gal  5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
Y2H  yeast two hybrid 
YFP yellow fluorescent protein 
YPD  yeast extract, peptone, dextrose 
µ-  micro (1 x 10-6) 
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SINGLE LETTER CODES FOR AMINO ACIDS 
 
A (Ala)  Alanine  
M (Met)  Methionine 
B  Asparagine or Aspartic acid  
N (Asn)  Asparagine 
C (Cys)  Cysteine  
P (Pro)  Proline 
D (Asp) Aspartic acid  
Q (Glu)  Glutamine 
E (Glu)  Glutamic acid  
R (Arg)  Arginine 
F (Phe)  Phenylalanine S (Ser) Serine 
G (Gly)  Glycine  
T (Thr)  Threonine 
H (His)  Histidine  
V (Val)  Valine 
I (Ile)  Isoleucine  
W (Trp)  Tryptophan 
K (Lys)  Lysine  
Y (Tyr)  Tyrosine 
L (Leu)  Leucine  
Z  Glutamine or Glutamic acid 
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